* * *	PUBLIC	DISCLOSURE	COPY	* * *
-------	--------	------------	------	-------

		~~	Return of Organization Exempt F	rom Ir	ncome Tax	OMB No. 1545-0047
Form 990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)						2021
1 01			Do not enter social security numbers on this form a			
Depa Inter	rtment	of the Treasury enue Service	Go to www.irs.gov/Form990 for instructions and	-	•	Open to Public Inspection
					AR 31, 2022	
Β	Check if	C Name of	organization		D Employer identifica	tion number
â	pplicab					
	Addr		HTFOCUS FOUNDATION			
	Name	ge Doing bi	usiness as		23-733722	Э
	Initial returr	Number	and street (or P.O. box if mail is not delivered to street address)	Room/suite	E Telephone number	
	Final returr		2 GATEWAY CENTER DRIVE		(301) 948-	
	termi ated	City or t	own, state or province, country, and ZIP or foreign postal code		G Gross receipts \$	68,033,506.
	Amer returr		KSBURG, MD 20871		H(a) Is this a group retu	
	Appli tion pend	F Name a	nd address of principal officer: STACY PAGOS HALLER		for subordinates?	Yes X No
		SAME	AS C ABOVE		H(b) Are all subordinates inclu	ded? Yes No
		empt status:		or 527	If "No," attach a lis	t. See instructions
			BRIGHTFOCUS.ORG		H(c) Group exemption r	
		f organization:	X Corporation Trust Association Other ►	L Year (of formation: 1973 M	State of legal domicile: DC
Pa	art I	Summary			~	
e	1		e the organization's mission or most significant activities: BRIGH			
anc			FOCUS) SEEKS A WORLD FREE FROM DIS			
Activities & Governance	2	Check this bo			1 1	
Š	3					<u> </u>
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	4		ependent voting members of the governing body (Part VI, line 1b)			66
ies	5		of individuals employed in calendar year 2021 (Part V, line 2a)			70
tivit	6		of volunteers (estimate if necessary)			0.
Ac			business revenue from Part VIII, column (C), line 12			0.
		Net unrelated	business taxable income from Form 990-T, Part I, line 11	<u></u>	Prior Year	Current Year
	8	Contributions	and grants (Part VIII, line 1h)		48,502,473.	46,522,410.
ant	9				0.	0.
Revenue	10	•	ce revenue (Part VIII, line 2g) come (Part VIII, column (A), lines 3, 4, and 7d)		1,768,676.	3,244,235.
Ŗ	11		(Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)		975,243.	991,083.
	12		- add lines 8 through 11 (must equal Part VIII, column (A), line 12)		51,246,392.	50,757,728.
	13		nilar amounts paid (Part IX, column (A), lines 1-3)		25,256,371.	23,651,211.
	14		o or for members (Part IX, column (A), line 4)		0.	0.
s	15	Salaries, other	compensation, employee benefits (Part IX, column (A), lines 5-10)		5,801,548.	5,534,304.
Jse	16a	Professional fu	undraising fees (Part IX, column (A), line 11e)		738,435.	798,203.
Expenses	b		ng expenses (Part IX, column (D), line 25)   9 , 847 , 11			
ŵ	17	Other expense	es (Part IX, column (A), lines 11a-11d, 11f-24e)		20,436,021.	24,073,639.
			s. Add lines 13-17 (must equal Part IX, column (A), line 25)		52,232,375.	54,057,357.
	19		expenses. Subtract line 18 from line 12		-985,983.	-3,299,629.

Net Assets or Fund Balances **Beginning of Current Year** End of Year 66,476,749. 33,442,032. 65,540,964. 36,521,089. 20 Total assets (Part X, line 16) 21 Total liabilities (Part X, line 26) 33,034,717. 29,019,875 

 Image: Second system
 Part II
 Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Deelaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

	Stacy boos Haller		A	ugust 4, 2022
Sign	-Signature of officer		Dat	e
Here	STACY PAGOS HALLER, PR	ESIDENT/CEO		
	Type or print name and title			
	Print/Type preparer's name	Preparer's signature	Date	Check PTIN
Paid	FRANK H. SMITH	Frank H. Smith	08/04/22	self-employed P00639053
Preparer	Firm's name 🕨 MARCUM , LLP		Firr	n's EIN ▶ 11-1986323
Use Only	Firm's address 🕨 1899 L STREET, N	W, SUITE 850		
	WASHINGTON, DC 2	0036	Pho	one no. (202) 227-4000
May the II	RS discuss this return with the preparer shown abo	ove? See instructions		X Yes No
132001 12-0	9-21 LHA For Paperwork Reduction Act Noti	ce, see the separate instructions.		Form <b>990</b> (2021)
S	EE SCHEDULE O FOR ORGANIZ	ATION MISSION STATEME	ENT CONT	INUATION
	*** ELECTRON	ICALLY FILED ON 08/04	4/22 ***	COPY

		23-7337	229	Page 2
Pa	rt III Statement of Program Service Accomplishments			v
_	Check if Schedule O contains a response or note to any line in this Part III			. X
1	Briefly describe the organization's mission: BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWI	ת היי ישת	┎┎┎╖╖	٦
	ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA A			-
	EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEAS			
	SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.		10	
2	Did the organization undertake any significant program services during the year which were not listed on the			
	prior Form 990 or 990-EZ?	[	Yes	X No
	If "Yes," describe these new services on Schedule O.			
3	Did the organization cease conducting, or make significant changes in how it conducts, any program services?	[	Yes	X No
	If "Yes," describe these changes on Schedule O.			
4	Describe the organization's program service accomplishments for each of its three largest program services, as me	easured by ex	penses.	
	Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others,	the total expe	enses, an	d
	revenue, if any, for each program service reported.			
4a	(Code: ) (Expenses 24,808,686. including grants of 13,577,827.) (Revenue	\$		
	ALZHEIMER'S DISEASE RESEARCH (ADR)			
	PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF	πυτ		
	ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.	106		
	ACCOMPTIBILITIENTS FOR ADDITED MER 5 DISEASE RESEARCH.			
4b	(Code: ) (Expenses \$ 10,835,704. including grants of \$ 6,533,700. ) (Revenue	¢		
чы	MACULAR DEGENERATION RESEARCH (MDR)	Φ		
	PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF	тир		
	ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.			
	ACCOMPTIBILITY FOR MACOLAR DEGENERATION REPEARCH:			
4c	(Code:) (Expenses \$4,530,788. including grants of \$3,539,684. ) (Revenue	\$		
	NATIONAL GLAUCOMA RESEARCH (NGR)	* <u> </u>		
	PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF	THE		
	ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.			
4d	Other program services (Describe on Schedule O.)			
чu			)	
40	(Expenses \$ including grants of \$ ) (Revenue \$       Total program service expenses ►     40,175,178.		/	
40			Form <b>9</b> 9	30 (202)
10000	SEE SCHEDULE O FOR CONTINUATIONS OF 4A, 4B,	& 4C	FOLD 3	-• (2021
13200	² ¹²⁻⁰⁹⁻²¹ <b>2</b>			
200		ייט דייי ערואו	[ <b></b>	1910'
408	303         150872         191978         2021.04012         BRIGHTFOCUS         FOU		PY	гата

 Form 990 (2021)
 BRIGHTFOCUS
 FOUNDATION

 Part IV
 Checklist of Required Schedules
 FOUNDATION

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?			
	If "Yes," complete Schedule A	1	X	
2	Is the organization required to complete Schedule B, Schedule of Contributors? See instructions	2	Х	
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for			
	public office? If "Yes," complete Schedule C, Part I	3		_X_
4	Section 501(c)(3) organizations. Did the organization engage in lobbying activities, or have a section 501(h) election in effect			
	during the tax year? If "Yes," complete Schedule C, Part II	4	X	
5	Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or			
	similar amounts as defined in Rev. Proc. 98-19? If "Yes," complete Schedule C, Part III	5		X
6	Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to			37
_	provide advice on the distribution or investment of amounts in such funds or accounts? If "Yes," complete Schedule D, Part I	6		X
7	Did the organization receive or hold a conservation easement, including easements to preserve open space,	_		v
-	the environment, historic land areas, or historic structures? If "Yes," complete Schedule D, Part II	7		X
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? If "Yes," complete			v
•	Schedule D, Part III	8		X
9	Did the organization report an amount in Part X, line 21, for escrow or custodial account liability, serve as a custodian for			
	amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services?			х
10	If "Yes," complete Schedule D, Part IV	9		л
10	Did the organization, directly or through a related organization, hold assets in donor-restricted endowments	10	х	
44	or in quasi endowments? If "Yes," complete Schedule D, Part V	10	<u>_</u>	
11	If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VII, IX, or X,			
•	as applicable.			
а	Did the organization report an amount for land, buildings, and equipment in Part X, line 10? If "Yes," complete Schedule D,	11a	х	
h	Part VI		- 23	
U	assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VII	11b		х
c	Did the organization report an amount for investments - program related in Part X, line 13, that is 5% or more of its total			
C	assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VIII	11c		х
Ь	Did the organization report an amount for other assets in Part X, line 15, that is 5% or more of its total assets reported in			
ŭ	Part X, line 16? If "Yes," complete Schedule D, Part IX	11d		х
e	Did the organization report an amount for other liabilities in Part X, line 25? If "Yes," complete Schedule D, Part X	11e	Х	
f	Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses			
-	the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? If "Yes," complete Schedule D, Part X	11f	х	
12a	Did the organization obtain separate, independent audited financial statements for the tax year? If "Yes," complete			
	Schedule D, Parts XI and XII	12a		х
b	Was the organization included in consolidated, independent audited financial statements for the tax year?			
	If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional	12b	Х	
13	Is the organization a school described in section 170(b)(1)(A)(ii)? If "Yes," complete Schedule E	13		Х
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a		Х
b	Did the organization have aggregate revenues or expenses of more than \$10,000 from grantmaking, fundraising, business,			
	investment, and program service activities outside the United States, or aggregate foreign investments valued at \$100,000			
	or more? If "Yes," complete Schedule F, Parts I and IV	14b	Х	
15	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of grants or other assistance to or for any			
	foreign organization? If "Yes," complete Schedule F, Parts II and IV	15	Х	
16	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of aggregate grants or other assistance to			
	or for foreign individuals? If "Yes," complete Schedule F, Parts III and IV	16		X
17	Did the organization report a total of more than \$15,000 of expenses for professional fundraising services on Part IX,			
	column (A), lines 6 and 11e? If "Yes," complete Schedule G, Part I. See instructions	17	Х	
18	Did the organization report more than \$15,000 total of fundraising event gross income and contributions on Part VIII, lines			
	1c and 8a? If "Yes," complete Schedule G, Part II	18		X
19	Did the organization report more than \$15,000 of gross income from gaming activities on Part VIII, line 9a? If "Yes,"			
	complete Schedule G, Part III	19		X
	Did the organization operate one or more hospital facilities? If "Yes," complete Schedule H	20a		Х
b	If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b		
21	Did the organization report more than \$5,000 of grants or other assistance to any domestic organization or			
	domestic government on Part IX, column (A), line 1? If "Yes." complete Schedule I. Parts I and II	21	X	
132003	12-09-21	Form	990	(2021)

132003 12-09-21

			Yes	No
22	Did the organization report more than \$5,000 of grants or other assistance to or for domestic individuals on			
	Part IX, column (A), line 2? If "Yes," complete Schedule I, Parts I and III	22		X
23	Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization's current			
	and former officers, directors, trustees, key employees, and highest compensated employees? If "Yes," complete			
	Schedule J	23	Х	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the			
	last day of the year, that was issued after December 31, 2002? If "Yes," answer lines 24b through 24d and complete			
	Schedule K. If "No," go to line 25a	24a		X
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease			
	any tax-exempt bonds?	24c		
Ь	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
	Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit	214		
200	transaction with a disqualified person during the year? If "Yes," complete Schedule L, Part I	25a		x
h	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and	200		
D D	that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? If "Yes," complete			
		25b		x
06	Schedule L, Part I	250		- 23
26	Did the organization report any amount on Part X, line 5 or 22, for receivables from or payables to any current			
	or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35%			v
	controlled entity or family member of any of these persons? If "Yes," complete Schedule L, Part II	26		X
27	Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee,			
	creator or founder, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled			
	entity (including an employee thereof) or family member of any of these persons? If "Yes," complete Schedule L, Part III	27		X
28	Was the organization a party to a business transaction with one of the following parties (see the Schedule L, Part IV,			
	instructions for applicable filing thresholds, conditions, and exceptions):			
а	A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? If			
	"Yes," complete Schedule L, Part IV	28a		X
b	A family member of any individual described in line 28a? If "Yes," complete Schedule L, Part IV	28b		X
с	A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? If			
	"Yes," complete Schedule L, Part IV	28c		X
29	Did the organization receive more than \$25,000 in non-cash contributions? If "Yes," complete Schedule M	29	Х	
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation			
	contributions? If "Yes," complete Schedule M	30		x
31	Did the organization liquidate, terminate, or dissolve and cease operations? If "Yes," complete Schedule N, Part I	31		X
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? If "Yes," complete			
	Schedule N, Part II	32		x
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations			
	sections 301.7701-2 and 301.7701-3? If "Yes," complete Schedule R, Part I	33	х	
34	Was the organization related to any tax-exempt or taxable entity? If "Yes," complete Schedule R, Part II, III, or IV, and			<u> </u>
54		34		x
<u> </u>	Part V, line 1			X
	Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a		
b	If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity	051		
20	within the meaning of section 512(b)(13)? If "Yes," complete Schedule R, Part V, line 2	35b		
36	Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization?	~~		v
	If "Yes," complete Schedule R, Part V, line 2	36		X
37	Did the organization conduct more than 5% of its activities through an entity that is not a related organization			37
	and that is treated as a partnership for federal income tax purposes? If "Yes," complete Schedule R, Part VI	37		X
38	Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19?			
	Note: All Form 990 filers are required to complete Schedule O	38	Х	
Pa				
	Check if Schedule O contains a response or note to any line in this Part V			
			Yes	No
1a	Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable 1a 176			
b	Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable 1b 0			
	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming			
	(gambling) winnings to prize winners?	1c	Х	
132004	¥ 12-09-21	Form	990	(2021)

#### 13420803 150872 191978

-	990 (2021) BRIGHTFOCUS FOUNDATION <b>t V</b> Statements Regarding Other IRS Filings and Tax Compliance (continued)	23-	73372	29	Р	age
	<b>t V</b> Statements Regarding Other IRS Filings and Tax Compliance (continued)				Yes	No
а	Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements,		Г		103	
	filed for the calendar year ending with or within the year covered by this return	2a	66			
b	If at least one is reported on line 2a, did the organization file all required federal employment tax return	าร?		2b	Х	
	Note: If the sum of lines 1a and 2a is greater than 250, you may be required to e-file. See instructions	S				
la	Did the organization have unrelated business gross income of \$1,000 or more during the year?			3a		X
b	If "Yes," has it filed a Form 990-T for this year? If "No" to line 3b, provide an explanation on Schedule	о		3b		
la	At any time during the calendar year, did the organization have an interest in, or a signature or other a	uthority over, a				
	financial account in a foreign country (such as a bank account, securities account, or other financial a	ccount)?		4a		X
b	If "Yes," enter the name of the foreign country					
	See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Ac	counts (FBAR).				
			····· –	5a		X
	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transact		·····	5b		X
	If "Yes" to line 5a or 5b, did the organization file Form 8886-T?			5c		
ba	Does the organization have annual gross receipts that are normally greater than \$100,000, and did the			•		<b>v</b>
	any contributions that were not tax deductible as charitable contributions?		······ –	6a		X
b	If "Yes," did the organization include with every solicitation an express statement that such contribution of the statement that such contribution of the statement that such contribution of the statement is a statement that such contribution of the statement is a statement that such contribution of the statement is a statement that such contribution of the statement is a statement that such contribution of the statement is a statement that such contribution of the statement is a statement in the statement in the statement is a statement in the statement in the statement is a statement in the statement in the statement is a statement in the statement in the statement in the statement is a statement in the statement in t			<b>a</b> .		
-	were not tax deductible?		····· –	6b		
7	Organizations that may receive deductible contributions under section 170(c).	visco providad to the	novor0	7-		x
	Did the organization receive a payment in excess of \$75 made partly as a contribution and partly for goods and ser			7a 7b		⊢^
			······ –	α/		
C	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it wa to file Form 8282?	•		7c	Х	
Ч		7d	·····i  -	10		
	If "Yes," indicate the number of Forms 8282 filed during the year			7e		x
e f	Did the organization receive any funds, directly of indirectly, to pay premiums on a personal benefit contra Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contra			7e 7f		X
' g	If the organization received a contribution of qualified intellectual property, did the organization file Fo		····· ⊢	7g		
-	If the organization received a contribution of qualified intellectual property, did the organization mer of If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization	-	···· -	79 7h		
3	Sponsoring organizations maintaining donor advised funds. Did a donor advised fund maintained					
		-	- E	8		
9	Sponsoring organizations maintaining donor advised funds.		····· –	Ŭ		
a			- E	9a		
				9b		
ົ	Section 501(c)(7) organizations. Enter:					
	Initiation fees and capital contributions included on Part VIII, line 12	10a				
	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities	10b				
1	Section 501(c)(12) organizations. Enter:					
	Gross income from members or shareholders	11a				
b	Gross income from other sources. (Do not net amounts due or paid to other sources against					
	amounts due or received from them.)	11b				
2a	Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form			12a		
b	If "Yes," enter the amount of tax-exempt interest received or accrued during the year	12b				
3	Section 501(c)(29) qualified nonprofit health insurance issuers.					
а	Is the organization licensed to issue qualified health plans in more than one state?			13a		
	Note: See the instructions for additional information the organization must report on Schedule O.					
b	Enter the amount of reserves the organization is required to maintain by the states in which the					
	organization is licensed to issue qualified health plans	13b				
с	Enter the amount of reserves on hand	13c				
4a			Ē	14a		X
b	If "Yes," has it filed a Form 720 to report these payments? If "No," provide an explanation on Schedul	e O		l4b		
5	Is the organization subject to the section 4960 tax on payment(s) of more than \$1,000,000 in remuner					
	excess parachute payment(s) during the year?		L	15		X
	If "Yes," see the instructions and file Form 4720, Schedule N.					
6	Is the organization an educational institution subject to the section 4968 excise tax on net investment	income?	L	16		X
	If "Yes," complete Form 4720, Schedule O.					
	Section 501(c)(21) organizations. Did the trust, any disqualified person, or mine operator engage in	any				
7			I	4 -		
7	activities that would result in the imposition of an excise tax under section 4951, 4952 or 4953?		······ 🛓	17		

13420803	150872	191978

Form	990	(2021)

<u>23-7337229</u> Page 6

 Form 990 (2021)
 BRIGHTFOCUS
 FOUNDATION
 23-7337229
 Page

 Part VI
 Governance, Management, and Disclosure.
 For each "Yes" response to lines 2 through 7b below, and for a "No" response

	to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.			
	Check if Schedule O contains a response or note to any line in this Part VI			X
Sec	tion A. Governing Body and Management			
			Yes	No
1a	Enter the number of voting members of the governing body at the end of the tax year 1a	11		
	If there are material differences in voting rights among members of the governing body, or if the governing			
	body delegated broad authority to an executive committee or similar committee, explain on Schedule O.			
b	Enter the number of voting members included on line 1a, above, who are independent 1b	11		
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other			
	officer, director, trustee, or key employee?	2		Х
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision			
	of officers, directors, trustees, or key employees to a management company or other person?	3		Х
4	Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4		Х
5	Did the organization become aware during the year of a significant diversion of the organization's assets?	5		Х
6	Did the organization have members or stockholders?	6		Х
7a	Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or			
	more members of the governing body?	7a		Х
b	Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or			
	persons other than the governing body?	7b		Х
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:			
а	The governing body?	8a	Х	
b	Each committee with authority to act on behalf of the governing body?	8b	Х	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the			
	organization's mailing address? If "Yes," provide the names and addresses on Schedule O	9		Х
Sec	tion B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)			
			Yes	No
10a	Did the organization have local chapters, branches, or affiliates?	10a		Х
I.	If IV/as II did the event institute policies and even advect structure the opticities of such short-two officiates			

iua	Did the organization have local chapters, branches, or anniates?	IUa		23
b	If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates,			
	and branches to ensure their operations are consistent with the organization's exempt purposes?	10b		
11a	Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	Х	
b	Describe on Schedule O the process, if any, used by the organization to review this Form 990.			
12a	Did the organization have a written conflict of interest policy? If "No," go to line 13	12a	Х	
b	Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	Х	
с	Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe			
	on Schedule O how this was done	12c	Х	
13	Did the organization have a written whistleblower policy?	13	Х	
14	Did the organization have a written document retention and destruction policy?	14	Х	
15	Did the process for determining compensation of the following persons include a review and approval by independent			
	persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
а	The organization's CEO, Executive Director, or top management official	15a	Х	
b	Other officers or key employees of the organization	15b	Х	
	If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a			
	taxable entity during the year?	16a		X
b	If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation			
	in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's			
	exempt status with respect to such arrangements?	16b		
Sec	tion C. Disclosure			

17	List the states with which a copy of this Form 990 is required to be filed ►AK, AL, AR, CA, CT, FL, GA, HI, IL, KS, KY, ME_
18	Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available
	for public inspection. Indicate how you made these available. Check all that apply.
	X Own website X Another's website X Upon request Other (explain on Schedule O)
19	Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial
	statements available to the public during the tax year.
20	State the name, address, and telephone number of the person who possesses the organization's books and records 🕨
	DAVID F. MARKS, CPA, CMA - (301) 948-3244
	22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871
13200	6 12-09-21 SEE SCHEDULE O FOR FULL LIST OF STATES Form 990 (2021)
	e

#### 13420803 150872 191978

Form 990 (2021)	BRIGHTFOCUS FOUNDATION	23-7337229	Page 7
Part VII Con	npensation of Officers, Directors, Trustees, Key Employees, Highest (	Compensated	
Emp	ployees, and Independent Contractors		
Chec	k if Schedule O contains a response or note to any line in this Part VII		
Section A. Offic	cers, Directors, Trustees, Key Employees, and Highest Compensated Employees		
1a Complete this	s table for all persons required to be listed. Report compensation for the calendar year ending	ng with or within the organization's	tax year.

• List all of the organization's current officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.

• List all of the organization's current key employees, if any. See the instructions for definition of "key employee."

• List the organization's five current highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than \$100,000 from the organization and any related organizations.

• List all of the organization's former officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations.

• List all of the organization's former directors or trustees that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.

Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A)	(B)			(0	C)			(D)	(E)	(F)
Name and title	Average	(do	Position (do not check more than one		Reportable	Reportable	Estimated			
	hours per	box	, unles	ss per	son is	s both	an	compensation	compensation	amount of
	week		cer an	nd a di	recto	r/trus	ee)	from	from related	other
	(list any	In dividual trustee or director						the	organizations	compensation
	hours for related	e or d	tee			sated		organization (W-2/1099-MISC/	(W-2/1099-MISC/ 1099-NEC)	from the organization
	organizations	ruste	al trus		yee	mpen		1099-NEC)	1033-NEO)	and related
	below	dual t	Institutional trustee		Key employee	sst co oyee	er			organizations
	line)	Indivi	Instit	Officer	Key e	Highest compensated employee	Former			C C
(1) STACY PAGOS HALLER	55.00									
PRESIDENT/CEO				Х				435,364.	0.	51,027.
(2) NANCY LYNN	45.00									
SR. VP STRATEGIC PARTNERSHIPS					Х			246,054.	0.	53,950.
(3) R. BRIAN ELDERTON	45.00									
SR. VP, DEVELOPMENT					Х			247,200.	0.	46,416.
(4) DAVID F. MARKS, CPA, CMA	45.00									
VP, FINANCE & ADMINISTRATION					Х			165,137.	0.	56,529.
(5) DIANE BOVENKAMP, PHD	45.00									
VP, SCIENTIFIC AFFAIRS					Х			179,717.	0.	20,889.
(6) MICHAEL BUCKLEY	45.00									
VP, PUBLIC AFFAIRS					Х			163,018.	0.	18,661.
(7) AYO ABRAHAM, CPA	40.00									
CONTROLLER						Х		140,557.	0.	8,353.
(8) JEFFREY HONAKER	40.00									
SR. MANAGER OPERATIONS & BUILDING						Х		104,049.	0.	38,719.
(9) LISA MORGAN	40.00									
DIRECTOR OF ANNUAL GIVING						Х		106,425.	0.	30,773.
(10) PREETI SUBRAMANIAN, DIR. OF	40.00									
SCIENT. PROGRAMS, VISION SCIENCE						Х		111,447.	0.	10,629.
(11) PATRICIA M. STEWART	10.00									
CHAIR		Х		X				0.	0.	0.
(12) CECILIA ARRADAZA	5.00									
VICE CHAIR		Х		X				0.	0.	0.
(13) MADDY DYCHTWALD	5.00									
SECRETARY		Х		X				0.	0.	0.
(14) ETHAN TREESE	5.00									
TREASURER		Х		X				0.	0.	0.
(15) EDWARD FINLEY	5.00									
DIRECTOR		Х						0.	0.	0.
(16) SHAWA GOTTLIEB	5.00							_		_
DIRECTOR		х						0.	0.	0.
(17) DANA GRIFFIN	5.00									
DIRECTOR		Х						0.	0.	0. Form <b>990</b> (2021)

132007 12-09-21

Form 990 (2021)

13420803 150872 191978

	BRIGHTFOC	CUS FOUN	ΙDΑ	TI	ON					23-73	337	229	Page <b>8</b>
Part	VII Section A. Officers, Directors, Trust	tees, Key Emp	oloy	ees,	and	l Hig	ghes	t C	ompensated Employee	s (continued)			
	(A)	(B)				C)			(D)	(E)		(	F)
	Name and title	Average	(do		Posi		ו than d	one	Reportable	Reportable		Estir	mated
		hours per	box	, unles	ss per	son i	is both pr/trus	n an	compensation	compensatio	n	amo	unt of
		week			uau	recio	T	lee)	from	from related			her .
		(list any hours for	recto						the	organization		•	ensation
		related	or di	ee			sated		organization (W-2/1099-MISC/	(W-2/1099-MIS 1099-NEC)	,C/		n the
		organizations	rustee	trus		ee	npen		1099-NEC)	1099-NEC)		•	nization related
		below	lual ti	tiona		Vold	st cor	-	1000 NEO				izations
		line)	Individual trustee or director	Institutional trustee	Officer	ƙey employee	Highest compensated employee	Former				er gun	
(18)	SCOTT KAISER, MD	5.00	_	_	0	×		_					
DIREC	TOR		х						0.		0.		Ο.
(19)	TONYA MATTHEWS, PHD	5.00											
DIREC	TOR		х						0.		0.		Ο.
(20)	BRIAN K. REGAN, PHD	5.00											
DIREC	TOR - UNTIL 06/2021		х						0.		0.		Ο.
(21)	SCOTT RODGVILLE, CPA	5.00											
DIREC	TOR - UNTIL 06/2021		х						0.		0.		Ο.
	ERIC SIEMERS, MD	5.00											
DIREC	TOR		х						0.		0.		Ο.
(23)	JAN M. STOUFFER, PHD	5.00											
DIREC	TOR		х						0.		0.		Ο.
1b	Subtotal								1,898,968.		0.	335	,946.
	Total from continuation sheets to Part VI								0.		0.		0.
	Total (add lines 1b and 1c)								1,898,968.		0.	335	,946.
	Total number of individuals (including but no							o re		000 of reportable	ı		·
	compensation from the organization						,		,				10
												Y	'es No
3	Did the organization list any <b>former</b> officer,	director, truste	ee, k	ey e	mpl	oye	e, or	hig	hest compensated emp	oyee on			
	line 1a? If "Yes," complete Schedule J for su	ich individual					-					3	X
	For any individual listed on line 1a, is the su												
	and related organizations greater than \$150											4 2	x
	Did any person listed on line 1a receive or a	,		•									
	rendered to the organization? If "Yes." com											5	X
	on B. Independent Contractors	<u>proto correduie</u>	<u> </u>	<u> </u>		2010					<u></u>		
1	Complete this table for your five highest cor	npensated ind	epe	nder	nt co	ontra	acto	rs th	nat received more than \$	100,000 of comp	ensat	ion from	
	the organization. Report compensation for t	he calendar ye	ear e	ndin	ıg wi	ith c	or wi	thin	the organization's tax y	ear.			
	(A)								(B)			(C)	
	Name and business	address							Description of s	ervices	С	ompens	ation
RKD	GROUP, 35 PARKWOOD DR	IVE, SU	IΤ	E I	16	Ο,			PUBLIC AWARE	NESS			
HOP	KINTON, MA 01748								CONSUL. & MA	TERIALS	9	,417	,726.
ALL	EGIANCE GROUP, 2300 CL	ARENDON	В	LV	D.	,			ONLINE PUBLI	2			
SUI	TE 925, ARLINGTON, VA	22201						į.	AWARENESS CO	SULTING		628	,947.
ADS	TRA LLC, 750 COLLEGE R	OAD EAS	т,	SI	UI	ΤE							
201	, PRINCETON, NJ 08540								LIST RENTAL			505	,173.
DAT	A MANAGEMENT, INC.												
	STONE STREET, STONEVI	LLE, NC	2	70	48				DATABASE MAN	AGEMENT		294	,513.
	GLE, 1600 AMPHITHEATRE								PUBLIC AWARE	NESS			
	NTAIN VIEW, CA 94043								ADVERTISING			<u>27</u> 7	,994.
	Total number of independent contractors (ir	ncluding but no	ot lin	nited	to t	thos	se lis	ted	above) who received mo	ore than			
	\$100,000 of compensation from the organiz	ation 🕨				17	7						
												Form 99	<b>90</b> (2021)

132008 12-09-21

Form	n 990 (i		GHTFOCUS 1	FOUNDATION	N		23-7337	229 Page 9
Pa	rt VII	I Statement of Re	venue					
		Check if Schedule O	contains a response	e or note to any lin	e in this Part VIII			
					<b>(A)</b> Total revenue	(B) Related or exempt function revenue	<b>(C)</b> Unrelated business revenue	<b>(D)</b> Revenue excluded from tax under sections 512 - 514
ς Ω	1 a	Federated campaigns	1a	255,977.				
unt	b	Membership dues		/ _				
, D Q U	с	Fundraising events						
ar A	d	Related organizations						
s, G	е	Government grants (contr	ibutions) <b>1e</b>					
tion S	f	All other contributions, gifts,						
Contributions, Gifts, Grants and Other Similar Amounts		similar amounts not included		46266433.				
onti	g	Noncash contributions included in		337,480.	46500410			
<u>o</u> e	h	Total. Add lines 1a-1f		Business Code	46522410.			
	0.0							
Program Service Revenue	2 a b							
Ser	c c							
ever	d							
ogra Be	е							
Pre	f	All other program service	revenue					
	g							
	3	Investment income (incluc						
		other similar amounts)			1,038,513.			1038513.
	4	Income from investment o	-	-	440,595.			440,595.
	5	Royalties	(i) Real	(ii) Personal	440,595.			440,595.
	6 2	Gross rents	6a 595, 253					
		Less: rental expenses	6b 52,265					
		Rental income or (loss)	6c 542,988					
		Net rental income or (loss)			542,988.			542,988.
	7 a	Gross amount from sales of	(i) Securities					
		assets other than inventory	7a1942923	5				
	b	Less: cost or other basis						
venue		and sales expenses	761722351					
0		Gain or (loss)	7c 2205722		2,205,722.			2205722.
Other R		Net gain or (loss)		▶	2,205,722.			2205722.
Ę	oa	Gross income from fundraisin including \$	-					
0		contributions reported on						
		Part IV, line 18	<i>'</i>	a				
	b	Less: direct expenses		b				
	с	Net income or (loss) from	fundraising events	►				
	9 a	Gross income from gamin	-					
		Part IV, line 19						
		Less: direct expenses		b				
		Net income or (loss) from	<b>-</b>	▶				
	iu a	Gross sales of inventory, I and allowances		)a				
	b	Less: cost of goods sold						
		Net income or (loss) from	····· <b></b>					
		,, ·· 2···	····· <b>)</b>	Business Code				
sno	11 a	SAVINGS BOND	PAYOUT	900099	7,500.			7,500.
Miscellaneous Revenue	b							
Seve	с							
Mis	d	All other revenue			7 500			
		Total. Add lines 11a-11d			7,500. 50757728.	0.	0.	4235318.
	<b>12</b> 9 12-09-	Total revenue. See instructio	eur	₽	50757720.		0.	Form <b>990</b> (2021

#### BRIGHTFOCUS FOUNDATION Form 990 (2021) Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Secu	ion 501(c)(3) and 501(c)(4) organizations must comp			ipiele column (A).	
	Check if Schedule O contains a respon	ise or note to any line in (A)	(B)	(C)	
	not include amounts reported on lines 6b,	Total expenses	Program service	Management and	<b>(D)</b> Fundraising
	8b, 9b, and 10b of Part VIII.		expenses	general expenses	expenses
1	Grants and other assistance to domestic organizations	10 102 252	10 102 252		
	and domestic governments. See Part IV, line 21	18,193,252.	18,193,252.		
2	Grants and other assistance to domestic				
	individuals. See Part IV, line 22				
3	Grants and other assistance to foreign				
	organizations, foreign governments, and foreign				
	individuals. See Part IV, lines 15 and 16	5,457,959.	5,457,959.		
4	Benefits paid to or for members				
5	Compensation of current officers, directors,				
	trustees, and key employees	1,685,216.	1,079,340.	339,220.	266,656.
6	Compensation not included above to disqualified				
	persons (as defined under section 4958(f)(1)) and				
	persons described in section 4958(c)(3)(B)				
7	Other salaries and wages	2,758,048.	1,435,538.	890,977.	431,533.
8	Pension plan accruals and contributions (include				
	section 401(k) and 403(b) employer contributions)	186,521.	97,082.	60,255.	29,184.
9	Other employee benefits	606,087.	315,463.	195,794.	94,830.
10	Payroll taxes	298,432.	155,331.	96,407.	46,694.
11	Fees for services (nonemployees):	•		-	· · ·
	Management				
	Legal	90,920.	47,447.	43,473.	
	Accounting	95,713.	57,550.	26,236.	11,927.
	Lobbying	•	,	,	· · ·
	Professional fundraising services. See Part IV, line 17	798,203.			798,203.
f	Investment management fees	351,028.		351,028.	
	Other. (If line 11g amount exceeds 10% of line 25,	,		,	
9	column (A), amount, list line 11g expenses on Sch 0.)	2,261,900.	2,002,855.	194,077.	64,968.
12	Advertising and promotion	672,932.	352,899.		320,033.
13	Office expenses	1,060,023.	464,160.	327,500.	268,363.
14	Information technology	1,162,877.	868,504.	200,947.	93,426.
		1,102,077.	000,001	200,5470	55,1201
15	Royalties	434,794.	255,882.	137,124.	41,788.
16		67,731.	32,444.	21,805.	13,482.
17	Travel	07,751.	52,444.	21,005.	15,402.
18	Payments of travel or entertainment expenses				
40	for any federal, state, or local public officials	414,029.	298,650.	3,800.	111,579.
19	Conferences, conventions, and meetings	2,448.	1,441.	772.	235.
20	Interest	4,440.	⊥,44⊥•	114•	<u> </u>
21	Payments to affiliates	308,229.	177,938.	94,428.	35,863.
22	Depreciation, depletion, and amortization	97,527.	32,086.	56,840.	8,601.
23		91,541.	54,000.	50,840.	0,001.
24	Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If				
	line 24e amount exceeds 10% of line 25, column (A),				
	amount, list line 24e expenses on Schedule 0.)	7 664 100		404 621	2 201 215
а	PUB. AWARENESS POSTAGE	7,664,190.	3,958,244.	484,631.	3,221,315.
b	PUB. AWARENESS PRINTING	5,671,895.	2,947,419.	324,318.	2,400,158.
С	PUB. AWARENESS COMP.	2,017,247.	1,058,022.	102,867.	856,358.
d	LIST RENTAL	1,700,156.	885,672.	82,570.	731,914.
е	All other expenses			4 005 000	0.045.446
25	Total functional expenses. Add lines 1 through 24e	54,057,357.	40,175,178.	4,035,069.	9,847,110.
26	Joint costs. Complete this line only if the organization				
	reported in column (B) joint costs from a combined				
	educational campaign and fundraising solicitation.				
	Check here 🕨 🗴 if following SOP 98-2 (ASC 958-720)	16,603,523.	7,872,444.	1,050,335.	7,680,744.
13201	0 12-09-21				Form <b>990</b> (2021)
		10			

10

13420803 150872 191978

13420803 150872 191978

Balance Sneet	
Check if Schedule O contains a response or note to any line in this Part X	
	<b>(A)</b> Beginning of year
Cash - non-interest-bearing	3,829,911.
Savings and temporary cash investments	621,981.
Pledges and grants receivable, net	10,272,457.

BRIGHTFOCUS FOUNDATION

	3	Pledges and grants receivable, net			10,272,457.	3	6,568,692.
	4	Accounts receivable, net				4	
	5	Loans and other receivables from any current or					
		trustee, key employee, creator or founder, substa					
		controlled entity or family member of any of these				5	
	6	Loans and other receivables from other disqualifi					
		under section 4958(f)(1)), and persons described				6	
s	7	Notes and loans receivable, net		7			
Assets	8	Inventories for sale or use			44,354.	8	37,046.
As	9	<b>–</b>			204,913.	9	322,345.
	10a	Land, buildings, and equipment: cost or other		Γ			
		basis. Complete Part VI of Schedule D	10a	12,764,795.			
	b	Less: accumulated depreciation	10b	4,603,680.	7,830,979.	10c	8,161,115.
	11	Investments - publicly traded securities			43,404,279.	11	45,203,665.
	12	Investments - other securities. See Part IV, line 1				12	
	13	Investments - program-related. See Part IV, line 1			13		
	14	Intangible assets		14			
	15	Other assets. See Part IV, line 11	267,875.	15	169,035.		
	16	Total assets. Add lines 1 through 15 (must equa			66,476,749.	16	65,540,964.
	17	Accounts payable and accrued expenses			871,196.	17	862,205.
	18	Grants payable	31,618,962.	18	34,865,851.		
	19	Deferred revenue		19			
	20	Tax-exempt bond liabilities		20			
	21	Escrow or custodial account liability. Complete F	f Schedule D		21		
Se	22	Loans and other payables to any current or forme	r, director,				
Liabilities		trustee, key employee, creator or founder, substa					
iab		controlled entity or family member of any of these	ns		22		
	23	Secured mortgages and notes payable to unrelate		· · · · · · · · · · · · · · · · · · ·		23	
	24	Unsecured notes and loans payable to unrelated				24	
	25	Other liabilities (including federal income tax, pay					
		parties, and other liabilities not included on lines	17-24).	Complete Part X	051 054		802 022
		of Schedule D		·····	951,874.		793,033.
	26			▶ ▼	33,442,032.	26	36,521,089.
ŝ		Organizations that follow FASB ASC 958, check	ck here				
Balances	07	and complete lines 27, 28, 32, and 33.			15,708,243.	27	13,864,090.
ala	27	Net assets without donor restrictions			17,326,474.		15,155,785.
	28	Net assets with donor restrictions			17,520,474.	28	15,155,765.
Fund		Organizations that do not follow FASB ASC 95	o, chec				
٩.	200	and complete lines 29 through 33. Capital stock or trust principal, or current funds				29	
ets	29					30	
Net Assets or	30 31	Paid-in or capital surplus, or land, building, or equipated exprising and expression accumulated inc				30	
et⊿	31	Retained earnings, endowment, accumulated inc			33,034,717.	31	29,019,875.
Ž	32	Total net assets or fund balances			66,476,749.	<u>3</u> 2	65,540,964.
	33	Total habilities and het assets/lund balances			JUI - 10 - 1 - J -	33	Form <b>990</b> (2021)
							Form <b>ອອບ</b> (2021)

**(B)** End of year

1

2

138,432.

4,940,634.

1

2

Form 990 (2021) Part X Ba

	1990 (2021) BRIGHTFOCUS FOUNDATION	23-	<u>7337</u>	229	Pa	_{ge} 12
Pa	rt XI Reconciliation of Net Assets					
	Check if Schedule O contains a response or note to any line in this Part XI		<u></u>			X
1	Total revenue (must equal Part VIII, column (A), line 12)	1		),75		
2	Total expenses (must equal Part IX, column (A), line 25)	2		,05	-	
3	Revenue less expenses. Subtract line 2 from line 1	3		3,29		
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4		3,03		
5	Net unrealized gains (losses) on investments	5	-1	.,60	5,8	10.
6	Donated services and use of facilities	6				
7	Investment expenses	7				
8	Prior period adjustments	8				
9	Other changes in net assets or fund balances (explain on Schedule O)	9		89	0,5	97.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32,					
	column (B))	10	29	,01	9,8	75.
Pa	rt XII Financial Statements and Reporting					
	Check if Schedule O contains a response or note to any line in this Part XII					
					Yes	No
1	Accounting method used to prepare the Form 990: Cash X Accrual Other					
	If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule	О.				
2a	Were the organization's financial statements compiled or reviewed by an independent accountant?			2a		X
	If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed	on a				
	separate basis, consolidated basis, or both:					
	Separate basis Consolidated basis Both consolidated and separate basis					
b	Were the organization's financial statements audited by an independent accountant?			2b	Х	
	If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate	basis,				
	consolidated basis, or both:					
	Separate basis X Consolidated basis Both consolidated and separate basis					
С	If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the					
	review, or compilation of its financial statements and selection of an independent accountant?			2c	Х	
	If the organization changed either its oversight process or selection process during the tax year, explain on Sch					
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Sin	gle Audi	t			
	Act and OMB Circular A-133?			3a		X
b	If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required					1
	or audits, explain why on Schedule O and describe any steps taken to undergo such audits		<u></u>	3b	000	

Form **990** (2021)

Department of the Treasury Internal Revenue Service

(Form 990)

### **Public Charity Status and Public Support**

Complete if the organization is a section 501(c)(3) organization or a section

4947(a)(1) nonexempt charitable trust. Attach to Form 990 or Form 990-EZ.

► Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047
2021
Open to Public Inspection

1

Name	of	the	organization
------	----	-----	--------------

Nan	ne of t	the organization							r identification number
			HTFOCUS FOU						3-7337229
	irt I	Reason for Public (					ee instruction	S.	
The	organ	ization is not a private found	ation because it is: (F	For lines 1 through 12, c	heck only o	one box.)			
1		A church, convention of ch	urches, or associatio	n of churches described	in sectio	on 170(b)(1	l)(A)(i).		
2		A school described in sect	ion 170(b)(1)(A)(ii). (/	Attach Schedule E (Forn	ו 990).)				
3		A hospital or a cooperative	hospital service orga	anization described in se	ection 170	(b)(1)(A)(ii	i).		
4		A medical research organiz	ation operated in cor	njunction with a hospital	described	in sectio	n 170(b)(1)(A	)(iii). Enter	the hospital's name,
		city, and state:							
5		An organization operated for	or the benefit of a col	lege or university owned	l or operate	ed by a go	vernmental u	nit describe	ed in
		section 170(b)(1)(A)(iv). (C	Complete Part II.)						
6		A federal, state, or local gov	vernment or governm	nental unit described in	section 17	70(b)(1)(A)	(v).		
7	X	An organization that norma	lly receives a substar	ntial part of its support fr	om a gove	ernmental	unit or from th	ne general j	public described in
		section 170(b)(1)(A)(vi). (C	omplete Part II.)						
8		A community trust describe	ed in section 170(b)(	(1)(A)(vi). (Complete Par	t II.)				
9		An agricultural research org	anization described	in section 170(b)(1)(A)(	ix) operate	ed in conju	inction with a	land-grant	college
		or university or a non-land-g	grant college of agricu	ulture (see instructions).	Enter the I	name, city	, and state of	the college	eor
		university:							
10		An organization that norma	Ily receives (1) more	than 33 1/3% of its supp	ort from c	ontributior	ns, membersh	ip fees, and	d gross receipts from
		activities related to its exem	npt functions, subjec	t to certain exceptions; a	and (2) no	more than	33 1/3% of its	s support f	rom gross investment
		income and unrelated busir	ness taxable income	(less section 511 tax) fro	m busines	sses acquii	red by the org	anization a	after June 30, 1975.
		See section 509(a)(2). (Con	mplete Part III.)						
11		An organization organized a	and operated exclusi	vely to test for public sa	fety. See	section 50	)9(a)(4).		
12		An organization organized a	and operated exclusi	vely for the benefit of, to	perform tl	he functior	ns of, or to ca	rry out the	purposes of one or
		more publicly supported or	ganizations describe	d in section 509(a)(1) d	r section !	509(a)(2).	See section &	509(a)(3). (	Check the box on
		lines 12a through 12d that	describes the type of	f supporting organizatior	n and com	plete lines	12e, 12f, and	12g.	
а		<b>Type I.</b> A supporting orga	anization operated, su	upervised, or controlled	by its supp	ported orga	anization(s), ty	pically by	giving
		the supported organization	on(s) the power to reg	gularly appoint or elect a	majority o	of the direc	tors or truste	es of the su	upporting
		organization. You must o	complete Part IV, Se	ections A and B.					
b		<b>Type II.</b> A supporting org	anization supervised	or controlled in connect	ion with its	s supporte	d organizatio	n(s), by hav	/ing
		control or management o	f the supporting orga	anization vested in the sa	ame perso	ns that co	ntrol or manag	ge the supp	ported
		organization(s). You mus	t complete Part IV,	Sections A and C.					
С		Type III functionally inte	grated. A supporting	g organization operated	in connect	tion with, a	and functional	ly integrate	ed with,
		its supported organization	n(s) (see instructions)	). You must complete I	Part IV, Se	ections A,	D, and E.		
c		Type III non-functionally	integrated. A supp	orting organization oper	ated in cor	nnection w	ith its suppor	ted organiz	zation(s)
		that is not functionally int	egrated. The organiz	ation generally must sat	isfy a distri	ibution rec	uirement and	an attentiv	veness
		requirement (see instructi	ions). You must con	nplete Part IV, Sections	A and D,	and Part	<b>V</b> .		
е		Check this box if the orga	anization received a v	written determination fro	m the IRS	that it is a	Туре I, Туре	II, Type III	
		functionally integrated, or	Type III non-functior	nally integrated supportion	ng organiz	ation.			
f	Ente	er the number of supported o	organizations						
<u> </u>		vide the following information			(iv) to the orga	anization listed			
	(	(i) Name of supported	(ii) EIN	(iii) Type of organization (described on lines 1-10	in your governi	ing document?	(v) Amount of support (see ir	-	(vi) Amount of other support (see instructions)
		organization		above (see instructions))	Yes	No	support (see ii	istructions	support (see instructions
_									
Tota	ai						1		1

Schedule A (Form 990) 2021



Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi) (Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization

fails to qualify under the tests listed below, please complete Part III.)

Sec	ction A. Public Support						
Cale	ndar year (or fiscal year beginning in) 🕨	(a) 2017	<b>(b)</b> 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1	Gifts, grants, contributions, and						
	membership fees received. (Do not						
	include any "unusual grants.")	32362197.	39635190.	35740875.	48502473.	46522410.	202763145
2	Tax revenues levied for the organ-						
	ization's benefit and either paid to						
	or expended on its behalf						
3	The value of services or facilities						
	furnished by a governmental unit to						
	the organization without charge						
4	Total. Add lines 1 through 3	32362197.	39635190.	35740875.	48502473.	46522410.	202763145
5	The portion of total contributions						
	by each person (other than a						
	governmental unit or publicly						
	supported organization) included						
	on line 1 that exceeds 2% of the						
	amount shown on line 11,						
	column (f)						711,894.
6	Public support. Subtract line 5 from line 4.						202051251
	ction B. Total Support					•	
Cale	ndar year (or fiscal year beginning in) 🕨	(a) 2017	<b>(b)</b> 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
	Amounts from line 4	32362197.	39635190.		48502473.	46522410.	202763145
8	Gross income from interest,						
	dividends, payments received on						
	securities loans, rents, royalties,						
	and income from similar sources	1641767.	1925519.	2176998.	1887633.	2074361.	9706278.
9	Net income from unrelated business						
	activities, whether or not the						
	business is regularly carried on						
10	Other income. Do not include gain						
	or loss from the sale of capital						
	assets (Explain in Part VI.)					7,500.	7,500.
11	<b>Total support.</b> Add lines 7 through 10						212476923
12		etc. (see instructio	ons)			12	•
13	First 5 years. If the Form 990 is for the	,	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	fourth, or fifth tax	year as a section 5	01(c)(3)	
	organization, check this box and <b>stop</b>	-					
Sec	ction C. Computation of Publi						
14	Public support percentage for 2021 (I	line 6, column (f), d	ivided by line 11, o	column (f))		14	95.09 %
15	Public support percentage from 2020	) Schedule A, Part	II, line 14			15	95.24 %
	33 1/3% support test - 2021. If the o					ore, check this bo	x and
	stop here. The organization qualifies						N V
b	33 1/3% support test - 2020. If the	organization did no	t check a box on	line 13 or 16a, and	line 15 is 33 1/3%	or more, check th	is box
	and stop here. The organization qual	lifies as a publicly s	supported organization	ation			
17a	10% -facts-and-circumstances test	t - 2021. If the org	anization did not o				
	and if the organization meets the fact						
	meets the facts-and-circumstances te			-	-	5	
b	10% -facts-and-circumstances test	•	•		•		
	more, and if the organization meets th	-					
	organization meets the facts-and-circi						
18	Private foundation. If the organization		•				s ►
			, · -				(Form 990) 2021

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Sec	ction A. Public Support		•	-	-		
Cale	ndar year (or fiscal year beginning in) 🕨	(a) 2017	<b>(b)</b> 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1	Gifts, grants, contributions, and						
	membership fees received. (Do not						
	include any "unusual grants.")	L					
2	Gross receipts from admissions, merchandise sold or services per- formed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3	Gross receipts from activities that are not an unrelated trade or bus-						
	iness under section 513						
4	Tax revenues levied for the organ- ization's benefit and either paid to						
-	or expended on its behalf						
5	The value of services or facilities furnished by a governmental unit to						
	the organization without charge						
	Total. Add lines 1 through 5						
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons						
	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
c	Add lines 7a and 7b	L					
8 Sec	Public support. (Subtract line 7c from line 6.)						
Cale	ndar year (or fiscal year beginning in) 🕨	(a) 2017	<b>(b)</b> 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
9	Amounts from line 6						
	Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b	Unrelated business taxable income						
	(less section 511 taxes) from businesses						
	acquired after June 30, 1975						
	Add lines 10a and 10b Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on						
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13	Total support. (Add lines 9, 10c, 11, and 12.)						
	First 5 years. If the Form 990 is for th	ne organization's fi	rst, second, third.	fourth, or fifth tax	year as a section 5	501(c)(3) organiz	zation,
_	check this box and <b>stop here</b>	U U					·
Sec	tion C. Computation of Publi						
15	Public support percentage for 2021 (I	ine 8, column (f), c	livided by line 13,	column (f))		15	%
16	Public support percentage from 2020	Schedule A, Part	III, line 15			16	%
Sec	ction D. Computation of Inves	stment Income	e Percentage				
17	Investment income percentage for 20	<b>)21</b> (line 10c, colui	mn (f), divided by	ine 13, column (f))		17	%
18	Investment income percentage from		B			18	%
19a	33 1/3% support tests - 2021. If the	organization did r				3 1/3%, and lin	e 17 is not
	more than 33 1/3%, check this box ar	-					
b	33 1/3% support tests - 2020. If the	organization did r	not check a box o	n line 14 or line 19	a, and line 16 is mo	ore than 33 1/39	%, and
	line 18 is not more than 33 1/3%, che	ck this box and <b>s</b> f	top here. The org	anization qualifies	as a publicly suppo	orted organizati	on ►
20	Private foundation. If the organizatio						
13202	23 01-04-22					Schedu	le A (Form 990) 2021
			15	5			-

2021.04012 BRIGHTFOCUS FOUNDACOPY 191978_1


#### Part IV Supporting Organizations

(Complete only if you checked a box in line 12 on Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

#### Section A. All Supporting Organizations

- 1 Are all of the organization's supported organizations listed by name in the organization's governing documents? If "No," describe in **Part VI** how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.
- 2 Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in **Part VI** how the organization determined that the supported organization was described in section 509(a)(1) or (2).
- **3a** Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.
- **b** Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in **Part VI** when and how the organization made the determination.
- c Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.
- **4a** Was any supported organization not organized in the United States ("foreign supported organization")? *If* "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.
- **b** Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? *If* "Yes," *describe in* **Part VI** *how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.*
- **c** Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? *If* "Yes," *explain in* **Part VI** *what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.*
- 5a Did the organization add, substitute, or remove any supported organizations during the tax year? If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).
- **b** Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?
- c Substitutions only. Was the substitution the result of an event beyond the organization's control?
- 6 Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? *If "Yes," provide detail in* **Part VI.**
- 7 Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? *If* "Yes," *complete Part I of Schedule L (Form 990).*
- 8 Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? *If* "Yes." *complete Part I of Schedule L (Form 990).*
- **9a** Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If "Yes," provide detail in **Part VI.**
- **b** Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? *If* "Yes," *provide detail in* **Part VI.**
- c Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? *If* "Yes," *provide detail in* **Part VI.**
- **10a** Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? *If* "Yes," *answer line 10b below.*
- **b** Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)

132024 01-04-21



Schedule A (Form 990) 2021

2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

16

Form 990) 2021	BRIGHTFOCUS	FOUNDATION

1

2

Yes No

2a

2b

3a

3b | | Schedule A (Form 990) 2021

Pa	rt IV Supporting Organizations (continued)			
			Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?			
а	A person who directly or indirectly controls, either alone or together with persons described on lines 11b and			
	11c below, the governing body of a supported organization?	11a	ľ	
b	A family member of a person described on line 11a above?	11b		
с	A 35% controlled entity of a person described on line 11a or 11b above? If "Yes" to line 11a, 11b, or 11c, provide		ſ	
	detail in Part VI.	11c	ľ	
Sec	tion B. Type I Supporting Organizations			
			Yes	No
1	Did the governing body, members of the governing body, officers acting in their official capacity, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's officers, directors, or trustees at all times during the tax year? If "No," describe in <b>Part VI</b> how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported			

		0	
	organization, describe how the powers to appoint and/or remove officers, direct	ors, or trustees were allocated a	among the
	supported organizations and what conditions or restrictions, if any, applied to su	ch powers during the tax year.	
2	2 Did the organization operate for the benefit of any supported organization other	than the supported	
	organization(s) that operated, supervised, or controlled the supporting organization	tion? If "Yes," explain in	
	Part VI how providing such benefit carried out the purposes of the supported or	ganization(s) that operated.	

supervised, or controlled the supporting organization.

<b>3</b> e	ction C. Type in Supporting Organizations		
		Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors		
	or trustees of each of the organization's supported organization(s)? If "No," describe in Part VI how control		
	or management of the supporting organization was vested in the same persons that controlled or managed		

Se	cion D. All Type in Supporting Organizations			
			Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the			
	organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax			
	year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the			
	organization's governing documents in effect on the date of notification, to the extent not previously provided?	1	ľ	
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported			
	organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how			
	the organization maintained a close and continuous working relationship with the supported organization(s).	2		
3	By reason of the relationship described on line 2, above, did the organization's supported organizations have a			
	significant voice in the organization's investment policies and in directing the use of the organization's			
	income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization's			
	supported organizations played in this regard	3		

#### Section E. Type III Functionally Integrated Supporting Organizations

1 Check	k the box next to the r	nethod that the o	proanization used	to satisfy the	Integral Part Te	st during the vear	(see instructions).
---------	-------------------------	-------------------	-------------------	----------------	------------------	--------------------	---------------------

- a ____ The organization satisfied the Activities Test. Complete line 2 below.
- **b** The organization is the parent of each of its supported organizations. *Complete* **line 3** *below.*

С		The organization supported a governmental entity.	Describe in Part VI how	you supported a governmental entity	(see instruction <u>s).</u>
---	--	---------------------------------------------------	-------------------------	-------------------------------------	-----------------------------

2 Activities Test. Answer lines 2a and 2b below.

supported organization(s)

- **a** Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in **Part VI identify those supported organizations and explain** how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.
- b Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? *If "Yes," explain in* Part VI the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.
- 3 Parent of Supported Organizations. Answer lines 3a and 3b below.

a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? *If* "Yes" or "No" provide details in **Part VI.** 

**b** Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? *If "Yes," describe in* **Part VI** *the role played by the organization in this regard.* 

132025 01-04-22

Schedule A (F

13420803 150872 191978

2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

17

į	Schedule A	(Form	990)	202
	Dart V	Typ	<u>ااا</u> م	No

# Form 990) 2021 BRIGHTFOCUS FOUNDATION Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 Check here if the organization satisfied the Integral Part Test as a qualify	ng trust on N	lov. 20, 1970 ( <i>explain in</i>	Part VI). See instruction
All other Type III non-functionally integrated supporting organizations mu	st complete S	Sections A through E.	1
Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1 Net short-term capital gain	1		
2 Recoveries of prior-year distributions	2		
3 Other gross income (see instructions)	3		
4 Add lines 1 through 3.	4		
5 Depreciation and depletion	5		
6 Portion of operating expenses paid or incurred for production or			
collection of gross income or for management, conservation, or			
maintenance of property held for production of income (see instructions)	6		
7 Other expenses (see instructions)	7		
8 Adjusted Net Income (subtract lines 5, 6, and 7 from line 4)	8		
Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1 Aggregate fair market value of all non-exempt-use assets (see			
instructions for short tax year or assets held for part of year):			
a Average monthly value of securities	1a		
b Average monthly cash balances	1b		
c Fair market value of other non-exempt-use assets	1c		
d Total (add lines 1a, 1b, and 1c)	1d		
e Discount claimed for blockage or other factors			
(explain in detail in Part VI):			
2 Acquisition indebtedness applicable to non-exempt-use assets	2		
3 Subtract line 2 from line 1d.	3		
4 Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount,			
see instructions).	4		
5 Net value of non-exempt-use assets (subtract line 4 from line 3)	5		
6 Multiply line 5 by 0.035.	6		
7 Recoveries of prior-year distributions	7		
8 Minimum Asset Amount (add line 7 to line 6)	8		
Section C - Distributable Amount			Current Year
1 Adjusted net income for prior year (from Section A, line 8, column A)	1		
2 Enter 0.85 of line 1.	2		
3 Minimum asset amount for prior year (from Section B, line 8, column A)	3		
4 Enter greater of line 2 or line 3.	4		
5 Income tax imposed in prior year	5		
6 Distributable Amount. Subtract line 5 from line 4, unless subject to			
emergency temporary reduction (see instructions).	6		

Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see 7 instructions)

Schedule A (Form 990) 2021

132026 01-04-22

23-733722<u>9 Page 7</u>

Sche	dule A (Form 990) 2021 BRIGHTFOCUS FO			2	3-7337229	Page 7
Par	t V Type III Non-Functionally Integrated 509(	a)(3) Supporting Orga	nizations (continu	ied)		
Sect	on D - Distributions				Current Yea	ar
_1	Amounts paid to supported organizations to accomplish exer	mpt purposes		1		
2	Amounts paid to perform activity that directly furthers exemp	t purposes of supported				
	organizations, in excess of income from activity		2			
3	Administrative expenses paid to accomplish exempt purpose	es of supported organizations	3	3		
4	Amounts paid to acquire exempt-use assets			4		
5	Qualified set-aside amounts (prior IRS approval required - pro	ovide details in Part VI)		5		
6	Other distributions ( <i>describe in</i> <b>Part VI</b> ). See instructions.			6		
7	Total annual distributions. Add lines 1 through 6.			7		
8	Distributions to attentive supported organizations to which the	e organization is responsive				
	(provide details in Part VI). See instructions.			8		
9	Distributable amount for 2021 from Section C, line 6			9		
10	Line 8 amount divided by line 9 amount	ſ	1	10		
Sect	on E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistribution Pre-2021	IS	(iii) Distributabl Amount for 20	
1	Distributable amount for 2021 from Section C, line 6					
2	Underdistributions, if any, for years prior to 2021 (reason-					
	able cause required - explain in Part VI). See instructions.					
3	Excess distributions carryover, if any, to 2021					
а	From 2016					
b	From 2017					
с	From 2018					
d	From 2019					
е	From 2020					
f	Total of lines 3a through 3e					
g	Applied to underdistributions of prior years					
h	Applied to 2021 distributable amount					
i	Carryover from 2016 not applied (see instructions)					
j	Remainder. Subtract lines 3g, 3h, and 3i from line 3f.					
4	Distributions for 2021 from Section D,					
	line 7: \$					
а	Applied to underdistributions of prior years					
b	Applied to 2021 distributable amount					
с	Remainder. Subtract lines 4a and 4b from line 4.					
5	Remaining underdistributions for years prior to 2021, if					
	any. Subtract lines 3g and 4a from line 2. For result greater					
	than zero, explain in Part VI. See instructions.					
6	Remaining underdistributions for 2021. Subtract lines 3h					
	and 4b from line 1. For result greater than zero, explain in					
	Part VI. See instructions.					
7	Excess distributions carryover to 2022. Add lines 3j					
	and 4c.					
8	Breakdown of line 7:					
а	Excess from 2017					
	Excess from 2018					
	Excess from 2019					
	Excess from 2020					
	Excess from 2021					

Schedule A (Form 990) 2021

Part VI Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions.)

#### SCHEDULE A, PART II, LINE 10, EXPLANATION FOR OTHER INCOME:

#### SAVINGS BOND PAYOUT

2021 AMOUNT: \$ 7,500.

Schedule A (Form 990) 2021

20 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

13420803 150872 191978

## Schedule B

(Form 990)

Department of the Treasury Internal Revenue Service

Name of the organization

** PUBLIC DISCLOSURE COPY **

## Schedule of Contributors

► Attach to Form 990 or Form 990-PF. Go to www.irs.gov/Form990 for the latest information. OMB No. 1545-0047

2021

Employer identification number

23-73372	29
----------	----

ne or the organizatio		
	BRIGHTFOCUS	FOUNDATION

Organization type (check one):					
Filers of:	Section:				
Form 990 or 990-EZ	X 501(c)( 3) (enter number) organization				
	4947(a)(1) nonexempt charitable trust <b>not</b> treated as a private foundation				
	527 political organization				
Form 990-PF	501(c)(3) exempt private foundation				
	4947(a)(1) nonexempt charitable trust treated as a private foundation				
	501(c)(3) taxable private foundation				

Check if your organization is covered by the **General Rule** or a **Special Rule**. **Note:** Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

#### **General Rule**

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling \$5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

#### **Special Rules**

X For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) \$5,000; or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than \$1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than \$1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the **General Rule** applies to this organization because it received *nonexclusively* religious, charitable, etc., contributions totaling \$5,000 or more during the year  $\dots \longrightarrow$ 

**Caution:** An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it **must** answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

LHA For Paperwork Reduction Act Notice, see the instructions for Form 990, 990-EZ, or 990-PF.

Schedule B (Form 990) (2021)



#### Schedule B (Form 990) (2021)

BRIGHTFOCUS FOUNDATION

Name of organization

Employer identification number

23-7337229

#### Part I **Contributors** (see instructions). Use duplicate copies of Part I if additional space is needed. (a) (d) (b) (c) No. Name, address, and ZIP + 4 **Total contributions** Type of contribution 1 X Person Payroll 1,003,346. Noncash \$ (Complete Part II for noncash contributions.) (a) (b) (c) (d) Type of contribution No. Name, address, and ZIP + 4 **Total contributions** 2 X Person Payroll 1,000,000. Noncash \$ (Complete Part II for noncash contributions.) (a) (b) (c) (d) Name, address, and ZIP + 4 **Total contributions** Type of contribution No. 3 X Person Payroll 961,432. Noncash \$ (Complete Part II for noncash contributions.) (a) (b) (c) (d) Name, address, and ZIP + 4 **Total contributions** Type of contribution No. Person Payroll Noncash \$ (Complete Part II for noncash contributions.) (a) (b) (c) (d) No. Name, address, and ZIP + 4 **Total contributions** Type of contribution Person Payroll Noncash (Complete Part II for noncash contributions.) (c) (d) (a) (b) **Total contributions** No. Name, address, and ZIP + 4 Type of contribution Person Payroll Noncash \$ (Complete Part II for noncash contributions.)

Schedule B (Form 990) (2021)

123452 11-11-21

10110804 150872 191978

3 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

Page 2

Schedule	В	(Form	990)	(2021)
----------	---	-------	------	--------

Name of organization

Page 3

Employer identification number

23-7337229

BRIGHTFOCUS FOUNDATION

Part II Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		\$	

10110804 150872 191978

Schedule E	B (Form 990) (2021)			Page 4			
Name of o	rganization			Employer identification number			
BRTGH	IFOCUS FOUNDATION			23-7337229			
Part III	Exclusively religious, charitable, etc., contribut from any one contributor. Complete columns (i completing Part III, enter the total of exclusively religious, Use duplicate copies of Part III if additional	a) through (e) and the following line en charitable, etc., contributions of \$1,000 or	try. For organizations	at total more than \$1,000 for the year			
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Desc	ription of how gift is held			
-		(e) Transfer of git	 it				
-	Transferee's name, address, a	and ZIP + 4	Relationship of tra	nsferor to transferee			
(a) No. from		[					
from Part I	(b) Purpose of gift	(c) Use of gift	(d) Desc	ription of how gift is held			
	(e) Transfer of gift						
-	Transferee's name, address, a	and ZIP + 4	Relationship of trai	nsferor to transferee			
(a) No. from	(b) Purpose of gift	(c) Use of gift	(d) Desc	ription of how gift is held			
Part I							
-		(e) Transfer of git					
-	Transferee's name, address, a	and ZIP + 4	Relationship of tra	nsferor to transferee			
(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Desc	ription of how gift is held			
-		(e) Transfer of gif	it				
-	Transferee's name, address, a	and ZIP + 4	Relationship of trai	nsferor to transferee			

Schedule B (Form 990) (2021)

10110804 150872 191978

SCHEDULE C	Po	litical Campaign	and Lobbyin	g Activities	OMB No. 1545-0047
(Form 990)					2021
	-	if the organization is described			
Department of the Treasury Internal Revenue Service	EZ. Open to Public Inspection				
If the organization answ	wered "Yes," on	Form 990, Part IV, line 3, or Fo	rm 990-EZ, Part V, lin	e 46 (Political Campaigr	Activities), then
<ul> <li>Section 501(c)(3) org</li> </ul>	anizations: Com	plete Parts I-A and B. Do not cor	nplete Part I-C.		
		1(c)(3)) organizations: Complete	Parts I-A and C below.	Do not complete Part I-B.	
<ul> <li>Section 527 organization</li> </ul>		,			
-		Form 990, Part IV, line 4, or Fo			
		nave filed Form 5768 (election un		•	•
	•	nave NOT filed Form 5768 (election Form 990, Part IV, line 5 (Prox	•		•
Tax) (See separate inst		Form 990, Part IV, line 5 (Frox)	y Tax) (See Separate I		-EZ, Part V, Inte SSC (Proxy
<i>,</i> , ,		ions: Complete Part III.			
Name of organization	, (, <b>U</b>	I		Em	ployer identification number
		OCUS FOUNDATION			23-7337229
Part I-A Comple	ete if the org	anization is exempt unde	er section 501(c) o	or is a section 527 o	rganization.
1 Provide a description	on of the organiz	ation's direct and indirect politica	al campaign activities ir	n Part IV.	
2 Political campaign	activity expendit	ures		►	\$
3 Volunteer hours for	political campai	gn activities			
Part I-B Comple	ete if the ora	anization is exempt unde	er section 501(c)(3	3).	
-		incurred by the organization unde			\$
		incurred by organization manage			
		n 4955 tax, did it file Form 4720 f			
		·			
b If "Yes," describe ir	n Part IV.				
Part I-C Comple	ete if the org	anization is exempt unde	er section 501(c),	except section 501	(c)(3).
1 Enter the amount d	irectly expended	by the filing organization for sec	tion 527 exempt functi	ion activities	\$
2 Enter the amount o	f the filing organ	ization's funds contributed to oth	er organizations for se	ction 527	
exempt function ac					\$
-	-	. Add lines 1 and 2. Enter here ar			
					\$
		<b>1120-POL</b> for this year?			
		ployer identification number (EIN ion listed, enter the amount paid			
		omptly and directly delivered to a			
		additional space is needed, provi		, ,	
(a) Name		(b) Address	(c) EIN	(d) Amount paid from	(e) Amount of political
(4) (4)			(0) =	filing organization's	contributions received and
				funds. If none, enter -0	- promptly and directly delivered to a separate
					political organization.
					If none, enter -0
			-		
			+		
			+		
For Paperwork Beduct	ion Act Notice	see the Instructions for Form 9	90 or 990-EZ	1	Schedule C (Form 990) 2021

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ. LHA

Schedule C (Form 990) 2021

132041 11-03-21

Schedule C (Form 990) 2021	BRIGHTFOCUS	FOUNDATION			337229 Page 2
Part II-A Complete if the org section 501(h)).	anization is exen	npt under section	1 501(c)(3) and file	ed Form 5768 (ele	ction under
	ation belongs to an affil	iated group (and list in	Part IV each affiliated	group member's name	, address, EIN,
expenses, and sha	re of excess lobbying e	expenditures).			
B Check 🕨 🔄 if the filing organiza	ation checked box A ar	d "limited control" pro	visions apply.		
	its on Lobbying Exper ditures" means amou			<b>(a)</b> Filing organization's totals	<b>(b)</b> Affiliated group totals
<b>1a</b> Total lobbying expenditures to infl	uence public opinion (g	grassroots lobbying)		0.	
<b>b</b> Total lobbying expenditures to infl	uence a legislative bod	y (direct lobbying)		0.	
c Total lobbying expenditures (add l	ines 1a and 1b)			0.	
d Other exempt purpose expenditur				<u>53,259,153.</u>	
e Total exempt purpose expenditure	es (add lines 1c and 1d)	)		53,259,153.	
f Lobbying nontaxable amount. Ent	er the amount from the	following table in both	n columns.	1,000,000.	
If the amount on line 1e, column (a) of		bying nontaxable amo	ount is:		
Not over \$500,000		the amount on line 1e.			
Over \$500,000 but not over \$1,00		0 plus 15% of the exce			
Over \$1,000,000 but not over \$1,5		0 plus 10% of the exce			
Over \$1,500,000 but not over \$17	, , , , , , , , , , , , , , , , , , ,	0 plus 5% of the exces	ss over \$1,500,000.		
Over \$17,000,000	\$1,000,0	J00.			
g Grassroots nontaxable amount (er	nter 25% of line 1f)			250,000.	
h Subtract line 1g from line 1a. If zer	,			0.	
i Subtract line 1f from line 1c. If zero	, , , , ,			0.	
j If there is an amount other than ze					
reporting section 4911 tax for this	year?				Yes No
	4-Year Ave	raging Period Under	Section 501(h)		
(Some organizations t		• •		of the five columns be	low.
	•	ate instructions for lin	• •		
	Lobbying Exper	nditures During 4-Yea	r Averaging Period	1	
Calendar year (or fiscal year beginning in)	<b>(a)</b> 2018	<b>(b)</b> 2019	(c) 2020	<b>(d)</b> 2021	<b>(e)</b> Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
<ul> <li>b Lobbying ceiling amount (150% of line 2a, column(e))</li> </ul>					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount	23070001	230,000	230,000	230,0001	1,000,000
(150% of line 2d, column (e))					1,500,000.
<u>.                                </u>					<b>-</b>
f Grassroots lobbying expenditures					
				Schedu	le C (Form 990) 2021

# Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description		(a)		(b)	
	e lobbying activity.	Yes	No	Amount	
1 a	During the year, did the filing organization attempt to influence foreign, national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of: Volunteers?				
b c	Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? Media advertisements?				
d	Mailings to members, legislators, or the public?				
	Publications, or published or broadcast statements?				
f	Grants to other organizations for lobbying purposes?				
g	Direct contact with legislators, their staffs, government officials, or a legislative body?				
h	Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?				
	Other activities?				
j	Total. Add lines 1c through 1i				
2a	Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?				
	If "Yes," enter the amount of any tax incurred under section 4912				
С	If "Yes," enter the amount of any tax incurred by organization managers under section 4912				
	If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?				
Par	t III-A Complete if the organization is exempt under section 501(c)(4), section	n 501(c)(5),	, or sec	tion	
	501(c)(6).				
				Yes	No
1	Were substantially all (90% or more) dues received nondeductible by members?				
2	Did the organization make only in-house lobbying expenditures of \$2,000 or less?		. 2		
3	Did the organization agree to carry over lobbying and political campaign activity expenditures from the		3		
Par	t III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered ' answered "Yes."				3, is
1	Dues, assessments and similar amounts from members		1		
2	Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of politic				
	expenses for which the section 527(f) tax was paid).				
а	Current year		2a		
	Carryover from last year		2b		
	Total		2c		
3			3		
4	If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the exce				
	does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and po				
	expenditure next year?		4		
5	Taxable amount of lobbying and political expenditures. See instructions		. 5		
Par	t IV Supplemental Information				
Prov	de the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group	list); Part II-A,	lines 1 a	nd 2 (See	

instructions); and Part II-B, line 1. Also, complete this part for any additional information.

Schedule C (Form 990) 2021

132043 11-03-21

SCHEDULE	D
----------	---

Department of the Treasury

### **Supplemental Financial Statements**

Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b. Attach to Form 990. OMB No. 1545-0047

Internal Revenue Service Name of the organization

Go to www.irs.gov/Form990 for	instructions and the latest information.								

Employer identification number

_	BRIGHTFOCUS FOUNDAT		23-7337229
Par			ccounts. Complete if the
	organization answered "Yes" on Form 990, Part IV, lin	e 6.	
		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year		
2	Aggregate value of contributions to (during year)		
3	Aggregate value of grants from (during year)		
4	Aggregate value at end of year		
5	Did the organization inform all donors and donor advisors in v	writing that the assets held in donor advised fur	nds
	are the organization's property, subject to the organization's	exclusive legal control?	YesNo
6	Did the organization inform all grantees, donors, and donor a	dvisors in writing that grant funds can be used o	only
	for charitable purposes and not for the benefit of the donor of	r donor advisor, or for any other purpose confer	ring
	impermissible private benefit?		
Par	t II Conservation Easements. Complete if the org	ganization answered "Yes" on Form 990, Part IV	/, line 7.
1	Purpose(s) of conservation easements held by the organization	on (check all that apply).	
	Preservation of land for public use (for example, recrea	tion or education) Preservation of a hist	torically important land area
	Protection of natural habitat	Preservation of a cer	tified historic structure
	Preservation of open space		
2	Complete lines 2a through 2d if the organization held a qualif	ied conservation contribution in the form of a co	onservation easement on the last
	day of the tax year.		Held at the End of the Tax Year
а	Total number of conservation easements		2a
b	Total acreage restricted by conservation easements		2b
с	Number of conservation easements on a certified historic stru	ucture included in (a)	2c
d	Number of conservation easements included in (c) acquired a	fter 7/25/06, and not on a historic structure	
	listed in the National Register		2d
3	Number of conservation easements modified, transferred, rele	eased, extinguished, or terminated by the orgar	nization during the tax
	year ▶		
4	Number of states where property subject to conservation eas	ement is located	
5	Does the organization have a written policy regarding the per	iodic monitoring, inspection, handling of	
	violations, and enforcement of the conservation easements it	holds?	Yes No
6	Staff and volunteer hours devoted to monitoring, inspecting,	handling of violations, and enforcing conservati	on easements during the year
	▶		
7	Amount of expenses incurred in monitoring, inspecting, hand	ling of violations, and enforcing conservation ea	asements during the year
	►\$		
8	Does each conservation easement reported on line 2(d) above	e satisfy the requirements of section 170(h)(4)(B	3)(i)
	and section 170(h)(4)(B)(ii)?		
9	In Part XIII, describe how the organization reports conservation	on easements in its revenue and expense stater	ment and
	balance sheet, and include, if applicable, the text of the footn	ote to the organization's financial statements th	nat describes the
	organization's accounting for conservation easements.		
Par			Similar Assets.
	Complete if the organization answered "Yes" on Form	990, Part IV, line 8.	
1a	If the organization elected, as permitted under FASB ASC 95	8, not to report in its revenue statement and ba	lance sheet works
	of art, historical treasures, or other similar assets held for pub	lic exhibition, education, or research in furthera	nce of public
	service, provide in Part XIII the text of the footnote to its finan	icial statements that describes these items.	
b	If the organization elected, as permitted under FASB ASC 95	8, to report in its revenue statement and balanc	e sheet works of
	art, historical treasures, or other similar assets held for public	exhibition, education, or research in furtherance	e of public service,
	provide the following amounts relating to these items:		
	(i) Revenue included on Form 990, Part VIII, line 1		► \$
	(ii) Assets included in Form 990, Part X		
2	If the organization received or held works of art, historical treat	asures, or other similar assets for financial gain,	provide
	the following amounts required to be reported under FASB A	SC 958 relating to these items:	
а	Revenue included on Form 990, Part VIII, line 1		▶ \$
b	Assets included in Form 990, Part X		. 🕨 \$
LHA	For Paperwork Reduction Act Notice, see the Instructions	for Form 990.	Schedule D (Form 990) 2021
132051	10-28-21		

29		
2021.04012	BRIGHTFOCUS	FOUNDATION

Sche		OCUS FOUNDA					23-73			_{age} 2
Pai	t III Organizations Maintaining C	ollections of Art	, Historical Tre	easures, or Of	ther S	imilar	Assets	<b>i</b> (contir	nued)	
3	Using the organization's acquisition, accession	on, and other records	s, check any of the	following that mal	ke signit	ficant u	ise of its			
	collection items (check all that apply):									
а	Public exhibition	d	Loan or exc	change program						
b	Scholarly research	е	Other							
с	Preservation for future generations									
4	Provide a description of the organization's co	llections and explain	how they further t	he organization's	exempt	purpos	se in Part	XIII.		
5	During the year, did the organization solicit or									
	to be sold to raise funds rather than to be ma	intained as part of th	e organization's co	llection?				Yes		No
Pa	t IV Escrow and Custodial Arrang	gements. Comple	te if the organizatio	on answered "Yes	on Fo	rm 990	, Part IV,	line 9, or		
	reported an amount on Form 990, Par		-							
1a	Is the organization an agent, trustee, custodia	an or other intermedi	ary for contribution	s or other assets	not incl	uded				
	on Form 990, Part X?						🗆	Yes		No
b	If "Yes," explain the arrangement in Part XIII a									
								Amoun	t	
с	Beginning balance					1c				
d	Additions during the year					1d				
е	Distributions during the year					1e				
f	Ending balance					1f				
2a	Did the organization include an amount on Fo	orm 990, Part X, line	21, for escrow or c	ustodial account l	iability?		L	Yes		No
	If "Yes," explain the arrangement in Part XIII.									
Pai	<b>t V</b> Endowment Funds. Complete in			, , ,				_		
	-	(a) Current year	(b) Prior year	(c) Two years ba			ears back	(e) Fou	-	
1a	Beginning of year balance	302,000.	302,000.	,			20,000.			000.
b	Contributions	36,634.	14,744.	14,77	78.		14,385.			806.
С	Net investment earnings, gains, and losses	23,000.				-	18,000.		10,	000.
d	Grants or scholarships									
е	Other expenditures for facilities									
	and programs	36,634.	14,744.	14,77	78.		14,385.		14,	806.
f	Administrative expenses									
g	End of year balance	325,000.	302,000.	302,00	00.	3	02,000.		320,	000.
2	Provide the estimated percentage of the curre	ent year end balance	e (line 1g, column (a	l)) held as:						
а	Board designated or quasi-endowment	.0000	_%							
b	Permanent endowment  100	%								
с	Term endowment ► .0000 g	%								
	The percentages on lines 2a, 2b, and 2c should be a should be should be a should be a should be a should be should be a should	uld equal 100%.								
3a	Are there endowment funds not in the posses	ssion of the organiza	tion that are held a	nd administered f	or the o	rganiza	ition			
	by:								Yes	No
	(i) Unrelated organizations							3a(i)	Х	
	(ii) Related organizations							3a(ii)		X
b	If "Yes" on line 3a(ii), are the related organization							3b		
4	Describe in Part XIII the intended uses of the		vment funds.							
Pa	<b>t VI</b> Land, Buildings, and Equipm		David IV / line 11a (			10				
	Complete if the organization answered									
	Description of property	(a) Cost or of	• • •		c) Accu		d	<b>(d)</b> Boo	k valu	е
		basis (investm	,	(other)	depree	Giacion		3,94	7 2	62
	Land	4 600		7,363.	2 0 4	2 6				
	Buildings		±00• 5,27	1,548.	3,84	3,04	±3•	3,05	1,3	03.
	Leasehold improvements		1	0 721	<b></b>	E 4/		1 1 1	1 0	6.2
	Equipment			9,731.		$\frac{5,46}{4}$		1,11	-	
	Other			.6,753.		4,50			$\frac{2,1}{1,1}$	
Tota	I <b>.</b> Add lines 1a through 1e. <i>(Column (d) must ed</i>	qual Form 990, Part )	K <u>. column (B). line 1</u>	0c.)			- · ·	8,16	-	
							Schedule	D (Forn	n 990)	2021

	(Form 990) 2021	BRIGHTFOCUS	FOUNDATION
Part VII	Investments -	Other Securities.	

Complete if the organization answered "Yes" or	n Form 990, Part IV, line	-	
(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-c	f-year market value
(1) Financial derivatives			
(2) Closely held equity interests			
(3) Other			
(A)			
(B)			
(C)			
(D)			
(E)			
(F)			
(G)			
(H)			
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 12.)			
Part VIII Investments - Program Related.			
Complete if the organization answered "Yes" or	n Form 990. Part IV. line	11c. See Form 990. Part X. line 13.	
(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-o	f-vear market value
	(2) 200. 14100		
(1)			
(2)			
(3)			
(4)			
(5)			
(6)			
(7)			
(8)			
(9)			
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 13.)			
Part IX Other Assets.			
Complete if the organization answered "Yes" or		11d. See Form 990, Part X, line 15.	
(a) D	Description		(b) Book value
(1)			
(2)			
(3)			
(4)			
(5)			
(6)			
(7)			
		· · · · · · · · · · · · · · · · · · ·	
(8)			
(8)			
(9)	15)		
(9)	15.)		
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities.			
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" of (b) Descriptions of light it			( <b>b)</b> Book value
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" of 1. (a) Description of liability			<b>(b)</b> Book value
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" of 1. (a) Description of liability (1) Federal income taxes			
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" of 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS (5)			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" of (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS (5) (6)			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS (5) (6) (7)			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS (5) (6) (7) (8)			756,074
(9) Total. (Column (b) must equal Form 990, Part X, col. (B) line Part X Other Liabilities. Complete if the organization answered "Yes" or 1. (a) Description of liability (1) Federal income taxes (2) CHARITABLE GIFT ANNUITIES (3) RENTAL DEPOSITS (4) CAPITAL LEASE OBLIGATIONS (5) (6) (7)	n Form 990, Part IV, line	11e or 11f. See Form 990, Part X, line 25.	756,074

organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII .... X

Schedule D (Form 990) 2021

132053 10-28-21

_	edule D (Form 990) 2021 BRIGHTFOCUS FOUNDATION				/33/229 Page 4
Pa	rt XI Reconciliation of Revenue per Audited Financial Stateme	ents Wit	th Revenue per Re	turn.	
	Complete if the organization answered "Yes" on Form 990, Part IV, line 12	a.			
1	Total revenue, gains, and other support per audited financial statements			1	61,811,216.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:				
а	Net unrealized gains (losses) on investments	2a			
b	Donated services and use of facilities	2b	12,439,938.	1	
с	Recoveries of prior year grants	2c	528,609.	1	
d	Other (Describe in Part XIII.)	2d			
е	Add lines 2a through 2d			2e	11,362,737.
3	Subtract line 2e from line 1			3	50,448,479.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:				
а	Investment expenses not included on Form 990, Part VIII, line 7b	4a	351,028.		
b	Other (Describe in Part XIII.)	4b	-41,779.		
	Add lines <b>4a</b> and <b>4b</b>			4c	309,249.
с					
5	Total revenue. Add lines <b>3</b> and <b>4c.</b> (This must equal Form 990. Part I. line 12.)			5	50,757,728.
5			ith Expenses per I		<u>50,757,728.</u> n.
5	Total revenue. Add lines 3 and 4c. ( <i>This must equal Form 990. Part I, line 12.</i> ) <b>t XII</b> Reconciliation of Expenses per Audited Financial Statem Complete if the organization answered "Yes" on Form 990, Part IV, line 12:	n <b>ents W</b> a.	ith Expenses per I		n.
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) rt XII Reconciliation of Expenses per Audited Financial Statem	n <b>ents W</b> a.	ith Expenses per I		50,757,728. n. 65,826,058.
5 Pa	Total revenue. Add lines 3 and 4c. ( <i>This must equal Form 990. Part I, line 12.</i> ) <b>t XII</b> Reconciliation of Expenses per Audited Financial Statem Complete if the organization answered "Yes" on Form 990, Part IV, line 12:	nents W a.	ith Expenses per I	Retur	n.
5 Pa	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) <b>t XII</b> Reconciliation of Expenses per Audited Financial Statem Complete if the organization answered "Yes" on Form 990, Part IV, line 12: Total expenses and losses per audited financial statements	nents W a.	ith Expenses per I	Retur	n.
5 Pa 1 2	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:	a. 2a	ith Expenses per I	Retur	n.
5 Pa 1 2	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities	nents W a. 2a 2b	ith Expenses per I	Retur	n.
5 Pa 1 2 a b	Total revenue. Add lines 3 and 4c. (This must equal Form 990. Part I. line 12.) <b>t XII</b> Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments	nents W a. 2a 2b 2c	ith Expenses per I	Retur	n. 65,826,058.
5 Pa 1 2 a b c d	Total revenue. Add lines 3 and 4c. (This must equal Form 990. Part I, line 12.) <b>Reconciliation of Expenses per Audited Financial Statem</b> Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses	nents W a. 2a 2b 2c 2d	ith Expenses per I	Retur	n. 65,826,058. 12,439,938.
5 Pa 1 2 a b c d	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)         Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12.         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments       Other losses         Other (Describe in Part XIII.)       Add lines 2a through 2d	nents W a. 2a 2b 2c 2d	ith Expenses per I	Retur	n. 65,826,058.
5 Par 1 2 a b c d e	Total revenue. Add lines 3 and 4c. (This must equal Form 990. Part I. line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses         Other (Describe in Part XIII.)	nents W a. 2a 2b 2c 2d	ith Expenses per I	Retur	n. 65,826,058. 12,439,938.
5 Par 1 2 a b c d e 3	Total revenue. Add lines 3 and 4c. (This must equal Form 990. Part I. line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses         Other (Describe in Part XIII.)         Add lines 2a through 2d         Subtract line 2e from line 1	nents W a. 2a 2b 2c 2d	ith Expenses per I 12,439,938. 351,028.	Retur	n. 65,826,058. 12,439,938.
5 Par 1 2 a b c d e 3 4	Total revenue. Add lines 3 and 4c. (This must equal Form 990. Part I, line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12:         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses         Other (Describe in Part XIII.)         Add lines 2a through 2d         Subtract line 2e from line 1         Amounts included on Form 990, Part IX, line 25, but not on line 1:	nents W a. 2a 2b 2c 2d	ith Expenses per I	Retur	n. 65,826,058. 12,439,938. 53,386,120.
5 Par 1 2 a b c d e 3 4	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) <b>Reconciliation of Expenses per Audited Financial Statem</b> Complete if the organization answered "Yes" on Form 990, Part IV, line 12.         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses         Other (Describe in Part XIII.)         Add lines 2a through 2d         Subtract line 2e from line 1         Amounts included on Form 990, Part IX, line 25, but not on line 1:         Investment expenses not included on Form 990, Part VIII, line 7b	nents W a. 2a 2b 2c 2d  2d	ith Expenses per F 12,439,938. 351,028. 320,209.	Retur	n. 65,826,058. 12,439,938. 53,386,120. 671,237.
5 Pa 1 2 a b c d e 3 4 a b c 5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.)         rt XII         Reconciliation of Expenses per Audited Financial Statem         Complete if the organization answered "Yes" on Form 990, Part IV, line 12.         Total expenses and losses per audited financial statements         Amounts included on line 1 but not on Form 990, Part IX, line 25:         Donated services and use of facilities         Prior year adjustments         Other losses         Other (Describe in Part XIII.)         Add lines 2a through 2d         Subtract line 2e from line 1         Amounts included on Form 990, Part IX, line 25, but not on line 1:         Investment expenses not included on Form 990, Part VIII, line 7b         Other (Describe in Part XIII.)	nents W a. 2a 2b 2c 2d  2d	ith Expenses per F 12,439,938. 351,028. 320,209.	Retur	n. 65,826,058. 12,439,938. 53,386,120.

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

#### PART V, LINE 4:

THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE

RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT

INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:

BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE

YEAR ENDED MARCH 31, 2022, AND DETERMINED THAT THERE WERE NO MATTERS THAT

WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT

32

MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XI, LINE 4B - OTHER ADJUSTMENTS:

132054 10-28-21

Schedule D (Form 990) 2021

Schedule D (Form 990) 2021         BRIGHTFOCUS         FOUNDATION           Part XIII         Supplemental Information (continued)         FOUNDATION	23-7337229 Page 5
DEPRECIATION OF RENTAL PROPERTY	-41,779.
PART XII, LINE 4B - OTHER ADJUSTMENTS:	
DEPRECIATION ON RENTAL PROPERTY	-41,779.
CHANGE IN PRESENT VALUE OF GRANTS	361,988.
TOTAL TO SCHEDULE D, PART XII, LINE 4B	320,209.
132055 10-28-21	Schedule D (Form 990) 2021

(Form 990)	Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15,					2021
Department of the Treasury	Co to	www.irc.gov/Ec	Attach to Form 990.	information		Open to Public Inspection
Internal Revenue Service Name of the organization	GO 10	www.irs.gov/Fd	rm990 for instructions and the latest	information.	Employer	identification number
Ū.						
BRIGHTFOCUS FO					23-73	
		ctivities Out	side the United States. Comple	te if the organ	nization answ	vered "Yes" on
Form 990, Par <b>1 For grantmakers.</b> Do	•	n maintain record	ds to substantiate the amount of its grar	ate and other	assistance	
•	•		the selection criteria used to award the g		-	X Yes 🗌 No
2 For grantmakers. De United States.	scribe in Part V the	e organization's	procedures for monitoring the use of its	grants and ot	her assistan	ce outside the
3 Activities per Region.	(The following Parl	I, line 3 table ca	an be duplicated if additional space is ne	eeded.)		
(a) Region	(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in the region (by type) (such as, fundraising, pro- gram services, investments, grants to recipients located in the region)	is a pro describe	vity listed in gram service specific typ e(s) in the reg	e, expenditures for and investments
EAST ASIA AND THE						
PACIFIC	0	0	GRANTMAKING			347,083.
EUROPE	0	0	GRANTMAKING			3,167,829.
MIDDLE EAST AND						
NORTH AFRICA -						
ALGERIA, BAHRAIN, DJIBOUTI, EGYPT,	0	0	GRANTMAKING			600,000.
NORTH AMERICA -						
CANADA AND MEXICO,						
BUT NOT THE UNITED						
STATES	0	0	GRANTMAKING			1,343,047.
3 a Subtotal		0				5,457,959.
b Total from continuation sheets to Part I		0				0.
c Totals (add lines 3a and 3b)	0	0				5,457,959.

**Statement of Activities Outside the United States** 

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule F (Form 990) 2021

OMB No. 1545-0047

132071 12-20-21

SCHEDULE F (Form 990)

Part II Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than \$5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	<b>(f)</b> Manner of cash disbursement	<b>(g)</b> Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FM\ appraisal, other)
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY LAIA					
		ICELAND &	MONTOLIU-GAYA, PHD,					
		GREENLAND)	ENTITLED: (A2022015F)	200,000.	WIRE TRANSFER	0.		
			ALZHEIMER'S DISEASE					
			RES. BY CHRISTOPHER					
			MORRONE, PHD,					
		NORTH AMERICA	ENTITLED: (A2022016F)	200,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE	,				
		EUROPE (INCLUDING	RESEARCH BY SANDRA O.					
		ICELAND &	TOME, PHD, ENTITLED:					
		GREENLAND)	(A2022019F)	200,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
			RESEARCH BY KRISTIE					
		EAST ASIA AND THE	STEFANOSKA, PHD,					
		PACIFIC	ENTITLED: (A2022022F)	199,034.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY LARISSA					
		ICELAND &	TRAXLER, PHD,					
		GREENLAND)	ENTITLED: (A2022024F)	200,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
			RESEARCH BY URI					
		MIDDLE EAST AND	ASHERY, PHD,					
		NORTH AFRICA	ENTITLED: (A2022029S)	300,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY SAMUEL					
		ICELAND &	BARNES, PHD,					
		GREENLAND)	ENTITLED: (A2022030S)	299,715.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RES. BY MARTA					
		ICELAND &	CORTES-CANTELI, PHD,					
		GREENLAND)	ENTITLED: (A2022034S)	300,000.	WIRE TRANSFER	٥.		
2 Enter total number of	recipient organization	ns listed above that are r	ecognized as charities by the t	oreign country. I	recognized as a tax			•
			or counsel has provided a sect		-	▶		22
3 Enter total number of	•	-	•			► _		(

See Schedule O for continuation of Grant Purposes, item (d)



Schedule F (Form 990)

BRIGHTFOCUS FOUNDATION

23-7337229

Page **2** 

		110000 100MD			20 / 0	0,222		Tage Z
Part II Continuation	n of Grants and Other	Assistance to Organiza	tions or Entities Outside the	United States.	(Schedule F (Form 9	90), Part II, line 1		1
1 (a) Name of organizatio	n (b) IRS code section and EIN (if applicable)		<b>(d)</b> Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FM\ appraisal, other)
			-			23313121100	23515121100	
			ALZHEIMER'S DISEASE					
			RESEARCH BY YUVAL					
		MIDDLE EAST AND	DOR, PHD, ENTITLED:					
		NORTH AFRICA	(A2022035S)	300,000.	WIRE TRANSFER	0.		
			ALZHEIMER'S DISEASE					
			RESEARCH BY SUE-ANN					
			MOK, PHD, ENTITLED:					
		NORTH AMERICA	(A2022044S)	299,851.	WIRE TRANSFER	0.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY DOMINIK					
		ICELAND &	PAQUET, PHD,					
		GREENLAND)	ENTITLED: (A2022045S)	300,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
			RESEARCH BY CARLOS					
			RONCERO, PHD,					
		NORTH AMERICA	ENTITLED: (A2022046S)	243,196.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY CARLOS					
		ICELAND &	SAURA, PHD, ENTITLED:					
		GREENLAND)	(A2022047S)	300,000.	WIRE TRANSFER	٥.		
			ALZHEIMER'S DISEASE					
		EUROPE (INCLUDING	RESEARCH BY DR.					
		ICELAND &	GAELLE CHETELAT					
		GREENLAND)	ENTITLED: (CA2021013)	68,278.	WIRE TRANSFER	0.		
			NATIONAL GLAUCOMA	,				
			RES. BY EMMANUELLE					
		EAST ASIA AND THE						
		PACIFIC	ENTITLED: (G2022002F)	148 049.	WIRE TRANSFER	0.		
			NATIONAL GLAUCOMA					
		EUROPE (INCLUDING	RESEARCH BY MARCO					
		ICELAND &	FELIGIONI, PHD,					
		GREENLAND)	ENTITLED: (G2022015S)	200 000	WIRE TRANSFER	0.		
			MACULAR DEGENERATION	200,000.				
		EUROPE (INCLUDING	RESEARCH BY NICOLE					
		ICELAND &	NOEL, PHD, ENTITLED:	100 000				
		GREENLAND)	(M2022002F)	таа, аа8.	WIRE TRANSFER	0.		

See Schedule O for continuation of Grant Purposes, item (d)

Schedule F (Form 990)	BRIGH	TFOCUS FOUND	ATION		23-73	37229		Page <b>2</b>
Part II Continuation o	f Grants and Other	Assistance to Organiza	tions or Entities Outside the	United States.	(Schedule F (Form 9	90), Part II, line 1	)	
<b>1</b> (a) Name of organization	<b>(b)</b> IRS code section and EIN (if applicable)	(c) Region	<b>(d)</b> Purpose of grant	<b>(e)</b> Amount of cash grant	(f) Manner of cash disbursement	<b>(g)</b> Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND &	MACULAR DEGENERATION RESEARCH BY LUCIA CELKOVA, PHD,					
		GREENLAND)	ENTITLED: (M2022004F)	200,000.	WIRE TRANSFER	Ο.		
			MACULAR DEGENERATION					
		EUROPE (INCLUDING ICELAND &	RESEARCH BY YARA LECHANTEUR, MD, PHD,					
		GREENLAND)	ENTITLED: (M2022013N)	449,838.	WIRE TRANSFER	Ο.		
			MACULAR DEGENERATION	,				
			RES. BY PRZEMYSLAW					
			SAPIEHA, PHD,					
		NORTH AMERICA	ENTITLED: (M2022015I)	600,000.	WIRE TRANSFER	Ο.		
			MACULAR DEGENERATION					
		EUROPE (INCLUDING	RESEARCH BY WEN HWA					
		ICELAND &	LEE, PHD, ENTITLED:					
		GREENLAND)	(CM2022002)	250,000.	WIRE TRANSFER	Ο.		

See Schedule O for continuation of Grant Purposes, item (d)

BRIGHTFOCUS FOUNDATION

23-7337229

Part III Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	<b>(b)</b> Region	(c) Number of recipients	<b>(d)</b> Amount of cash grant	<b>(e)</b> Manner of cash disbursement	<b>(f)</b> Amount of noncash assistance	(g) Description of noncash assistance	<b>(h)</b> Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2021

Page 3

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)	Yes	X No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)	Yes	X No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? <i>If</i> "Yes," <i>the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see Instructions for Form 5471)</i>	Yes	X No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? <i>If</i> "Yes," <i>the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see Instructions for Form 8621)</i>	Yes	X No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? <i>If</i> "Yes," <i>the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see Instructions for Form 8865)</i>	Yes	X No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? <i>If</i> "Yes," <i>the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990)</i>	Yes	X No

Schedule F (Form 990) 2021

132074 12-20-21

Schedule F (Form 990) 2021

#### Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT **REQUIRED REPORTS.** 

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY 132075 12-20-21 Schedule F (Form 990) 2021 40

Schedule F (Form 990) 2021 Part V | Supplemental Information Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions. AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN

ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS

FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE

DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE

FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO

ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM

STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS,

COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE

ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS

ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR

OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP

PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE

BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS. Schedule F (Form 990) 2021 132075 12-20-21 41

13420803 150872 191978

		BRIGHTFOCUS	FOUNDATION
Part V	Supplemental	Information	

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

## PART I, LINE 3:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED

IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD

USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

Schedule F (Form 990) 2021

⁴² 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

132075 12-20-21

13420803 150872 191978

(Form 990) Complete i		Form									
	Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than \$15,000 on Form 990-EZ, line 6a. Attach to Form 990 or Form 990-EZ. Ope										
Department of the Treasury	•					_	Open to Public Inspection				
	Go to www.irs.gov/Form990 for instr	uction	s and	the latest informati	on.	Employer	dentification number				
Name of the organization	FOCUS FOUNDATION					23-733					
		and IN									
required to complete this	<b>es.</b> Complete if the organization answe	erea " Y	es" or	1 Form 990, Part IV, I	ine 1	(. Form 990-i	-2 filers are not				
<ol> <li>Indicate whether the organization         <ul> <li>X</li> <li>Mail solicitations</li> <li>X</li> <li>Internet and email solicitations</li> <li>C</li> <li>Phone solicitations</li> <li>In-person solicitations</li> </ul> </li> <li>2 a Did the organization have a writt key employees listed in Form 99</li> </ol>	raised funds through any of the followir e X Solicita	tion of tion of fundra (incluc rofessi	non-g gover aising ling of onal fu	overnment grants nment grants events ficers, directors, trus undraising services?	-	XY					
compensated at least \$5,000 by	the organization.										
(i) Name and address of individual or entity (fundraiser)	I (III) ACTIVITY have custody 1					Amount paid or retained by fundraiser ted in col. <b>(i)</b>	) <b>(vi)</b> Amount paid to (or retained by) organization				
RKD GROUP - 35 PARKWOOD	FUNDRAISING AND	Yes	No								
DRIVE, STE. 160, HOPKINTON,	COMMUNICATIONS CONSULTANT		х	31,064,820.		471,000	30,593,820.				
ALLEGIANCE GROUP - 2300	FUNDRAISING AND										
CLARENDON BLVD., STE. 925,	COMMUNICATIONS CONSULTANT		x	2,158,912.		327,203	1,831,709.				
Total	ation is registered or licensed to solicit	contrib		33,223,732. or has been notified	it is e	798,203	, ,				
or licensing. AK , AL , AR , AZ , CA , CO , C	T, DC, FL, GA, HI, IL, KS, I R, PA, RI, SC, TN, UT, VA, N	KY,I	JA, M	IA, MD, ME, MI		-					

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ. SEE PART IV FOR CONTINUATIONS Schedule G (Form 990) 2021

132081 10-21-21

Part

BRIGHTFOCUS FOUNDATION

Fundraising Events.	Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than \$15,000
of fundraising event contri	outions and gross income on Form 990-FZ, lines 1 and 6b. List events with gross receipts greater than \$5,000.

		of fundraising event contributions and gr	(a) Event #1	(b) Event #2	(c) Other events	(d) Total events (add col. (a) through col. (c))
Ð			(event type)	(event type)	(total number)	
Revenue	1	Gross receipts				
	2	Less: Contributions				
	3	Gross income (line 1 minus line 2)				
	4	Cash prizes				
	5	Noncash prizes				
Direct Expenses	6	Rent/facility costs				
irect E>	7	Food and beverages				
	8	Entertainment				
	9	Other direct expenses				
	10	Direct expense summary. Add lines 4 through	h 9 in column (d)		►	
_	11	Net income summary. Subtract line 10 from I				
Pa	nrt I		answered "Yes" on Form	990, Part IV, line 19, or	reported more than	
		\$15,000 on Form 990-EZ, line 6a.	[	(L) Dull tobo/instant		
Revenue			(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))
Re	1	Gross revenue				
ses	2	Cash prizes				
kpens	3	Noncash prizes				
Direct Expenses	4	Rent/facility costs				
	5	Other direct expenses				
		· · · · · · · · · · · · · · · · · · ·	<b>Yes</b> %	<b>Yes</b> %	<b>Yes</b> %	
	6	Volunteer labor	No	Νο	No	
	7	Direct expense summary. Add lines 2 through	n 5 in column (d)		►	
	8	Net gaming income summary. Subtract line 7	' from line 1, column (d)		►	
		<u> </u>				
		er the state(s) in which the organization condu				
		he organization licensed to conduct gaming a				Yes No
b	) If "	No," explain:				
		re any of the organization's gaming licenses re Yes," explain:			year?	Yes No
		-21-21			Sche	dule G (Form 990) 2021

Schedule G (Form 990) 2021

									229	
		gaming activities with							Yes	
		eneficiary or trustee of							Vaa	
		ng activity conducted							Tes	
								13a		
14 Enter the name	e and address of	the person who prepa	ires the orga	nization's gam	ing/special eve	ents books and	records:		•	
Name 🕨										
Address 🕨 _										
<b>15a</b> Does the orgar	nization have a co	ontract with a third pa	rty from who	om the organiza	ation receives g	aming revenue	?		Yes	
<b>b</b> If "Yes," enter	the amount of ga	iming revenue receive	d by the orga	anization 🕨 S	\$	and th	e amount			
		the third party $\blacktriangleright$ $\$$ _								
c If "Yes," enter	name and addres	ss of the third party:								
Name 🕨										
Address 🕨 _										
16 Gaming manag	ger information:									
Name 🕨										
Gamino manao	ger compensation	n 🕨 \$								
Gaming manag	ger compensatior	n ▶ \$								
Description of		▶ \$ d ▶ Employee								
Description of Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G	services provided or/officer attion required unc e gaming license? unt of distributior <u>own exempt acti</u> <b>blemental Info</b> (5c, 16, and 17b, <b>5, PART I</b>	Employee Er state law to make required under state vities during the tax yr prmation. Provide as applicable. Also pr , LINE 2B,	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF	Independen	nt contractor n the gaming put ther exempt orgony Part I, line 2b nation. See instr	roceeds to ganizations or s o, columns (iii) a ructions.	pent in the nd (v); and Pa	🗔	Yes	Db, 10b
Description of Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G	services provided or/officer ation required unce e gaming license? unt of distributior own exempt acti <b>Diemental Info</b> (5c, 16, and 17b, <b>5, PART I</b>	Employee Ber state law to make required under state vities during the tax yr prmation. Provide as applicable. Also pr , LINE 2B, ISER: RKD G	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF	Independen	nt contractor n the gaming put ther exempt orgony Part I, line 2b nation. See instr	roceeds to ganizations or s o, columns (iii) a ructions.	pent in the nd (v); and Pa	🗔	Yes	
Description of Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G (I) NAME O (I) ADDRES	services provided or/officer stributions: ation required unce e gaming license? unt of distributior own exempt action own exempt action of distribution own exempt action own exempt action	Employee Employee Ser state law to make Ser sequired under state Ser sequired under state Ser sequired under state Ser state law to make Ser state law to	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF ROUP	Independen	nt contractor n the gaming pu ther exempt orgonation. See instr IGHEST P.	roceeds to ganizations or s o, columns (iii) a ructions.	pent in the nd (v); and Pa	🗔	Yes	
Description of Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G (I) NAME O (I) ADDRES	services provided or/officer stributions: ation required unce e gaming license? unt of distributior own exempt action own exempt action of distribution own exempt action own exempt action	Employee Ber state law to make required under state vities during the tax yr prmation. Provide as applicable. Also pr , LINE 2B, ISER: RKD G	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF ROUP	Independen	nt contractor n the gaming put ther exempt orgony Part I, line 2b nation. See instr	roceeds to ganizations or s o, columns (iii) a ructions.	pent in the nd (v); and Pa	🗔	Yes	
Description of Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1: SCHEDULE G (I) NAME O (I) ADDRES 35 PARKWOO	services provided or/officer stributions: ation required und e gaming license? unt of distributior own exempt acti <b>Demental Info</b> (5c, 16, and 17b, <b>5</b> , <b>PART I</b> <b>DF FUNDRA</b> <b>3</b> S OF FUNI OD DRIVE,	Employee Employee Ser state law to make Ser sequired under state Ser sequired under state Ser sequired under state Ser state law to make Ser state law to	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF ROUP	Independen	nt contractor n the gaming pu ther exempt orgonation. See instr IGHEST P.	roceeds to ganizations or s o, columns (iii) a ructions.	pent in the nd (v); and Pa	🗔	Yes	
Description of Director Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G (I) NAME O (I) ADDRES 35 PARKWOO (I) NAME O (I) NAME O	services provided or/officer stributions: ation required unce e gaming license? unt of distribution own exempt action of distribution own exempt action of ferental Info (5c, 16, and 17b, 5, PART I OF FUNDRA: SS OF FUND OD DRIVE, OF FUNDRA: SS OF FUND	Employee Employee Mer state law to make Sorrequired under state ins required under state ins required under state ins required under state instant on Provide as applicable. Also provide as applicable. Also provide ISER: RKD G DRAISER: STE. 160, ISER: ALLEG DRAISER:	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF ROUP HOPKINT	Independen	at contractor In the gaming pur- ther exempt orgon by Part I, line 2b ation. See instr IGHEST P. 01748	roceeds to ganizations or s o, columns (iii) a ructions. AID FUNE	pent in the nd (v); and Pa	🗔	Yes	
Description of Director Director Director Director Director Director a Is the organiza retain the state b Enter the amou organization's Part IV Supp 15b, 1 SCHEDULE G (I) NAME O (I) ADDRES 35 PARKWOO (I) NAME O (I) NAME O	services provided or/officer stributions: ation required unce e gaming license? unt of distribution own exempt action of distribution own exempt action of femental Info (5c, 16, and 17b, 5, PART I OF FUNDRA: SS OF FUND OD DRIVE, OF FUNDRA: SS OF FUND	Employee Employee Ser state law to make Ser sequired under state Ser sequired under state Ser state law to make Ser state law to ma	charitable dis e law to be d ear ▶ \$ the explanation ovide any ad LIST OF ROUP HOPKINT	Independen	nt contractor n the gaming pu ther exempt orgonation. See instr IGHEST P.	roceeds to ganizations or s o, columns (iii) a ructions. AID FUNE	pent in the nd (v); and Pa	🗔	Yes nes 9, 9	9b, 10b

PART I, LINE 2B, COLUMN (V):

IN THE CONTRACT WITH THE RKD GROUP, THE MANAGEMENTS FEES ARE FIXED

AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS \$1,106,496 PER YEAR,

OF WHICH \$635,496 HAS BEEN ALLOCATED UNDER PART XI, LINE 11(G) TO PROGRAM

AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING

CONSULTANT FEE.

Schedule G (Form 990)

132084 11-18-21

46 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

13420803 150872 191978

SCHEDULE I	G	arants and Oth	ner Assistan	ce to Organ	izations.		OMB No. 1545-0047
(Form 990)	Go	vernments, ar ete if the organizatio	nd Individual	s in the Ŭni [·]	ted States		2021
Department of the Treasury	Comp		Attach to For				Open to Public
Internal Revenue Service		Go to www.ir	rs.gov/Form990 fo		nation.		Inspection
Name of the organization BRIGHTFOC	US FOUNDA	TION					Employer identification number 23-7337229
Part I General Information on Grants a							
1 Does the organization maintain records t	o substantiate the	amount of the grants	or assistance, the	grantees' eligibility	for the grants or assis	stance, and the selecti	on
criteria used to award the grants or assis						, 	
2 Describe in Part IV the organization's pro							
Part II Grants and Other Assistance to	Domestic Organiz	zations and Domestic	c Governments. C	omplete if the orga	anization answered "Y	′es" on Form 990, Part	IV, line 21, for any
recipient that received more than S	5,000. Part II can	be duplicated if additi	onal space is need	ed.			
<b>1 (a)</b> Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
							ALZHEIMER'S DISEASE
ALBANY MEDICAL COLLEGE							RESEARCH BY CHARLY ABI
47 NEW SCOTLAND AVENUE							GHANEM, PHD, ENTITLED:
ALBANY, NY 12208	14-1338310	501(C)(3)	200,000.	0.			(A2022001F)
							ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY ANA RITA AGRA
55 FRUIT STREET							DE ALMEIDA QUADROS, PHD,
BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ENTITLED: (A2022002F)
							ALZHEIMER'S DISEASE
WEILL MEDICAL COLLEGE OF CORNELL							RESEARCH BY ANTOINE
UNIVERSITY - 1300 YORK AVE - NEW							ANFRAY, PHD, ENTITLED:
YORK, NY 10065	13-1623978	501(C)(3)	200,000.	0.			(A2022003F)
							ALZHEIMER'S DISEASE
STANFORD UNIVERSITY							RESEARCH BY CHING-CHIEH
450 JANE STANFORD WAY							CHOU, PHD, ENTITLED:
STANFORD, CA 94305	94-1156365	501(C)(3)	200,000.	0.			(A2022004F)
							ALZHEIMER'S DISEASE
UNIVERSITY OF CALIFORNIA, IRVINE							RESEARCH BY CHRISTIAN
160 ALDRICH HALL	05 0000000	501 ( 2) ( 2)					CROUZET, PHD, ENTITLED:
IRVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			(A2022005F)
UNIVERSITY OF MASSACHUSETTS CHAN							ALZHEIMER'S DISEASE
MEDICAL SCHOOL - OFFICE OF							RESEARCH BY VIOLETA DURAN
SPONSORED PROGRAMS, 55 LAKE AVENUE	04 2167250	E01(C)(2)	200 000	^			LAFORET, PHD, ENTITLED:
NORTH - WORCESTER, MA 01655	04-3167352		200,000.	0.			(A2022006F)
2 Enter total number of section 501(c)(3) and							53.
3 Enter total number of other organizations LHA For Paperwork Reduction Act Notice,							Schedule I (Form 990) 2021
	366 me 1150 000						

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990.

(a) Name and address of organization or government	<b>(b)</b> EIN	<b>(c)</b> IRC section if applicable	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	<b>(h)</b> Purpose of grant or assistance
							ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT							RESEARCH BY GABRIELA
SINAI - ONE GUSTAVE L. LEVY PLACE,							FARIAS QUIPILDOR, PHD,
BOX 1075 - NEW YORK, NY 10029	13-6171197	501(C)(3)	200,000.	Ο.			ENTITLED: (A2022007F)
NIVERSITY OF CALIFORNIA, SAN							ALZHEIMER'S DISEASE
RANCISCO - 490 ILLINOIS STREET,							RESEARCH BY BRANDON
TH FLOOR - SAN FRANCISCO, CA							HOLMES, PHD, ENTITLED:
, , , , , , , , , , , , , , , , , , , ,	94-6036493	501(C)(3)	200,000.	Ο.			(A2022008F)
			, -				ALZHEIMER'S DISEASE
ASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY HOANG LE,
55 FRUIT STREET							PHD, ENTITLED:
BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	Ο.			(A2022009F)
0010N, MI 02143	04 2007000	501(0)(3)	200,000.	•.			ALZHEIMER'S DISEASE
ASHINGTON UNIVERSITY IN ST. LOUIS							RESEARCH BY ALEXANDRA
DNE BROOKINGS DRIVE, CAMPUS BOX 105	43-0653611	E01/(0)/(2)	200,000	0.			LITVINCHUK, PHD,
ST. LOUIS, MO 63130	43-0055011	501(C)(3)	200,000.	0.			ENTITLED: (A2022010F) ALZHEIMER'S DISEASE
ASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY CHAO LIU,
55 FRUIT STREET	04 0605000						PHD, ENTITLED:
BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			(A2022011F)
							ALZHEIMER'S DISEASE
NIVERSITY OF PENNSYLVANIA							RESEARCH BY COURTNEY
451 WALNUT STREET							MARSHALL, PHD, ENTITLED:
PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	200,000.	0.			(A2022012F)
ASHINGTON UNIVERSITY, SCHOOL OF							ALZHEIMER'S DISEASE
EDICINE - 660 S. EUCLID AVENUE,							RESEARCH BY NICOLE MCKAY
AMPUS BOX 8233 - SAINT LOUIS, MO							PHD, ENTITLED:
53110	43-0653611	501(C)(3)	98,221.	٥.			(A2022013F)
ASHINGTON UNIVERSITY, SCHOOL OF							ALZHEIMER'S DISEASE
MEDICINE - 660 S. EUCLID AVENUE,							RESEARCH BY PETER MILLAF
CAMPUS BOX 8233 - SAINT LOUIS, MO							PHD, ENTITLED:
53110	43-0653611	501(C)(3)	200,000.	Ο.			(A2022014F)
							ALZHEIMER'S DISEASE
INDIANA UNIVERSITY							RESEARCH BY MIGUEL
509 E 3RD STREET							MOUTINHO, PHRMD, PHD,
BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	200,000.	Ο.			ENTITLED: (A2022017F)

Schedule I (Form 990)

COPY



(a) Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section if applicable	<b>(d)</b> Amount of cash grant	(e) Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							ALZHEIMER'S DISEASE
JNIVERSITY OF CALIFORNIA, IRVINE							RESEARCH BY TATSUKI
.60 ALDRICH HALL							NAKAGAWA, PHD, ENTITLED:
RVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			(A2022018F)
							ALZHEIMER'S DISEASE
EMORIAL SLOAN KETTERING CANCER							RESEARCH BY SAHIL SHARM2
ENTER - 1275 YORK AVENUE, BOX 701							PHD, ENTITLED:
NEW YORK, NY 10065	13-1924236	501(C)(3)	200,000.	0.			(A2022020F)
							ALZHEIMER'S DISEASE
NIVERSITY OF CALIFORNIA, IRVINE							RESEARCH BY LORENA SORDO
.60 ALDRICH HALL							PHD, ENTITLED:
RVINE, CA 92697	95-2226406	501(C)(3)	199,396.	Ο.			(A2022021F)
							ALZHEIMER'S DISEASE
ORTHWESTERN UNIVERSITY - EVANSTON							RESEARCH BY XIAOJING SU
AMPUS - 750 NORTH LAKE SHORE							PHD, ENTITLED:
DRIVE - CHICAGO, IL 60611	36-2167817	501(C)(3)	200,000.	Ο.			(A2022023F)
							ALZHEIMER'S DISEASE
NIVERSITY OF COLORADO, BOULDER							RESEARCH BY MEAGHAN VAN
100 MARINE STREET							ALSTYNE, PHD, ENTITLED:
BOULDER, CO 80309	84-6000555	501(C)(3)	200,000.	Ο.			(A2022025F)
							ALZHEIMER'S DISEASE
OSTON CHILDREN'S HOSPITAL							RESEARCH BY HUIXIN XU,
00 LONGWOOD AVENUE							PHD, ENTITLED:
OSTON, MA 02115	04-2774441	501(C)(3)	199,678.	Ο.			(A2022026F)
NIVERSITY OF CALIFORNIA, SAN							ALZHEIMER'S DISEASE
RANCISCO - 490 ILLINOIS STREET,							RESEARCH BY ANDREW YANG
TH FLOOR - SAN FRANCISCO, CA							PHD, ENTITLED:
4143	94-6036493	501(C)(3)	200,000.	0.			(A2022027F)
			, ,				ALZHEIMER'S DISEASE
ASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY QIUCHEN ZHAG
5 FRUIT STREET							PHD, ENTITLED:
OSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			(A2022028F)
, - · ·							ALZHEIMER'S DISEASE
NIVERSITY OF CALIFORNIA, IRVINE							RESEARCH BY KEVIN BEIER
60 ALDRICH HALL							PHD, ENTITLED:
IRVINE, CA 92697	95-2226406	501(C)(3)	300,000.	0.			(A2022031S)

Schedule I (Form 990)

COPY

(a) Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section if applicable	(d) Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST. LOUIS							RESEARCH BY THOMAS BRETT,
ONE BROOKINGS DRIVE							PHD, ENTITLED:
ST. LOUIS, MO 63130	43-0653611	501(C)(3)	300,000.	0.			(A2022032S)
							ALZHEIMER'S DISEASE
NEW YORK UNIVERSITY SCHOOL OF							RESEARCH BY OMONIGHO
MEDICINE - ONE PARK AVENUE, 6TH							BUBU, MD, PHD, ENTITLED:
FLOOR - NEW YORK, NY 10016	13-5562308	501(C)(3)	300,000.	0.			(A2022033S)
UNIVERSITY OF KANSAS CENTER FOR							ALZHEIMER'S DISEASE
RESEARCH, INC 2385 IRVING HILL							RESEARCH BY LAN GUO, PHD,
ROAD - LAWRENCE, KS 66045	48-0680117	501(C)(3)	300,000.	0.			ENTITLED: (A2022036S)
				- •			ALZHEIMER'S DISEASE
BRIGHAM YOUNG UNIVERSITY							RESEARCH BY DAVID HANSEN
A-285 ASB CAMPUS DRIVE							PHD, ENTITLED:
PROVO, UT 84602	87-0217280	501(C)(3)	300,000.	0.			(A2022037S)
	.,						ALZHEIMER'S DISEASE
WASHINGTON UNIVERSITY IN ST. LOUIS							RESEARCH BY KEITH HENGEN
ONE BROOKINGS DRIVE							PHD, ENTITLED:
ST. LOUIS, MO 63130	43-0653611	501(C)(3)	300,000.	0.			(A2022038S)
				- •			ALZHEIMER'S DISEASE
COLORADO STATE UNIVERSITY							RESEARCH BY SEONIL KIM,
2002 CAMPUS DELIVERY							PHD, ENTITLED:
FORT COLLINS, CO 80523	84-6000545	501(C)(3)	300,000.	0.			(A2022039S)
							ALZHEIMER'S DISEASE
RICE UNIVERSITY							RESEARCH BY STEPHANIE
6100 S. MAIN MS-16							LEAL, PHD, ENTITLED:
HOUSTON, TX 77005	74-1109620	501(C)(3)	299,943.	0.			(A2022040S)
		,		· ·			ALZHEIMER'S DISEASE
SEATTLE INSTITUTE FOR BIOMEDICAL							RESEARCH BY NICOLE
AND CLINICAL RESEARCH - 1660 S.							LIACHKO, PHD, ENTITLED:
COLUMBIAN WAY - SEATTLE, WA 98108	91-1452438	501(C)(3)	300,000.	0.			(A2022041S)
,		,		· ·			ALZHEIMER'S DISEASE
HEBREW REHABILITATION CENTER							RESEARCH BY BRAD MANOR,
1200 CENTRE STREET							PHD, ENTITLED:
BOSTON, MA 02131	04-2104298	501(C)(3)	300,000.	0.			(A2022042S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purposes, item (h)



(a) Name and address of organization or government	<b>(b)</b> EIN	<b>(c)</b> IRC section if applicable	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							ALZHEIMER'S DISEASE
ICAHN SCHOOL OF MEDICINE AT MOUNT							RESEARCH BY ALEJANDRO
SINAI - ONE GUSTAVE L. LEVY PLACE,							MARTIN TRUJILLO, PHD,
BOX 1075 - NEW YORK, NY 10029	13-6171197	501(C)(3)	300,000.	Ο.			ENTITLED: (A2022043S)
							ALZHEIMER'S DISEASE
GEORGIA TECH RESEARCH CORPORATION							RESEARCH BY ANNABELLE
926 DALNEY STREET NW							SINGER, PHD, ENTITLED:
ATLANTA, GA 30332	58-0603146	501(C)(3)	299,993.	Ο.			(A2022048S)
							ALZHEIMER'S DISEASE
TRUSTEES OF BOSTON UNIVERSITY							RESEARCH BY JULIA TCW,
85 EAST NEWTON, M-921							PHD, ENTITLED:
, BOSTON, MA 02218	04-2103547	501(C)(3)	300,000.	Ο.			(A2022049S)
							ALZHEIMER'S DISEASE
JNIVERSITY OF MICHIGAN							RESEARCH BY PETER
3003 S. STATE STREET							TESSIER, PHD, ENTITLED:
ANN ARBOR, MI 48109	38-6006309	501(C)(3)	200,000.	Ο.			(A2022050S)
							ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY SUSANNE VAN
55 FRUIT STREET							VELUW, PHD, ENTITLED:
BOSTON, MA 02145	04-2697983	501(C)(3)	300,000.	Ο.			(A2022051S)
							ALZHEIMER'S DISEASE
PRESIDENT & FELLOWS OF HARVARD							RESEARCH BY LIMOR COHEN
COLLEGE - 1033 MASSACHUSETTS AVE,							PHD, ENTITLED:
5TH FLOOR - CAMBRIDGE, MA 02138	04-2103580	501(C)(3)	200,000.	Ο.			(A2022052F)
STILLFBOOK CAMBRIDGE, MA 02150	04 2103300	501(0/(5/	200,000.	••			(A2022032F)
MAYO CLINIC, JACKSONVILLE							ALZHEIMER'S DISEASE
4500 SAN PABLO ROAD, ROOM 110							RESEARCH, ENTITLED:
JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	235,163.	0.			(CA2021010)
INTERNATIONAL SOCIETY FOR	55 5557020	501(0)(5)	233,103.	υ.			(
MOLECULAR NEURODEGENERATION - 1001							ALZHEIMER'S DISEASE
MAYPORT RD - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	115 000	0.			RESEARCH, ENTITLED: (CA2021011)
52235	00-290/045	SOT(C)(S)	115,000.	υ.			ALZHEIMER'S DISEASE
MASSACHUSETTS GENERAL HOSPITAL							RESEARCH BY BECKY
55 FRUIT STREET				_			CARLYLE, PHD, ENTITLED:
CHARLESTOWN, MA 02114	04-1564655	501(C)(3)	30,000.	0.		1	(A2019182S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purposes, item (h)



(a) Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section if applicable	<b>(d)</b> Amount of cash grant	(e) Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							ALZHEIMER'S DISEASE
JOHNS HOPKINS UNIVERSITY							RESEARCH BY PETER ABADIR
733 NORTH BROADWAY, SUITE 117							PHD, ENTITLED:
BALTIMORE, MD 21205	52-0595110	501(C)(3)	67,582.	0.			(A2019634S)
							ALZHEIMER'S DISEASE
JOHNS HOPKINS UNIVERSITY							RESEARCH BY QUINCY SAMUS
400 NORTH BROADWAY							PHD, ENTITLED:
BALTIMORE, MD 21211	52-0595110	501(C)(3)	123,767.	0.			(CA2021001)
FOUNDATION FOR THE NATIONAL							
INSTITUTES OF HEALTH - 11400							ALZHEIMER'S DISEASE
ROCKVILLE PIKE, SUITE 600 - NORTH							RESEARCH, ENTITLED:
BETHESDA, MD 20852	52-1986675	501(C)(3)	100,000.	0.			(CA2021012)
							ALZHEIMER'S DISEASE
BOSTON UNIVERSITY SCHOOL OF							RESEARCH BY BENJAMIN
MEDICINE - 72 EAST CONCORD STREET							WOLOZIN, MD, PHD
- BOSTON, MA 02215	04-2103547	501(C)(3)	317,298.	0.			ENTITLED: (CA2020002)
							ALZHEIMER'S DISEASE
UNIVERSITY OF DENVER							RESEARCH BY ANN CHARLOTTI
2155 E. WESLEY AVENUE							GRANHOLM-BENTLEY, PHD,
DENVER, CO 80208	84-0404231	501(C)(3)	81,710.	0.			ENTITLED: (CA2018010)
							NATIONAL GLAUCOMA
INDIANA UNIVERSITY							RESEARCH BY ALESSANDRA
509 E 3RD STREET							CARMICHAEL-MARTINS, PHD,
BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	147,339.	0.			ENTITLED: (G2022001F)
							NATIONAL GLAUCOMA
INDIANA UNIVERSITY							RESEARCH BY CATIA GOMES,
509 E 3RD STREET							PHD, ENTITLED:
BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	150,000.	0.			(G2022003F)
UNIVERSITY OF NORTH TEXAS HEALTH							NATIONAL GLAUCOMA
SCIENCE CENTER AT FORT WORTH -							RESEARCH BY PRABHAVATHI
3500 CAMP BOWIE BLVD FORT							MADDINENI, PHD, ENTITLED
WORTH, TX 76107	75-6064033	501(C)(3)	150,000.	0.			(G2022004F)
		-	, ,				NATIONAL GLAUCOMA
JOHNS HOPKINS UNIVERSITY SCHOOL OF							RESEARCH BY THOMAS
MEDICINE - 733 NORTH BROADWAY,							JOHNSON, MD, PHD,
SUITE 117 - BALTIMORE, MD 21205	52-0595110	501(C)(3)	200,000.	0.			ENTITLED: (G2022005S)

Schedule I (Form 990)



2	3 –	73	37229	Page 1
---	-----	----	-------	--------

(a) Name and address of organization or government	<b>(b)</b> EIN	<b>(c)</b> IRC section if applicable	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							NATIONAL GLAUCOMA
GOOD SAMARITAN FOUNDATION (LHS)							RESEARCH BY KAZUHIRO
1015 NW 22ND AVENUE							KUROKAWA, PHD, ENTITLED:
PORTLAND, OR 97210	23-7017276	501(C)(3)	200,000.	٥.			(G2022006S)
MICHIGAN STATE UNIVERSITY							NATIONAL GLAUCOMA
HANNAH ADMINISTRATION, 426							RESEARCH BY ANDRAS
AUDITORIUM ROAD - EAST LANSING, MI							KOMAROMY, DVM, PHD,
48824	38-6005984	501(C)(3)	199,992.	Ο.			ENTITLED: (G2022007S)
			,				NATIONAL GLAUCOMA
GOOD SAMARITAN FOUNDATION (LHS)							RESEARCH BY HONGLI YANG,
1015 NW 22ND AVENUE							PHD, ENTITLED:
PORTLAND, OR 97210	23-7017276	501(C)(3)	199,992.	0.			(G2022008S)
	20 /02/2/0						NATIONAL GLAUCOMA
CEDARS-SINAI MEDICAL CENTER							RESEARCH BY SHAOMEI WANG
8700 BEVERLY BOULEVARD, SUITE 1800							MD, PHD, ENTITLED:
LOS ANGELES, CA 90048	95-1644600	501(C)(3)	199,381.	0.			(G2022009S)
LOS ANGELES, CA 90040	99-1044000	501(0/(5/	199,301.	0.			NATIONAL GLAUCOMA
DURE INTREDUTER ACUAN OF MEDIATNE							
DUKE UNIVERSITY SCHOOL OF MEDICINE							RESEARCH BY MYOUNGSUP
2200 WEST MAIN STREET, SUITE 820, E	56 0520100	F01 ( a) ( 2)					SIM, PHD, ENTITLED:
DURHAM, NC 27705	56-0532129	501(C)(3)	200,000.	0.			(G2022010S)
							NATIONAL GLAUCOMA
VANDERBILT UNIVERSITY MEDICAL							RESEARCH BY MICHAEL
CENTER - 3319 WEST END AVENUE,							RISNER, PHD, ENTITLED:
SUITE 970 - NASHVILLE, TN 37203	35-2528741	501(C)(3)	196,512.	0.			(G2022011S)
							NATIONAL GLAUCOMA
EMORY UNIVERSITY							RESEARCH BY JIAXING WANG,
1599 CLIFTON ROAD NE, 4TH FLOOR							PHD, ENTITLED:
ATLANTA, GA 30322	58-0566256	501(C)(3)	200,000.	٥.			(G2022012S)
							NATIONAL GLAUCOMA
TRUSTEES OF BOSTON UNIVERSITY							RESEARCH BY HAIYAN GONG,
85 EAST NEWTON, M-921							MD, PHD, ENTITLED:
BOSTON, MA 02218	04-2103547	501(C)(3)	200,000.	0.			(G2022013S)
							NATIONAL GLAUCOMA
INDIANA UNIVERSITY							RESEARCH BY JASON MEYER,
509 E 3RD STREET							PHD, ENTITLED:
BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	200,000.	0.			(G2022014S)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purposes, item (h)



(a) Name and address of organization or government	<b>(b)</b> EIN	<b>(c)</b> IRC section if applicable	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							NATIONAL GLAUCOMA
NIVERSITY OF CALIFORNIA DAVIS							RESEARCH BY NICK
850 RESEARCH PARK DRIVE, SUITE 300							MARSH-ARMSTRONG, PHD,
DAVIS, CA 95618	94-6036494	501(C)(3)	200,000.	0.			ENTITLED: (G2022016S)
							NATIONAL GLAUCOMA
HE UNIVERSITY OF IOWA							RESEARCH BY MICHAEL
GILMORE HALL							ANDERSON, PHD, ENTITLED
OWA CITY, IA 52242	42-6004813	501(C)(3)	200,000.	0.			(G2022017S)
INTERNATIONAL SOCIETY FOR EYE							
RESEARCH - 655 BEACH STREET - SAN							TRAVEL GRANTS FOR
FRANCISCO, CA 94109	51-0171667	501(C)(3)	5,900.	0.			CONFERENCE ATTENDANCE
,							NATIONAL GLAUCOMA
TANFORD UNIVERSITY							RESEARCH BY JEFFREY
452 WATSON CT							GOLDBERG, PHD, ENTITLED
ALO ALTO, CA 94305	94-1156365	501(C)(3)	342,519.	0.			(CG2022001)
HE UNIVERSITY OF NORTH CAROLINA							MACULAR DEGENERATION
T CHAPEL HILL - 104 AIRPORT							RESEARCH BY YONGSU KWON
RIVE, SUITE 2200 - CHAPEL HILL,							PHD, ENTITLED:
IC 27599	56-6001393	501(C)(3)	200,000.	0.			(M2022001F)
	50 0001555	501(0)(3)	200,000.				MACULAR DEGENERATION
NIVERSITY OF WASHINGTON							RESEARCH BY DANIEL HASS
333 BROOKLYN AVE, NE							PHD, ENTITLED:
EATTLE, WA 98195	91-6001537	501(C)(3)	200,000.	0.			(M2022003F)
HE UNIVERSITY OF TEXAS	91-0001337	501(0/(5/	200,000.	0.			MACULAR DEGENERATION
OUTHWESTERN MEDICAL CENTER - 5323							RESEARCH BY STEFFI
ARRY HINES BLVD DALLAS, TX		F01(G)(2)		0			DANIEL, PHD, ENTITLED:
5390	75-6002868	501(C)(3)	200,000.	0.			(M2022005F)
							MACULAR DEGENERATION
EATTLE CHILDREN'S HOSPITAL							RESEARCH BY LEAH
900 NINTH AVENUE, M/S: 818-S							VANDENBOSCH, PHD,
EATTLE, WA 98101	91-0564748	DUT(C)(3)	200,000.	0.			ENTITLED: (M2022006F)
							MACULAR DEGENERATION
NIVERSITY OF ROCHESTER							RESEARCH BY KRISTEN
518 HYLAN BLDG. BOX 270140							BOWLES JOHNSON, PHD, OD
ROCHESTER, NY 14627	16-0743209	501(C)(3)	200,000.	٥.		1	ENTITLED: (M2022007F)

Schedule I (Form 990)

See Schedule O for continuation of Grant Purposes, item (h)



2	3-	73	37	22	9	Page 1

(a) Name and address of organization or government	<b>(b)</b> EIN	(c) IRC section if applicable	<b>(d)</b> Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
							MACULAR DEGENERATION
THE REGENTS OF THE UNIVERSITY OF							RESEARCH BY THOMAS
MICHIGAN - 3003 S. STATE STREET -							WUBBEN, PHD, ENTITLED:
ANN ARBOR, MI 48109	38-6006309	501(C)(3)	450,000.	٥.			(M2022008N)
							MACULAR DEGENERATION
OREGON HEALTH & SCIENCE UNIVERSITY							RESEARCH BY YIFAN JIAN,
3181 SW SAM JACKSON PARK RD.							PHD, ENTITLED:
PORTLAND, OR 97239	93-1176109	501(C)(3)	449,323.	Ο.			(M2022009N)
							MACULAR DEGENERATION
UNIVERSITY OF NEVADA, RENO							RESEARCH BY ALBERT
1664 N VIRGINIA ST, MAIL STOP 325							GONZALES, PHD, ENTITLED:
RENO, NV 89557	88-6000024	501(C)(3)	446,943.	Ο.			(M2022010N)
							MACULAR DEGENERATION
THE REGENTS OF THE UNIVERSITY OF							RESEARCH BY LEV PRASOV,
MICHIGAN - 3003 S. STATE STREET -							PHD, ENTITLED:
ANN ARBOR, MI 48109	38-6006309	501(C)(3)	450,000.	Ο.			(M2022011N)
							MACULAR DEGENERATION
UNIVERSITY OF SOUTH FLORIDA							RESEARCH BY MANAS BISWAL,
3702 SPECTRUM BLVD, SUITE 165							PHD, ENTITLED:
TAMPA, FL 33612	59-3102112	501(C)(3)	450,000.	٥.			(M2022012N)
							MACULAR DEGENERATION
JOHNS HOPKINS UNIVERSITY SCHOOL OF							RESEARCH BY SRINIVASA RAO
MEDICINE - 733 NORTH BROADWAY,							SRIPATHI, PHD, ENTITLED:
SUITE 117 - BALTIMORE, MD 21205	52-0595110	501(C)(3)	450,000.	Ο.			(M2022014N)
							MACULAR DEGENERATION
THE JACKSON LABORATORY							RESEARCH BY PATSY
600 MAIN STREET							NISHINA, PHD, ENTITLED:
BAR HARBOR, ME 04609	01-0211513	501(C)(3)	600,000.	Ο.			(M2022016I)
			,				MACULAR DEGENERATION
DRUSOLV THERAPUTICS, INC							RESEARCH BY JOHN G.
1425 LOCUST STREET, UNIT 7C							EDWARDS, MS/MBA,
PHILADELPHIA, PA 19102	82-2704169		500,000.	0.			ENTITLED: (CM2022001)
RD MEETING, INC.							TRAVEL GRANTS FOR MACULAR
5200 NW 43RD STREET, SUITE 102-279							DEGENERATION FAST TRACK
GAINESVILLE, FL 32606	84-1992631	501(C)(3)	12,358.	٥.			MEETING

Schedule I (Form 990)

See Schedule O for continuation of Grant Purposes, item (h)



# BRIGHTFOCUS FOUNDATION

art II Continuation of Grants and Other		nestic Organizations	and Domestic Go	vernments (Sche	edule I (Form 990), Pa	rt II.) T	
(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	<b>(e)</b> Amount of noncash assistance	<b>(f)</b> Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
EVO FOUNDATION FOR EYE RESEARCH 01 ROCKVILLE PIKE, SUITE 400 DCKVILLE, MD 20852	52-2322462	501(C)(3)	10,000.	0.			2022 EYEFIND RESEARCH GRANT SPONSORSHIP
WO FOUNDATION FOR EYE RESEARCH 01 ROCKVILLE PIKE, SUITE 400 OCKVILLE, MD 20852	52-2322462	501(C)(3)	15,240.	0.			2022 TRAVEL GRANTS FOR CONFERENCE ATTENDEES

Schedule I (Form 990)



Schedule I (Form 990) 2021

BRIGHTFOCUS FOUNDATION

Page 2

Part III Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	<b>(c)</b> Amount of cash grant	(d) Amount of non- cash assistance	<b>(e)</b> Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance				
Part IV Supplemental Information. Provide the information req	uired in Part I, lin	ie 2; Part III, column	(b); and any other ac	ditional information.					
PART I, LINE 2:									
BRIGHTFOCUS INTERACTS WITH ALL GRAM	BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT								

SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT

RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC

PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE

BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF

WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING

PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND

GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE

# Schedule I (Form 990) BRIGHTFOCUS FOUNDATION Part IV Supplemental Information

PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY Schedule I (Form 990) 132291 04-01-21

58

13420803 150872 191978

THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Schedule I (Form 990)

132291 04-01-21

	SCHEDULE J Compensation Information									
(Fo	rm 990)	For certain Officers, Directors, Trustees, Key			20	91	1			
		Compensated Employe Complete if the organization answered "Yes" or	es Form 990 Part IV line 23		20		1			
Depa	tment of the Treasury	Attach to Form 990.			Open to		ic			
Intern	al Revenue Service	Go to www.irs.gov/Form990 for instructions	and the latest information.		Inspe					
Nan	e of the organization			Employer i			nber			
Do		BRIGHTFOCUS FOUNDATION		23-7	33722	9				
Pa	rt I Question	Regarding Compensation								
4-			u fau a managa liatad an Fauna	000		Yes	No			
а		ate box(es) if the organization provided any of the following to a		990,						
	First-class or c	ine 1a. Complete Part III to provide any relevant information re								
	Travel for com		wance or residence for perso or business use of personal re							
			cial club dues or initiation fee							
			vices (such as maid, chauffer							
				ii, cheij						
h	If any of the boxes	on line 1a are checked, did the organization follow a written po	licy regarding payment or							
D	•	rovision of all of the expenses described above? If "No," comp			1b					
2		require substantiation prior to reimbursing or allowing expense								
2		s, including the CEO/Executive Director, regarding the items c			2					
	trustees, and onloc	s, molitaring the OLO/Executive Director, regarding the items of								
3	Indicate which if a	y, of the following the organization used to establish the comp	ensation of the organization's							
-		ctor. Check all that apply. Do not check any boxes for method	-							
		tion of the CEO/Executive Director, but explain in Part III.								
	X Compensation		loyment contract							
			on survey or study							
	X Form 990 of o	· ·	the board or compensation c	ommittee						
		· · · · ,								
4	During the year, did	any person listed on Form 990, Part VII, Section A, line 1a, wit	h respect to the filing							
	organization or a re									
а	Receive a severand	e payment or change-of-control payment?			4a		X			
b	Participate in or rec	eive payment from a supplemental nonqualified retirement plar	ı?		4b		X			
с	Participate in or rec	eive payment from an equity-based compensation arrangemen	t?		4c		X			
	If "Yes" to any of lir	es 4a-c, list the persons and provide the applicable amounts fo	or each item in Part III.							
	Only section 501(c	(3), 501(c)(4), and 501(c)(29) organizations must complete I	ines 5-9.							
5	For persons listed of	n Form 990, Part VII, Section A, line 1a, did the organization pa	ay or accrue any compensatio	n						
	contingent on the r									
							X			
		ation?					X			
		r 5b, describe in Part III.								
6	For persons listed of	n Form 990, Part VII, Section A, line 1a, did the organization pa	ay or accrue any compensatio	n						
	contingent on the r	-								
b		ation?			6b		X			
		r 6b, describe in Part III.								
7		n Form 990, Part VII, Section A, line 1a, did the organization p	• • •							
		es 5 and 6? If "Yes," describe in Part III			7		X			
8		eported on Form 990, Part VII, paid or accrued pursuant to a c		le			37			
		ption described in Regulations section 53.4958-4(a)(3)? If "Yes			8		X			
9		d the organization also follow the rebuttable presumption proc								
		53.4958-6(c)?					<u> </u>			
LHA	For Paperwork R	duction Act Notice, see the Instructions for Form 990.		Sched	ule J (Forn	n <b>990</b> )	2021			

132111 11-02-21

#### Part II Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

		<b>(B)</b> Breakdown of W	/-2 and/or 1099-MIS0 compensation	C and/or 1099-NEC	(C) Retirement and other deferred	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B)
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	compensation			reported as deferred on prior Form 990
(1) STACY PAGOS HALLER	(i)	388,780.	45,000.	1,584.	26,100.	24,927.	486,391.	0.
PRESIDENT/CEO	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) NANCY LYNN	(i)	241,970.	2,500.	1,584.	23,006.	30,944.	300,004.	0.
SR. VP STRATEGIC PARTNERSHIPS	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) R. BRIAN ELDERTON	(i)	235,152.	10,000.	2,048.	22,654.	23,762.	293,616.	0.
SR. VP, DEVELOPMENT	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) DAVID F. MARKS, CPA, CMA	(i)	161,053.	2,500.	1,584.	15,876.	40,653.	221,666.	0.
VP, FINANCE & ADMINISTRATION	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) DIANE BOVENKAMP, PHD	(i)	176,665.	2,500.	552.	16,125.	4,764.	200,606.	0.
VP, SCIENTIFIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) MICHAEL BUCKLEY	(i)	159,966.	2,500.	552.	14,622.	4,039.	181,679.	0.
VP, PUBLIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

Schedule J (Form 990) 2021

#### Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Schedule J (Form 990) 2021

COPY

#### SCHEDULE M (Form 990)

# **Noncash Contributions**

OMB No. 1545-0047

Department of the Treasury	
Internal Revenue Service	

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30. Attach to Form 990. ►

ſ 1 ΖU L **Open to Public** Inspection

Employer identification number

Name o	of the or	raanizatior	า

Go to www.irs.gov/Form990	for instructions and the latest information.
de le minisigen i crinere	

of	the	orga	inizat	ion	

BRIGHTFOCUS	FOUNDATION

	BRIGHTFOCUS FOUNDATION			23-7	23-7337229			
Pa								
		<b>(a)</b> Check if applicable	<b>(b)</b> Number of contributions or items contributed	<b>(c)</b> Noncash contribution amounts reported on Form 990, Part VIII, line 1g	<b>(d)</b> Method of de noncash contribu			}
1	Art - Works of art							
2	Art - Historical treasures							
3	Art - Fractional interests							
4	Books and publications							
5	Clothing and household goods							
6	Cars and other vehicles							
7	Boats and planes							
8	Intellectual property							
9	Securities - Publicly traded	X	29	203,467.	FMV			
10	Securities - Closely held stock							
11	Securities - Partnership, LLC, or							
	trust interests							
12	Securities - Miscellaneous							
13	Qualified conservation contribution -							
	Historic structures							
14	Qualified conservation contribution - Other $\dots$							
15	Real estate - Residential	X	1	134,013.	DISPOSITION	PRIC	E	
16	Real estate - Commercial							
17	Real estate - Other							
18	Collectibles							
19	Food inventory							
20	Drugs and medical supplies							
21	Taxidermy							
22	Historical artifacts							
23	Scientific specimens							
24	Archeological artifacts							
25	Other ► ()							
26	Other ► ()							
27	Other ► ()							
28	Other  ( )							
29	Number of Forms 8283 received by the organiz	zation during	the tax year for co	ontributions				
	for which the organization completed Form 82	83, Part V, D	onee Acknowledg	ement 29				
						Y	es	No
30a	During the year, did the organization receive by	y contributio	n any property rep	orted in Part I, lines 1 throug	h 28, that it			
	must hold for at least three years from the date	e of the initia	l contribution, and	which isn't required to be us	ed for			
	exempt purposes for the entire holding period?	?				30a		<u>X</u>
b	If "Yes," describe the arrangement in Part II.							
31	Does the organization have a gift acceptance p	policy that re	equires the review o	of any nonstandard contribut	ons?	31 Ž	ζ	
32a	Does the organization hire or use third parties	or related or	ganizations to solid	cit, process, or sell noncash				
	contributions?					32a 🛛	ζ	
b	If "Yes," describe in Part II.							
33	If the organization didn't report an amount in c	olumn (c) foi	a type of property	r for which column (a) is chec	ked,			
	describe in Part II.							

LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990. Schedule M (Form 990) 2021

132141 11-17-21

Part II Supplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN (B).

SCHEDULE M, LINE 32B:

BRIGHTFOCUS RECEIVED DONATED RESIDENTIAL REAL ESTATE IN APRIL 2021. IN

JUNE 2021, BRIGHTFOCUS SOLD THE REAL ESTATE WITH THE ASSISTANCE OF A

REAL ESTATE AGENT.

Schedule M (Form 990) 2021

23-7337229

Page 2

132142 11-17-21

⁶⁴ 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

13420803 150872 191978

SCHEDULE O (Form 990)

Department of the Treasury

Name of the organization

Internal Revenue Service

#### Supplemental Information to Form 990 or 990-EZ Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information. ► Attach to Form 990 or Form 990-EZ. ► Go to www.irs.gov/Form990 for the latest information.

Employer identification number 23 - 7337229

OMB No. 1545-0047

BRIGHTFOCUS FOUNDATION

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWIDE TO DEFEAT

ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES

EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A

WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, 1 IN 16

PEOPLE OVER THE AGE OF 40 IN THE U.S. HAS ONE OF THESE DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST

INNOVATIVE, EARLY-STAGE RESEARCH SEEKING BETTER UNDERSTANDING,

TREATMENTS, OR, ULTIMATELY, A CURE FOR THESE DISEASES. SINCE 1973,

BRIGHTFOCUS HAS AWARDED OVER \$270 MILLION IN RESEARCH GRANTS TO

THOUSANDS OF SCIENTISTS AROUND THE WORLD. OUR RESEARCH FUNDING HAS LED

TO MAJOR CONTRIBUTIONS TO THE UNDERSTANDING OF THESE DISEASES AND

SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING

TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES

OF KNOWLEDGE IS THAT BRIGHTFOCUS-SUPPORTED RESEARCH WAS RECENTLY FOUND

TO HAVE HAD TWICE THE IMPACT ON DRIVING FUTURE SCIENCE THAN WORK

SUPPORTED BY MANY OTHER ORGANIZATIONS.

 THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON

 THE CUTTING-EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS

 AS A CATALYST IN EARLY-STAGE RESEARCH. THE BRIGHTFOCUS RESEARCH

 PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE

 EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL

 PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST

 RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM

 LHA For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

132211 11-11-21

65

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229		
OTHER SOURCES THAT ARE UP TO 10 TIMES LARGER THAN THE ORIG	INAL		
BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVEST	MENT SPEAKS		
TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES			
AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM B	ELIEF THAT		
HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD	ТО		
REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS.			

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES TO SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF THOSE IMPACTED BY THESE DISEASES NATIONWIDE. WE ROOT THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS.

BRIGHTFOCUS INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSA) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S. MAKE A PLAN TODAY: GET YOUR EYES CHECKED AND NOW IS THE MOMENT TO STOP ALZHEIMER'S DISEASE POWERFULLY SEEK TO RAISE AWARENESS AND EARLY DETECTION, AND SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2022, THESE PSA MESSAGES GENERATED \$12,439,938 IN DONATED MEDIA SERVICES AND GARNERED OVER 693 MILLION IMPRESSIONS.

66

132212 11-11-21

Schedule O (Form 990) 2021	Page 2			
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229			
SINCE 2014, THE BRIGHTFOCUS CHATS HAVE BROUGHT TOGETHER PA	TIENTS AND			
CAREGIVERS FOR FREE, INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN				
FROM, AND ASK QUESTIONS OF, LEADING RESEARCHERS AND SPECIA	LISTS ON			
VISION DISEASES. THE CHATS ARE ARCHIVED ON OUR WEB SITE,	WITH AUDIO			
AND PRINT TRANSCRIPTS AVAILABLE IN A NUMBER OF ACCESSIBLE	FORMATS.			

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY UNVEIL NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES.

PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING BETTER EDUCATE THE PUBLIC ON THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH AS A WAY TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES.

SPECIFICALLY, BRIGHTFOCUS IS PRODUCING AND DISSEMINATING BRAIN INFO LIVE, A SUSTAINED, EPISODIC VIRTUAL EDUCATION SERIES TAILORED TO DIVERSE COMMUNITIES ACROSS THE US. BRIGHTFOCUS IS PREPARING TO ALSO PRESENT AN UPCOMING DOCUMENTARY, "WILDER: HIS LIFE, LEGACY AND BATTLE WITH ALZHEIMER'S DISEASE," AND WILL EXECUTE AN ASSOCIATED EDUCATIONAL IMPACT CAMPAIGN. THE FILM WILL BE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE THE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH.

WE HAVE EXPANDED OUR WRITTEN CONTENT OF KEY RESEARCH FINDINGS,

PROMOTING AND SHARING THIS INFORMATION THROUGH OUR WEB SITE AND SOCIAL

MEDIA PLATFORMS. BRIGHTFOCUS INFOGRAPHICS EASILY AND VISUALLY
132212 11-11-21
Schedule O (Form 990) 2021
67

13420803 150872 191978

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
COMMUNICATE INFORMATION ON ALZHEIMER'S, MACULAR DEGENERATI	ON, AND
GLAUCOMA. IN THE SPRING OF 2020, WE LAUNCHED A FULL SECTI	ON OF OUR
WEBSITE DEDICATED TO SHARING EXCLUSIVE CONTENT ON COVID-19	FOR FAMILIES
IMPACTED BY DISEASES OF MIND AND SIGHT.	

MORE SPECIFICALLY, EACH OF THESE PROGRAM AREAS MAIL AWARENESS-RAISING MATERIALS TO HUNDREDS OF THOUSANDS OF HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

- RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND

STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.

- LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO

TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.

- RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS,

GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA TO CALL GREATER

ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH

AND BEST PRACTICES WITH THE PUBLIC FIGURES AND KEY STAKEHOLDERS.

THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS ACTIVE ROLES IN ADVOCACY

COALITIONS WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER

POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH, AND

SEARCHING FOR CURES FOR, THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH

 YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR

 132212 11-11-21
 Schedule O (Form 990) 2021

 68

13420803 150872 191978

BRIGHTFOCUS FOUNDATION

DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO

CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC

SECTORS.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:

ALZHEIMER'S DISEASE RESEARCH (ADR) -

ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 5.5 MILLION AMERICANS HAVE ALZHEIMER'S DISEASE, ABOUT TWO-THIRDS ARE WOMEN.

BRIGHTFOCUS' ADR PROGRAM FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, ITS EARLY DETECTION, AND TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE INCEPTION, BRIGHTFOCUS HAS CONTRIBUTED MORE THAN \$167 MILLION TO THE CONQUERING OF ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDED MARCH 31, 2022, ADR AWARDED \$12,439,027 IN PEER-REVIEWED GRANT AWARDS TO 52 NEW RESEARCH PROJECTS AND THREE OTHER NEW SCIENTIFIC AWARDS TO MAKE A TOTAL OF \$13,577,827 IN FUNDING.

69

132212 11-11-21

Schedule O (Form 990) 2021

Schedule O (Form 990) 2021	Page <b>2</b>			
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229			
NOTABLE PROJECTS INCLUDE: USING THE EYE AND VARIOUS IMAGIN	G METHODS TO			
DETECT DEMENTIA; HYPERTENSION AND LIFESTYLE EFFECTS ON RIS	K OF			
ALZHEIMER'S (INCLUDING LIPIDS); DRUG DISCOVERY AND BIOMARK	ERS; THE ROLE			
OF INFLAMMATION, MICROGLIA AND VASCULAR HEALTH IN DISEASE	RISK; LOOKING			
AT THE MITOCHONDRIA AND CELL ENERGY DEFICIENCIES; ROLE OF SLEEP				
DISTURBANCES CAUSING INCREASED RISK OF COGNITIVE ISSUES; DIFFERENCES IN				
GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS; AND BETTER				
USE OF MODERN TECHNOLOGIES, INCLUDING BIG DATA/AI AND SYSTEMS GENETICS				
ANALYSIS FOR INCREASED AND DECREASED RISKS. ADDITIONAL INFORMATION				
ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.				

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS: DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE.

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL "MOLECULAR NEURODEGENERATION" AS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN "OPEN ACCESS" JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND 132212 11-11-21 TO Schedule O (Form 990) 2021 70

13420803 150872 191978

BRIGHTFOCUS FOUNDATION

LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS

ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:

#### MACULAR DEGENERATION RESEARCH (MDR) -

AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AS MANY AS 11 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES. THIS NUMBER IS EXPECTED TO DOUBLE TO NEARLY 22 MILLION BY 2050.

MACULAR DEGENERATION RESEARCH (MDR), A PROGRAM OF BRIGHTFOCUS, HAS AWARDED MORE THAN \$45 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS FOR THE DISEASE, UNDERSTANDING ITS CAUSES AND PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF THE METABOLISM IN DISEASE RISK, GENES, THE ROLE OF THE IMMUNE RESPONSE IN DISEASE RISK, AND NEW IMAGING, MACHINE LEARNING AND SCREENING TECHNIQUES.

MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE.

MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG

SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT
132212 11-11-21
Schedule O (Form 990) 2021
71

13420803 150872 191978

Employer identification number 23-7337229

Page 2

APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON

SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2022, MDR AWARDED \$5,746,102 IN

PEER-REVIEWED GRANT AWARDS TO 16 NEW RESEARCH PROJECTS, WITH 5

ADDITIONAL SCIENTIFIC PROJECTS THAT TAKE THE TOTAL FUNDING TO

\$6,533,701. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES

<u>F & I.</u>

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:

NATIONAL GLAUCOMA RESEARCH (NGR) -

GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE, ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN THREE MILLION AMERICANS, OVER THE AGE OF 40 ARE LIVING WITH GLAUCOMA, WITH AN ESTIMATED 2.7 MILLION HAVE OPEN-ANGLE GLAUCOMA, THE MOST COMMON TYPE. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE. 132212 11-11-21 Schedule O (Form 990) 2021

72

BRIGHTFOCUS' NGR PROGRAM HAS AWARDED MORE THAN \$46 MILLION WORLDWIDE FOR THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS BEEN FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND RISK OF DEVELOPING GLAUCOMA, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS.

NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2022, NGR AWARDED \$3,191,265 IN PEER-REVIEWED GRANT AWARDS FOR 17 NEW PROJECTS AND 2 OTHER SCIENTIFIC AWARDS TO MAKE A TOTAL OF \$3,539,684 IN FUNDING. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

73

FORM 990, PART VI, SECTION B, LINE 11B:

132212 11-11-21

Schedule O (Form 990) 2021

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDI	T COMMITTEE FOR
REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SE	RVICE. THE DRAFT
FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EA	CH COMMITTEE
MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUE	MISSION OF
QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FI	NAL FEDERAL FORM
990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIR	ECTORS PRIOR TO
BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT C	R FINAL FEDERAL
FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-	MAIL, OR FAX.
FORM 990, PART VI, SECTION B, LINE 12C:	

CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY.

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING. 132212 11-11-21 13420803 150872 191978 13420803 150872 191978 13420803 150872 191978 FORM 990, PART VI, SECTION B, LINE 15:

BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED ANNUALLY BY THE BOARD OF DIRECTORS THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT INCLUDES A SELF ASSESSMENT AND A BOARD OF DIRECTORS ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD SHALL SET	FORTH THE	BASIS FOR	ITS DECISIO	ONS WITH	RESPECT TO	
132212 11-11-21					Schedule O (Form S	990) 2021
420803 150872 191978		2021.	04012 BRIGH	TFOCUS FO		191978_1

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DE	CISIONS ARE MADE,
INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS	FOR DETERMINING
THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT	OF THE
EVALUATION AND COMPARABILITY DATA.	

THE PRESIDENT/CEO IS CHARGED WITH THE SETTING OF SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990: AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME,MD,MA,MI,MN,MO,MS,NC,ND,NH,NJ,NM,NY,OH OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

FORM 990, PART VI, SECTION C, LINE 19:

BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON OUR WEBSITE.

76

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:	
RECOVERIES OF PRIOR YEAR GRANTS	528,609.
CHANGE IN PRESENT VALUE OF GRANTS	361,988.
TOTAL TO FORM 990, PART XI, LINE 9	890,597.
SCHEDULE F, PART II, LINE 1, COLUMN D:	
REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE F	RESEARCH BY
LAIA MONTOLIU-GAYA, PHD, ENTITLED: (A2022015F) SIMULTANEOU	JS MEASUREMENT
OF SIX TAU PHOSPHORYLATIONS IN BLOOD TO STAGE ALZHEIMER'S	DISEASE.
INVESTIGATOR'S SUMMARY: A RELIABLE BLOOD TEST WOULD HAVE A	A GREAT
POTENTIAL FOR DIAGNOSIS OF ALZHEIMERS DISEASE (AD). IN THE	E RECENT
YEARS, MANY ASSAYS HAVE BEEN DEVELOPED TO MEASURE DIFFEREN	νT
PATHOLOGICAL VARIANTS OF A PROTEIN CALLED TAU IN BLOOD. WE	IEN TRYING TO
DETERMINE WHICH VARIANT IS THE BEST BIOMARKER, STUDIES CAN	N ONLY COMPARE
THE ASSAYS, BUT NOT THE LEVELS OF THE VARIANTS BECAUSE THE	EY ARE
MEASURED DIFFERENTLY. WE HAVE DEVELOPED A NOVEL METHOD THA	AT CAN COMPARE
ALL THESE VARIANTS AT THE SAME TIME IN THE SAME SAMPLE. WE	E AIM TO USE
THIS METHOD TO DETERMINE THE BEST BLOOD BIOMARKER FOR THE	DIFFERENT
STAGES OF AD. GRANT AWARDED: \$200,000, UNIVERSITY OF GOTHE	ENBURG,
INSTITUTE FOR NEUROSCIENCE AND PHYSIOLOGY, GOTHENBURG, SWE	EDEN. FOR
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022015F	
REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DI	ISEASE
RESEARCH BY CHRISTOPHER MORRONE, PHD, ENTITLED: (A2022016	F) IMPAIRMENTS
IN SLEEP AND PROTEOSTASIS ACCELERATE ALZHEIMER'S DISEASE F	PROGRESSION.
INVESTIGATOR'S SUMMARY: I HYPOTHESIZE THAT SLEEP LOSS AND	PROTEIN

 RECYCLING FAILURE ARE INTERACTIVE EVENTS IN ALZHEIMER'S DISEASE (AD),

 132212 11-11-21
 Schedule O (Form 990) 2021

 77
 77

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
THAT PRECEDE MEMORY LOSS AND PREDICT DISEASE PROGRESSION.	TO TEST THIS,
I WILL LOOK AT SLEEP AND MEMORY, NEURONAL FUNCTION, AND MA	RKERS OF
PROTEIN RECYCLING AND PATHOLOGY IN AN AD MOUSE MODEL TO SE	EIF
IMPROVING PROTEIN RECYCLING CAN RESCUE BEHAVIOR. ARTIFICIA	L
INTELLIGENCE MODELS WILL BE USED TO ASSESS THE CONTRIBUTIO	N OF THESE
BIOLOGICAL EVENTS TO PREDICT MEMORY LOSS AND DISEASE RISK,	FACILITATING
THE DISCOVERY OF NOVEL BIOMARKERS AND TREATMENTS FOR AD. G	RANT AWARDED:
\$200,000, CENTRE FOR ADDICTION AND MENTAL HEALTH, TORONTO,	ONTARIO,
CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBS	ITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2022016F	
REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE R SANDRA O. TOME, PHD, ENTITLED: (A2022019F) INVESTIGATING T	
IN ALZHEIMER'S DISEASE AND LATE: IMPACT ON THE CLINICAL DI	
INVESTIGATOR'S SUMMARY: DEMENTIA AFFECTS AROUND 50 MILLION	
WORLDWIDE, CAUSING DEVASTATING CONSEQUENCES TO THESE PATIE	
FAMILIES AND SOCIETY. ALZHEIMER'S DISEASE (AD) AND LATE AR	
COMMON DEMENTIAS IN THE ELDERLY. A LINK BETWEEN THESE DISE PRESENCE OF PATHOLOGICAL AGGREGATES WITH TDP-43 PROTEIN. I	
THE MAJOR CAUSE OF THE DISEASE WHILE IN AD IT ACCUMULATES	
AMYLOID-BETA AND TAU PROTEINS, WORSENING COGNITION. A RELE	
IS WHETHER THE TDP-43 PATHOLOGY OBSERVED IN AD AND LATE IS	
SIMILAR AND HOW IT IMPACTS THE CLINICAL DIAGNOSIS OF THESE	PATIENTS.
GRANT AWARDED: \$200,000, CATHOLIC UNIVERSITY OF LEUVEN, B	ELGIUM. FOR
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022019F	

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE

78

Schedule O (Form 990) 2021

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
RESEARCH BY KRISTIE STEFANOSKA, PHD, ENTITLED: (A2022022F)	MASTER SITES
OF TAU PHOSPHORYLATION AS TREATMENT TARGETS FOR ALZHEIMER'	S DISEASE.
INVESTIGATOR'S SUMMARY: THE PROGRESSION OF ALZHEIMER'S DIS	EASE
CORRELATES WITH THE ABNORMAL ACCUMULATION OF A BRAIN MOLEC	ULE CALLED
TAU. TAU UNDERGOES MODIFICATION, WHICH SUBSEQUENTLY CAUSES	IT TO
COLLECT WITH OTHER TAU PROTEINS AND FORM LARGER, ABNORMAL	STRUCTURES IN
THE BRAIN. I MADE THE DISCOVERY THAT TAU CONTAINS DISEASE-	PROMOTING
SITES, WHICH ARE ESSENTIAL IN DRIVING MODIFICATION IN THIS	PROTEIN AND
I AIM TO INVESTIGATE HOW REMOVING THE DISEASE-PROMOTING SI	TES ON TAU
COULD REDUCE ABNORMAL MODIFICATION OF TAU, AND THUS BE USE	D AS A NOVEL
THERAPEUTIC APPROACH TO MITIGATE PROCESSES UNDERLYING ALZH	EIMER'S
DISEASE. GRANT AWARDED: \$199,034, THE FLINDERS UNIVERSITY	OF SOUTH
AUSTRALIA, BEDFORD PARK, ADELAIDE, AUSTRALIA. FOR MORE I	NFORMATION,
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A	2022022F
REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE R	ESEARCH BY
LARISSA TRAXLER, PHD, ENTITLED: (A2022024F) ASSESSMENT OF	THE PYRUVATE

KINASE ISOFORM IMBALANCE IN THE LOSS OF CELL IDENTITY IN ALZHEIMER'S

DISEASE NEURONS AND NEUROINFLAMMATION. INVESTIGATOR'S SUMMARY:

ALZHEIMER'S DISEASE (AD) IS A FATAL NEURODEGENERATIVE DISEASE WITH NO

CURE IN SIGHT. BY GENERATING PATIENT-SPECIFIC INDUCED NEURONS (INS), WE

FOUND THAT ALZHEIMER NEURONS BEHAVE SIMILARLY TO CANCER CELLS, AS THEY

DE-DIFFERENTIATE TOWARDS A PRECURSOR STATE. HOWEVER, INSTEAD OF

INITIATING PROLIFERATION, NEURONS GET VULNERABLE TO STRESS-INDUCED

PROGRAMMED CELL DEATH. IN THIS PROJECT, WE WILL DEEPLY CHARACTERIZE

PYRUVATE KINASE M (PKM) IN THIS PROCESS IN POST-MITOTIC NEURONS, AND

ASSESS PKM AS A THERAPEUTIC TARGET FOR REVERSING THE AD PHENOTYPE.

GRANT AWARDED: \$200,000, UNIVERSITAT INNSBRUCK, AUSTRIA. FOR MORE Schedule O (Form 990) 2021 132212 11-11-21 79

13420803 150872 191978

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number 23-7337229

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022024F

REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY URI ASHERY, PHD, ENTITLED: (A2022029S) TOWARDS NANOSCALE BLUEPRINTS OF EARLY MOLECULAR, SYNAPTIC AND PHYSIOLOGICAL CHANGES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DEGENERATION OF SYNAPTIC CONTACTS BETWEEN NEURONS IN THE BRAIN IS ONE OF THE FIRST PROCESSES THAT LEAD TO ALZHEIMER'S DISEASE (AD). THIS OCCURS NEAR AMYLOID DEPOSITS, WHICH ARE THE MAIN HALLMARKS OF AD. HOWEVER, WHAT CAUSES SYNAPTIC LOSS IS NOT KNOWN. WE WILL USE, FIRST TIME IN AD, A NOVEL PLATFORM WE DEVELOPED, TO DETECT MOLECULAR CHANGES OF HUNDREDS OF GENES IN INTACT BRAIN TISSUES AT EARLY DISEASE STAGES, RELATE THEM TO SPECIFIC CELL TYPES, PROXIMITY TO AMYLOID DEPOSITS, AND SEX DIFFERENCES. UNDERSTANDING THESE MECHANISMS WILL HELP DEVELOP THERAPEUTICS TO HINDER AND PREVENT THESE PROCESSES. GRANT AWARDED: \$300,000, TEL AVIV UNIVERSITY, ISRAEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022029S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAMUEL BARNES, PHD, ENTITLED: (A2022030S) FUNCTIONAL AND MOLECULAR MAPPING OF VULNERABLE GABAERGIC SYNAPSES IN EARLY-STAGE AD PATHOPHYSIOLOGY. INVESTIGATOR'S SUMMARY: LOSS OF SYNAPTIC CONNECTION POINTS BETWEEN BRAIN CELLS HAS BEEN LINKED TO MEMORY LOSS IN ALZHEIMER'S DISEASE (AD). HOWEVER, NOT ALL SYNAPSES ARE LOST DURING THE DISEASE, WITH SOME REPORTS FINDING APPROXIMATELY 60% SYNAPTIC SURVIVAL. WE AIM TO UNDERSTAND THE MOLECULES AND RESPONSE PROPERTIES THAT MAKE SOME SYNAPSES VULNERABLE AND OTHERS RESILIENT. TO DO THIS, WE WILL USE 132212 11-11-21 80

13420803 150872 191978

	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
MOUSE MODELS AND HUMAN AD BRAIN TISSUE TO IDENTIFY KEY MOI	LECULES AT
SYNAPSES WITH NORMAL AND ABNORMAL RESPONSES DURING DISEASI	E PROGRESSION.
WE WILL USE THIS INFORMATION TO DEVELOP NEW MEDICAL APPROA	ACHES TO BOOST
SYNAPSE SURVIVAL IN AD. GRANT AWARDED: \$299,715, IMPERIAL	COLLEGE OF
SCIENCE, TECHNOLOGY AND MEDICINE, LONDON, UNITED KINGDOM.	FOR MORE
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTA CORTES-CANTELI, PHD, ENTITLED: (A2022034S) UNDERSTANDING THE IMPACT OF MIDLIFE CARDIOVASCULAR RISK FACTORS & SUBCLINICAL ATHEROSCLEROSIS ON BRAINS HEALTH: A ROLE ON ALZHEIMERS PATHOLOGY. INVESTIGATOR'S SUMMARY: CARDIOVASCULAR RISK FACTORS INCREASE THE LIKELIHOOD OF DEVELOPING MEMORY PROBLEMS IN THE ELDERLY AND, INDEED, CARDIOVASCULAR DISORDERS AND ALZHEIMER'S DISEASE APPEAR TOGETHER IN SYMPTOMATIC STAGES. AS BOTH DISEASES SHARE RISK FACTORS AND HAVE LONG SUBCLINICAL PHASES, WE PROPOSE TO ANALYZE WHAT IS HAPPENING DURING THE 10-20 YEARS BEFORE THE SYMPTOMS OF BOTH PATHOLOGIES APPEAR. OUR STUDIES WILL DECIPHER WHETHER NOT MAINTAINING A HEALTHY LIFESTYLE WHEN YOU ARE IN YOUR 50'S COULD START HAVING NEGATIVE CONSEQUENCES FOR YOUR BRAIN AT THAT MOMENT AND CONTRIBUTE TO MEMORY PROBLEMS A DECADE LATER. GRANT AWARDED: \$300,000, CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.), MADRID, SPAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022034S

SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:

REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH

BY YUVAL DOR, PHD, ENTITLED: (A2022035S) LIQUID BIOPSY FOR DETECTION OF
132212 11-11-21
Schedule O (Form 990) 2021
81

Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
CELL DEATH IN ALZHEIMER'S DISEASE BASED ON CFDNA METHYLATI	ON PATTERNS.
INVESTIGATOR'S SUMMARY: WE PROPOSE TO ESTABLISH A NOVEL TY	PE OF BLOOD
TEST A LIQUID BIOPSY - TO IDENTIFY AND MONITOR CELL DEATH	IN THE BRAIN
AND IN OTHER KEY TISSUES IN PATIENTS DEVELOPING ALZHEIMER'	S DISEASE
(AD). THE APPROACH IS BASED ON A NEW TECHNOLOGY THAT ALLOW	IS TO
DETERMINE THE TISSUE SOURCES OF DNA MOLECULES RELEASED FRO	M DYING CELLS
TO THE BLOOD, USING CELL TYPE-SPECIFIC DNA METHYLATION PAT	TERNS. THE
ASSAY WILL BE APPLIED TO BLOOD SAMPLES OBTAINED FROM HEALT	НҮ
INDIVIDUALS, PEOPLE WITH MILD COGNITIVE IMPAIRMENT THAT GO	ON TO
DEVELOP AD, AND PATIENTS WITH ESTABLISHED DISEASE. GRANT A	WARDED:
\$300,000, HEBREW UNIVERSITY OF JERUSALEM, ISRAEL. FOR MO	RE
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022035S	
REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DI	SEASE
RESEARCH BY SUE-ANN MOK, PHD, ENTITLED: (A2022044S) DISSEC	TING HOW PTMS
REGULATE TAU AGGREGATE STRAIN FORMATION. INVESTIGATOR'S S	UMMARY: IN
ALZHEIMER'S DISEASE, MOLECULES OF TAU PROTEIN FORM VERY SP	ECIFIC SHAPES
AS THEY STACK TOGETHER TO CREATE LARGE STRUCTURES CALLED A	GGREGATES
THAT ARE THOUGHT TO CONTRIBUTE TO DEVELOPMENT AND PROGRESS	ION OF
DISEASE. IF WE COULD FIGURE OUT THE FACTORS THAT CAUSE TAU	TO TAKE ON
THE SPECIFIC SHAPES WE OBSERVE IN DISEASE, WE MAY BE ABLE	

THIS PATHOLOGICAL PROCESS. WE ARE USING ADVANCED BIOCHEMICAL

TECHNOLOGIES TO STUDY HUNDREDS OF POTENTIAL FACTORS, CALLED

POST-TRANSLATIONAL MODIFICATIONS, AND IDENTIFY THE KEY FACTORS LEADING

TO THE TAU SHAPES OBSERVED IN ALZHEIMER'S. GRANT AWARDED: \$299,851,

UNIVERSITY OF ALBERTA, EDMONTON, CANADA. FOR MORE INFORMATION, VISIT

82

THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022044S

Schedule O (Form 990) 2021

132212 11-11-21

BRIGHTFOCUS FOUNDATION

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DOMINIK PAQUET, PHD, ENTITLED: (A2022045S) DEVELOPMENT OF A HUMAN IPSC-BASED TAUOPATHY MODEL SHOWING ADVANCED PHENOTYPES. INVESTIGATOR'S SUMMARY: INVESTIGATING THE MECHANISMS LEADING TO NERVE CELL DECLINE IN DEMENTIAS REQUIRES EXPERIMENTAL DISEASE MODELS. WE WILL DEVELOP A HUMAN MODEL OF TAU-RELATED DEMENTIAS, SUCH AS ALZHEIMER'S AND FTD. THE TAU PROTEIN PLAYS A CENTRAL ROLE IN DEMENTIA FORMATION AND NERVE CELL DEATH. BUT ITS REGULATION IN HUMAN NERVE CELLS DIFFERS FROM MICE, WHICH ARE CURRENTLY USED AS MODELS. USING BRAIN CELLS DERIVED FROM HUMAN STEM CELLS AND GENOME EDITING WITH CRISPR, WE AIM TO GENERATE BRAIN TISSUE WITH GENETIC ALTERATIONS IN THE TAU GENE LEADING TO DEMENTIA IN PATIENTS, TO INVESTIGATE HUMAN DISEASE MECHANISMS. GRANT AWARDED: \$300,000, HOSPITAL OF THE LUDWIG MAXIMILIAN, UNIVERSITY OF MUNICH, FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: GERMANY. WWW.BRIGHTFOCUS.ORG/GRANT/A2022045S

Schedule O (Form 990) 2021 Name of the organization	Page 2
BRIGHTFOCUS FOUNDATION	23-7337229
RESPONDS TO TDCS. THESE RESULTS WILL HELP US OPTIMIZE ANI	D TAILOR TDCS
FOR PEOPLE WITH AD. GRANT AWARDED: \$243,196, BAYCREST CEN	NTRE FOR
GERIATRIC CARE, TORONTO, CANADA. FOR MORE INFORMATION,	VISIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022046S	
REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE	RESEARCH BY
CARLOS SAURA, PHD, ENTITLED: (A2022047S) TARGETING EXCITA	ATORY NEURAL
CIRCUITS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY	COMMUNICATION
OF NEURONS IS FUNDAMENTAL FOR BRAIN FUNCTION DURING COGN	ITION, MEMORY
AND MENTAL PROCESSES. DISRUPTION OF MEMORY NEURAL CIRCUIT	IS CONTRIBUTES
TO PATHOLOGY, NEURODEGENERATION AND MEMORY LOSS EARLY IN	ALZHEIMER'S
DISEASE (AD), BUT THE MECHANISMS INVOLVED REMAIN UNKNOWN	. THIS PROJECT
WILL EMPLOY NOVEL STATE-OF-THE ART MOUSE MODELS AND TECHN	NIQUES TO
UNRAVEL THE MECHANISMS UNDERLYING MEMORY CIRCUIT DISRUPT	ION AND HOW IT
CONTRIBUTES TO MEMORY LOSS EARLY IN AD. FINALLY, WE WILL	DEVELOP NOVEL
PHARMACOGENETIC AND GENE THERAPY APPROACHES TO ACTIVATE N	NEURAL CIRCUITS
AND MEMORY IN AD. GRANT AWARDED: \$300,000, UNIVERSITY AU	FONOMA OF
BARCELONA, BELLATERRA, SPAIN. FOR MORE INFORMATION, VIS	SIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022047S	
REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE	RESEARCH BY
DR. GAELLE CHETELAT ENTITLED: (CA2021013) SEX DIFFERENCES	5 IN RISK

PROFILES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. INVESTIGATOR'S

SUMMARY: THIS PROJECT, WHICH WILL TAKE PLACE AT UNIVERSITY OF CAEN

NORMANDIE. BASED ON TWO EXISTING COHORTS OF PEOPLE AT DIFFERENT STAGES

OF ALZHEIMER'S DISEASE, DR. CHETELAT'S TEAM WILL HIGHLIGHT

GENDER-SPECIFIC RISK PROFILES AND ASSESS THEIR ABILITY TO PREDICT THE

 CLINICAL COURSE OF PATIENTS. NEXT, THE TEAM WILL INVESTIGATE WHETHER

 132212 11-11-21
 Schedule O (Form 990) 2021

 84

13420803 150872 191978

Name of the organization BRIGHTFOCUS FOUNDATION THESE RISK PROFILES CAN BE REDUCED BY AN INTERVENTION BAS: TRAINING (THROUGH MEDITATION OR LEARNING ENGLISH). IDENTION DISTINGUISHING THE RISK FACTORS THAT ARE SPECIFIC TO MEN SHOULD ALLOW BETTER CONSIDERATION OF SEX-RELATED DIFFERENCE LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS OF PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED THE DISEASE, TAKING INTO ACCOUNT THE SPECIFICITIES OF MEN	FYING AND AND WOMEN CES AND THUS OF THIS MANAGEMENT OF AND WOMEN.
TRAINING (THROUGH MEDITATION OR LEARNING ENGLISH). IDENTI DISTINGUISHING THE RISK FACTORS THAT ARE SPECIFIC TO MEN SHOULD ALLOW BETTER CONSIDERATION OF SEX-RELATED DIFFEREN LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS OF PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED	FYING AND AND WOMEN CES AND THUS OF THIS MANAGEMENT OF AND WOMEN.
DISTINGUISHING THE RISK FACTORS THAT ARE SPECIFIC TO MEN SHOULD ALLOW BETTER CONSIDERATION OF SEX-RELATED DIFFEREN LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED	AND WOMEN CES AND THUS OF THIS MANAGEMENT OF AND WOMEN.
SHOULD ALLOW BETTER CONSIDERATION OF SEX-RELATED DIFFEREN LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS ( PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED	CES AND THUS OF THIS MANAGEMENT OF AND WOMEN.
LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS OF THE DISEASE. THE RESULTS OF PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED	OF THIS MANAGEMENT OF AND WOMEN.
PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED	MANAGEMENT OF AND WOMEN.
	AND WOMEN.
THE DISEASE, TAKING INTO ACCOUNT THE SPECIFICITIES OF MEN	
	S, FRANCE.
GRANT AWARDED: \$68,278, FONDATION VAINCRE ALZHEIMER, PARI	
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/CA2021013	
REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: NATIONA	L GLAUCOMA
RESEARCH BY EMMANUELLE SOUZEAU, PHD, ENTITLED: (G2022002F	)
INVESTIGATING NOVEL GENETIC COUNSELING AND COMMUNICATION	STRATEGIES FOR
POLYGENIC RISK TESTING IN GLAUCOMA. INVESTIGATOR'S SUMMA	RY: THE RECENT
DEVELOPMENT OF POLYGENIC RISK SCORES (PRS) FOR GLAUCOMA M	AKES GENETIC
TESTING AN IDEAL STRATEGY TO IDENTIFY AT-RISK INDIVIDUALS	WHO CAN
BENEFIT FROM EARLY MANAGEMENT TO REDUCE PREVENTABLE BLIND	NESS. HOWEVER,
THE CURRENT LACK IN REPORTING STRATEGIES TO EFFICIENTLY C	OMMUNICATE PRS
TO PATIENTS IMPEDES THE IMPLEMENTATION OF TESTING IN CLIN	ICAL PRACTICE.
THIS PROPOSAL AIMS TO DEVELOP THE FIRST PATIENT-FRIENDLY	REPORTS AND
ASSESS DELIVERY METHODS FOR RISK COMMUNICATION OF PRS FOR	GLAUCOMA,
WHICH WILL ULTIMATELY BENEFIT AT-RISK INDIVIDUALS GLOBALL	Y. GRANT
AWARDED: \$148,049, THE FLINDERS UNIVERSITY OF SOUTH AUSTR	ALIA, BEDFORD
PARK, ADELAIDE, AUSTRALIA. FOR MORE INFORMATION, VISIT	THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022002F	

132212 11-11-21 Schedule O (Form 990) 2021	REGION:	EUROPE	(D)	PURPOSE	OF	GRANT:	NATIONAL	GLAUCOMA	RESEARCH	BY
05	132212 11-11-21								Sch	edule O (Form 990) 2021

Schedule O (Form 990) 2021

Page **2** 

Schedule O (Form 990) 2021	Page 2
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
MARCO FELIGIONI, PHD, ENTITLED: (G2022015S) SPECIFICALLY T	ARGETING
GLUTAMATE RELEASE TO TACKLE RETINAL GANGLION CELL DEGENERA	TION IN
GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A PROGRESSI	VE AND
NEURODEGENERATIVE DISORDER AFFECTING RETINAL CELLS VIABILI	ТҮ WHICH
PROGRESSIVELY BRINGS TO BLINDNESS. DESPITE THE PHARMACOLOG	ICAL
TREATMENTS AVAILABLE ON THE MARKET, NORMALLY LIMITED TO	
ANTIHYPERTENSIVE DRUGS, THERE ARE NO TREATMENTS TO PROTECT	THE RETINA
AND OPTIC NERVE FROM THE PROGRESSIVE DAMAGE. THEREFORE NEU	ROPROTECTION
IS AN UNMET MEDICAL NEED FOR WHICH THE RESEARCH IS TRYING	TO GIVE NEW
ANSWER. IN THIS CONTEXT, THIS PROJECT AIMS AT INVESTIGATIN	G THE
PROPERTIES OF OUR NEW DRUG AGAINST DEGENERATION OF RETINAL	GANGLIAL
CELLS GRANT AWARDED: \$200,000, FONDAZIONE EBRI "RITA LEVI-	MONTALCINI",
ROME, ITALY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS	WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022015S	

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NICOLE NOEL, PHD, ENTITLED: (M2022002F) ASSESSING RETINAL DISEASE MANIFESTATION AND NEUROPROTECTION IN THE KILLIFISH MODEL OF AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THIS WORK PROVIDES THE UNIQUE OPPORTUNITY TO DEVELOP KILLIFISH AS A RETINAL AGEING MODEL, DETERMINE THE CELLULAR MECHANISMS THAT LEAD TO AMD, AND ASSESS HOW HEALTHY RETINAL AGEING CAN BE PROMOTED IN A MODEL OF AGE-RELATED RETINAL DEGENERATION. GRANT AWARDED: \$199,998, UNIVERSITY COLLEGE LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022002F

SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:

 REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY

 132212 11-11-21
 Schedule O (Form 990) 2021

 86

Schedule O (Form 990) 2021 Name of the organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
BRIGHTICCOD TOORBHITOR	23 1331223
LUCIA CELKOVA, PHD, ENTITLED: (M2022004F) AN INVESTIGATION	INTO THE
ROLE OF PANOPTOSIS IN GEOGRAPHIC ATROPHY. INVESTIGATOR'S	SUMMARY: THE
RESEARCH PROPOSED HERE AIMS TO EXPLORE A MASTER "DECISION	MAKER" WHICH
COULD INTEGRATE AND PROCESS THESE TRIGGERS AND GUIDE THE F	ATE OF RPE
CELLS EITHER TOWARDS SURVIVAL OR DEATH. THROUGH THIS, WE W	ILL NOT ONLY
GAIN A BETTER UNDERSTANDING OF THE COMPLEX PROCESS UNDERLY	ING RPE CELL
DEATH, BUT WILL ALSO IDENTIFY POTENTIAL NEW TARGETS AND ST	RATEGIES FOR
THERAPEUTIC INTERVENTION IN DRY AMD. GRANT AWARDED: \$200,	000, COLLEGE
OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, DUBL	IN, IRELAND.
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/M2022004F	

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YARA LECHANTEUR, MD, PHD, ENTITLED: (M2022013N) CLINICAL AND MOLECULAR CHARACTERIZATION OF EARLY ONSET DRUSEN MACULOPATHY. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION IS THE MOST COMMON CAUSE OF BLINDNESS. IT USUALLY STARTS AT AN AFTER THE AGE OF 65 BUT SOME PATIENTS DEVELOP A SIMILAR PHENOTYPE ALREADY BEFORE THEY TURN 50. WE AIM TO STUDY THESE YOUNG ONSET CASES BY STUDYING THEIR FAMILY MEMBERS AND BY LOOKING AT GENETIC FACTORS AND SPECIFIC MARKERS IN BLOODSAMPLES. OUR AIM IS TO IDENTIFY NEW FACTORS THAT ARE INVOLVED IN THIS DISEASE. BETTER KNOWLEDGE ABOUT THE DISEASE CAN AID IN DEVELOPMENT OF FUTURE THERAPIES AND MAY BRING US A STEP CLOSER TOWARDS TREATMENT. GRANT AWARDED: \$449,838, RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE, NIJMEGEN, NETHERLANDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022013N

87

REGION:	NORTH	AMERICA	(D)	PURPOSE	OF	GRANT:	MACULAR	DEGENERATION
---------	-------	---------	-----	---------	----	--------	---------	--------------

Schedule O (Form 990) 2021

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
RESEARCH BY PRZEMYSLAW SAPIEHA, PHD, ENTITLED: (M2022015I)	EARLY LIFE
METABOLIC EVENTS INFLUENCE AGE-RELATED MACULAR DEGENERATION	N
INVESTIGATOR'S SUMMARY: IMMUNE CELLS, WHICH PLAY A KEY ROL	E IN THE
ABERRANT BLOOD VESSEL GROWTH DURING AMD, ARE ALTERED FOLLO	WING
ENCOUNTERS WITH PATHOGENS, AS WELL AS DURING PERSISTENT EV	ENTS SUCH AS
OBESITY, POTENTIALLY IMPACTING DISEASE DEVELOPMENT. IN THI	S PROPOSAL,
WE WILL ASSESS WHETHER IMMUNE CELLS ARE MODIFIED IN A WAY	THAT
INCREASES THE RISK OF AMD FOLLOWING WEIGHT GAIN AND SUBSEQ	UENT WEIGHT
LOSS. UNDERSTANDING HOW IMMUNE CELLS RESPOND IN THE CONTEX	T OF PAST
OBESITY WILL ALLOW US TO GAIN INSIGHT ON MECHANISMS THAT C	AUSE AMD AND
POTENTIALLY LEAD THE WAY TO DEVELOPING TARGETED INTERVENTION	ONS. GRANT
AWARDED: \$600,000, HOSPITAL MAISONNEUVE-ROSEMONT, MONTREAL	, QUEBEC,
CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBS	ITE:
WWW.BRIGHTFOCUS.ORG/GRANT/M20220151	

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY WEN HWA LEE, PHD, ENTITLED: (M2022002) CREATING FORESIGHT: CHARITY-LED BIG DATA RESOURCE FOR DISCOVERY OF NOVEL BIOMARKERS FOR MULTIPLE CONDITIONS USING EYE SCANS. INVESTIGATOR'S SUMMARY: THE GOAL OF THIS PROJECT IS TO BUILD A PROSPECTIVE DATASET OF HIGH-CONTENT IMAGES AND 3D SUB-TISSUE RETINAL SCANS OF 500,000 PARTICIPANTS WITH CONSENT FOR SECONDARY USE AND LINKAGE TO OTHER HEALTH DATASETS. PARTICIPANTS AND DATA COLLECTION WILL BE DISEASE AGNOSTIC AND WILL INCLUDE HEALTHY PARTICIPANTS; 500,000 MILESTONE TO BE REACHED BY YEAR 3; ETHICAL, TRANSPARENT, AND PUBLICLY SUPPORTED DATA ACCESS MODEL; PARTICIPANTS' EYE SCANS CAN BE LINKED TO GENOTYPING DATA TO BE GENERATED BY UK'S OUR FUTURE HEALTH INITIATIVE. FURTHER THIS DATASET WILL BE MADE AVAILABLE FOR RESEARCH VIA COLLABORATION WITH SCIENTISTS FROM ACADEMIA AND/OR Schedule O (Form 990) 2021 132212 11-11-21 88

13420803 150872 191978

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
SMES. GRANT AWARDED: \$250,000, ACTION AGAINST AMD, LONDON	
KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEB	-
WWW.BRIGHTFOCUS.ORG/GRANT/CM2022002	
SCHEDULE I, PART II, LINE I, COLUMN (H):	
	. (H)
SCHEDULE I, PART II, LINE 1, COLUMN (H): NAME OF ORGANIZATION OR GOVERNMENT: ALBANY MEDICAL COLLEGE PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHARLY A	

DEMENTIA. INVESTIGATOR'S SUMMARY: LOW TESTOSTERONE LEVELS IN MEN ARE A

RISK FACTOR FOR DEMENTIA AND ARE ASSOCIATED WITH COGNITIVE DECLINE.

THIS STUDY WILL INVESTIGATE THE EFFECTS OF TESTOSTERONE REMOVAL AND

TREATMENT ON COGNITIVE DECLINE AND PATHOLOGY IN A NEW MOUSE MODEL OF

MULTI-ETIOLOGY DEMENTIA. THIS ADDRESSES A MAJOR BRAIN HEALTH ISSUE IN

MEN (DEMENTIA) AND CONTRIBUTES TO THE DEVELOPMENT OF NEW TREATMENTS AND

PREVENTIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022001F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANA RITA AGRA DE ALMEIDA QUADROS, PHD, ENTITLED: (A2022002F) TDP-43-DEPENDENT TRUNCATION OF STATHMIN-2 MRNA AS A NOVEL TARGET IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ACCUMULATION OF TOXIC PROTEINS IN THE BRAIN FROM PATIENTS WITH ALZHEIMER'S DISEASE (AD) CONTRIBUTES TO NEURODEGENERATION. TDP-43 IS ONE OF THE PROTEINS THAT ABNORMALLY ACCUMULATES IN UP TO 50% OF AD PATIENTS. RECENTLY, MY LABORATORY AND OTHERS SHOWED THAT STATHMIN-2, A PROTEIN CRUCIAL FOR NEURONAL FUNCTION, IS LOST IN NEURONS WITH ABNORMAL TDP-43. I WILL DETERMINE WHETHER STATHMIN-2 IS ALTERED IN ALZHEIMER'S DISEASE PATIENTS AND REPRESENTS A 12212 11-121 89

13420803 150872 191978

NEW POTENTIAL THERAPEUTIC TARGETS FOR PATIENTS WITH TDP-43 PATHOLOGY.

FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022002F

NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL

UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY

ANTOINE ANFRAY, PHD, ENTITLED: (A2022003F) ROLE OF PERIVASCULAR

MACROPHAGES IN APOE4-INDUCED NEUROVASCULAR DYSFUNCTION. INVESTIGATOR'S

SUMMARY: ACCUMULATING EVIDENCE SUGGEST THAT EARLY ALTERATION IN THE

BLOOD FLOW IN THE BRAIN IS AN IMPORTANT CONTRIBUTING FACTOR TO

ALZHEIMER'S DISEASE (AD). INDIVIDUALS WITH APOLIPOPROTEIN E E4 (APOE4),

A LEADING GENETIC RISK FACTOR FOR AD, HAVE REDUCED BLOOD FLOW TO THE

BRAIN; HOWEVER, THE UNDERLYING MECHANISMS ARE UNKNOWN. THEREFORE, THE

AIM OF THIS PROJECT IS TO STUDY THE BRAIN BLOOD FLOW DYSFUNCTION CAUSED

BY APOE4 WITH THE ULTIMATE GOAL OF IDENTIFYING NEW PATHWAYS THAT COULD

BE USED TO DEVELOP NEW DRUGS FOR THE PREVENTION AND TREATMENT OF

DEMENTIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022003F

NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHING-CHIEH CHOU, PHD, ENTITLED: (A2022004F) ROLE OF AGE-RELATED LYSOSOMAL VULNERABILITY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: LYSOSOMAL VULNERABILITY IS CRITICAL TO THE DEVELOPMENT OF ALZHEIMER'S DISEASE (AD), WHEREAS THE MOLECULAR BASIS OF THE DEFICIT IN HUMAN NEURONS IS NOT FULLY UNDERSTOOD. I HARNESS THE LINEAGE REPROGRAMMING TECHNOLOGY TO TRANSDIFFERENTIATE HUMAN SOMATIC CELLS INTO NEURONS (TNEURONS) TO FACILITATE THE LEARNING OF DISEASE BIOLOGY AND TEST THERAPEUTIC 19212 11-11-21 Schedule O (Form 990) 2021

13420803 150872 191978

Schedule O (Form 990) 2021 Name of the organization	Page 2 Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
STRATEGIES FOR AD. THE OUTCOMES WILL ADVANCE OUR UNDERSTAN	IDING OF
LYSOSOMAL DYSFUNCTION AND LYSOSOME-TARGETING COMPOUNDS FOR	AD AND
POTENTIALLY AND OTHER DEMENTIAS. FOR MORE INFORMATION, VI	SIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022004F	
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORM	IIA (IRVINE).
(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHRI	ISTIAN
CROUZET, PHD, ENTITLED: (A2022005F) THE EFFECT OF HYPERTEN	ISION ON
NEUROVASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE PROGRESS	SION DURING
MIDLIFE. INVESTIGATOR'S SUMMARY: MIDLIFE HYPERTENSION IS	AN
INCREASINGLY IMPORTANT RISK FACTOR FOR ALZHEIMER'S DISEASE	E (AD) AND
RELATED DEMENTIAS. WE WILL INVESTIGATE HOW HYPERTENSION AF	FECTS THE
PROGRESSION OF ALZHEIMER'S DISEASE FROM A BLOOD FLOW, COGN	NITIVE, AND
PATHOLOGICAL PERSPECTIVE THROUGH MIDLIFE. WE WILL TEST IF	
ANTI-HYPERTENSIVE MEDICATION CAN SLOW THE PROGRESSION OF A	AD AND IMPROVE
COGNITIVE FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGH	ITFOCUS
WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022005F	
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MASSACHU	JSETTS CHAN
MEDICAL SCHOOL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE	E RESEARCH BY
VIOLETA DURAN LAFORET, PHD, ENTITLED: (A2022006F) HARNESS	ING SPATIAL
TRANSCRIPTOMICS TO INVESTIGATE THE INTERSECTION OF SENESCE	ENCE AND
INFLAMMATION IN NEURODEGENERATION. INVESTIGATOR'S SUMMARY	AGING IS
THE MAJOR RISK FACTOR FOR ALZHEIMER'S DISEASE (AD). SENESC	CENCE, A
HALLMARK OF AGING, IS A PROCESS BY WHICH A CELL NO LONGER	CAN
PROLIFERATE. SINCE MICROGLIA, THE PRIMARY IMMUNE CELL OF 7	THE CENTRAL

NERVOUS SYSTEM, BECOME SENESCENT IN AD, I WILL INVESTIGATE IF THEY

INITIATE THE INFLAMMATORY PROCESS IN THE AGING BRAIN AND STUDY IF
132212 11-11-21
Schedule O (Form 990) 2021
91

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229			
SENESCENT CELLS ARE PRESENT IN SPECIFIC LOCATIONS WITHIN T	THE BRAIN IN			
AD. TO DO SO, I WILL IMPLEMENT AN INNOVATIVE APPROACH CALI	LED MERFISH TO			
LOOK AT 100'S OF GENES DIRECTLY IN TISSUE. ULTIMATELY, TH	IS STUDY COULD			
RESULT IN IDENTIFYING NEW THERAPEUTIC TARGETS. FOR MORE INFORMATION,				
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A	A2022006F			
NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICI	INE AT MOUNT			
SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH	I BY GABRIELA			
FARIAS QUIPILDOR, PHD, ENTITLED: (A2022007F) SCRUTINIZING	THE FUNCTION			
OF TREM2 AND TYROBP IN MICROGLIAL HOMEOSTASIS AND ACTIVATI	ION.			
INVESTIGATOR'S SUMMARY: DURING NORMAL AGING AND ALZHEIMER	S DISEASE			
(AD), MICROGLIA, THE PRIMARY IMMUNE CELL IN THE BRAIN, HAV	/E SHOWN TO			
HAVE A DIFFERENT PHENOTYPE, MORPHOLOGY, AND FUNCTION UPON	ACTIVATION.			
HOWEVER, THERE ARE STILL MANY UNKNOWNS IN RELATION TO THE	MECHANISMS			
INVOLVED IN THE DIFFERENT ACTIVATION STATES OF MICROGLIA.	THEREFORE ,			
THIS STUDY PROPOSES TO DISSECT THE INVOLVEMENT OF KEY REGULATORS OF				
MICROGLIAL ACTIVATION IN NORMAL PHYSIOLOGY AND DISEASE AND	) TO PROVIDE			
NEW INSIGHTS ON THE ROLE OF MICROGLIA IN AD PATHOGENESIS V	VITH THE			
POTENTIAL TO UNEARTH NEW THERAPEUTIC TARGETS. FOR MORE IN	IFORMATION,			
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/	A2022007F			

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRANDON HOLMES, PHD, ENTITLED: (A2022008F) INTERROGATING AND TARGETING THE MICROGLIA CELL-SURFACE IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE MICROGLIA SURFACEOME SERVES AS A CRITICAL CELLULAR HUB THAT ENABLES NEUROPROTECTIVE, NEUROTOXIC, AND NEUROINFLAMMATORY SIGNALING IN THE DISEASED BRAIN. THE ABILITY TO PRECISELY TARGET AND 132212 11-11-21 Schedule O (Form 990) 2021

13420803 150872 191978

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
MANIPULATE DIVERSE MICROGLIA STATES THEREFORE HOLDS TREMEN	IDOUS
EXPERIMENTAL, DIAGNOSTIC, AND THERAPEUTIC POTENTIAL. THE E	ROPOSED
PROJECT WILL USE INNOVATIVE TECHNOLOGIES TO COMPREHENSIVE	Y DEFINE THE
SURFACEOME CHANGES OF ALZHEIMER'S DISEASE MICROGLIA AND WI	LL THEREFORE
PROVIDE THE FIRST HUMAN CELL-SURFACE PROTEIN MAP IN THIS C	ELL TYPE AND

DISEASE CONTEXT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022008F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HOANG LE, PHD, ENTITLED: (A2022009F) UNDERSTANDING THE IMPACT OF TREM2 T96K MUTATION IN THE LIGAND-BINDING DOMAIN ON ALZHEIMER'S DISEASE PATHOGENESIS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE LEADING CAUSE OF DEMENTIA AFFECTING MORE THAN 5.8 MILLION PEOPLE IN THE UNITED STATES; HOWEVER, WE STILL DO NOT HAVE EFFECTIVE THERAPIES TO PREVENT OR DELAY THIS DEBILITATING DISEASE. THIS PROPOSED STUDY AIMS TO UNDERSTAND THE IMPACT OF THE AD-ASSOCIATED MUTATION TREM2 T96K ON AD PATHOGENESIS USING A NOVEL TREM2 T96K KNOCK-IN MICE CROSSED WITH THE 5XFAD MOUSE MODEL OF AD AS WELL AS IN VITRO MICROGLIAL MODELS. THE INSIGHTS OBTAINED SHOULD BE USEFUL FOR AD DRUG DISCOVERY AND DEVELOPMENT TARGETING TREM2. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022009F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED: NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALEXANDRA LITVINCHUK, PHD, ENTITLED: (A2022010F) THE ROLE OF ABCA1 IN REGULATION OF GLIAL LIPID METABOLISM IN APOE4-INDUCED TAUOPATHY AND ALZHEIMER'S

93

13420803 150872 191978

132212 11-11-21

Schedule O (Form 990) 2021

Schedule O (Form 990) 2021 Name of the organization	Page 2 Employer identification number			
BRIGHTFOCUS FOUNDATION	23-7337229			
DISEASE. INVESTIGATOR'S SUMMARY: APOE4 IS THE STRONGEST GENETIC RISK				
FACTOR FOR DEVELOPING LATE-ONSET AD AND WAS SHOWN TO MARKE	FACTOR FOR DEVELOPING LATE-ONSET AD AND WAS SHOWN TO MARKEDLY ELEVATE			
TAU PATHOLOGY AND NEURODEGENERATION IN THE P301S/APOE4 TAU	OPATHY MICE.			
A DISRUPTION OF LIPID METABOLISM IN GLIA IS LINKED TO NEUR	OINFLAMMATION			
AND NEURODEGENERATION IN SEVERAL STUDIES; WE RECENTLY DETE	CTED A			
SIGNIFICANT BUILDUP OF LIPIDS IN GLIA OF AGED P301S/APOE4	ANIMALS. IN			
THIS STUDY, WE WILL ASSESS THE ROLE OF ABCA1 LIPID TRANSPO	RTER IN			
MODULATION OF GLIAL LIPID METABOLISM IN THE P301S/APOE4 MI	CE, THUS,			
PROVIDING NOVEL THERAPEUTIC AVENUES FOR TREATING TAUOPATHY	AND AD. FOR			
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:				
WWW.BRIGHTFOCUS.ORG/GRANT/A2022010F				
NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL	HOSPITAL.			
(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHAO	LIU, PHD,			
ENTITLED: (A2022011F) DEVELOPING A NOVEL OPTICAL IMAGING M	IETHOD TO			
INVESTIGATE THE RELATIONSHIP OF WHITE MATTER ABNORMALITY A	ND			
VASCULATURE IN CEREBRAL AMYLOID ANGIOPATHY. INVESTIGATOR'	S SUMMARY:			
WHITE MATTER HYPERINTENSITY (WMH) IS A TYPICAL NEUROIMAGE	MARKER FOR			
THE DIAGNOSTICS OF CEREBRAL AMYLOID ANGIOPATHY (CAA), HOWE	VER, ITS ROLE			
IN NEURODEGENERATION IS NOT FULLY UNDERSTOOD. THE PROPOSED	PROJECT AIMS			
TO ESTABLISH A VERSATILE TOOL, AUTOMATIC SERIAL 3D OPTICAL	COHERENCE			
SCANNER (AS-3DOCS), WHICH WILL UNRAVEL THE SOURCES FOR WMH	IN CLINICAL			
MRI. THE HIGH-RESOLUTION AS-3DOCS DATA WILL ENABLE ACCURAT	'E			
QUANTIFICATION OF MYELINATION AND HAVE THE POTENTIALS TO G	UIDE MRI IN			
DEVELOPING MORE SENSITIVE BIOMARKERS FOR EARLY-STAGE CAA A	ND TARGETED			
THERAPY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBS	ITE:			
WWW.BRIGHTFOCUS.ORG/GRANT/A2022011F				

132212 11-11-21

Schedule O (Form 990) 2021

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLV	ANIA. (H)
PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY COURTNEY	MARSHALL,
PHD, ENTITLED: (A2022012F) IN VIVO CX-4945 INDUCED CK2 INH	IBITION
TREATMENT OF ALZHEIMER'S DISEASE PATHOLOGY AND COGNITIVE S	YMPTOMS.
INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) GENERATES	PATHOLOGICAL
CHANGES IN TAU IN ADDITION TO COGNITIVE DECLINE, YET AD RE	SEARCH HAS
YET TO IDENTIFY A DISEASE MODIFYING TREATMENT. MEMANTINE I	S CURRENTLY
USED TO TREAT COGNITIVE IMPAIRMENT IN AD PATIENTS. THIS PH	ARMACEUTICAL
TOOL SELECTIVELY INHIBITS EXTRASYNAPTIC NR2B ACTIVITY. PRI	OR STUDIES
HAVE ESTABLISHED THAT CASEIN KINASE 2 (CK2) REGULATES	
SYNAPTIC/EXTRASYNAPTIC NR2B LOCATION AND SUGGEST A POTENTI	AL
THERAPEUTIC EFFECT OF CK2 INHIBITION. WE PROPOSE USING A C	LINICALLY
APPROVED CK2 INHIBITOR TO TEST THIS EFFECT IN AN AD MOUSE	MODEL. FOR
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022012F	

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY, SCHOOL OF

MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NICOLE

MCKAY, PHD, ENTITLED: (A2022013F) INVESTIGATING HOW WHITE MATTER

INTEGRITY AND TAUOPATHY UNDERPIN COGNITIVE DECLINE IN AUTOSOMAL

DOMINANT ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: IN THE YEARS

LEADING UP TO ALZHEIMER DISEASE DIAGNOSIS, THE BRAIN BEGINS TO

DETERIORATE. SCIENTISTS BELIEVE THAT ABNORMAL FORMS OF THE TAU PROTEIN

MAY BE PARTIALLY RESPONSIBLE FOR THESE CHANGES. THIS EXCESSIVE AND

ABNORMAL TAU CAN SPREAD ALONG WHITE MATTER PATHWAYS CAUSING A BREAKDOWN

IN THE WAY OUR BRAIN FUNCTIONS. UNFORTUNATELY, THESE WHITE MATTER

PATHWAYS ARE CRITICAL FOR OUR ABILITY TO PERFORM MEMORY AND

ATTENTION-BASED TASKS. OUR PROJECT AIMS TO UNDERSTAND HOW LEVELS OF TAU
132212 11-11-21
Schedule O (Form 990) 2021
95

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
IMPACT THE INTEGRITY OF OUR BRAIN'S PATHWAYS AND LEADS TO	A DECLINE IN
COGNITION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WE	BSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2022013F	

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY, SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER MILLAR, PHD, ENTITLED: (A2022014F) MODELING BRAIN-PREDICTED AGE IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: RECENT MACHINE LEARNING TOOLS CAN MEASURE HOW "OLD" A PERSON'S BRAIN APPEARS, COMPARED TO OTHER HEALTHY BRAINS. IN SYMPTOMATIC ALZHEIMER'S DISEASE (AD), BRAINS APPEAR OLDER THAN EXPECTED, E.G., A 75-YEAR-OLD AD BRAIN MIGHT RESEMBLE A HEALTHY 84-YEAR-OLD'S BRAIN. WE WILL STUDY PEOPLE WITH A RARE GENETIC MUTATION FOR EARLY-ONSET ALZHEIMER'S DISEASE, TO TEST IF THEIR BRAINS BEGIN TO APPEAR OLDER AS THEY APPROACH THEIR EXPECTED DEMENTIA ONSET. THESE ANALYSES WILL EVALUATE WHETHER CLINICIANS CAN USE THIS BRAIN-AGE APPROACH TO IDENTIFY PEOPLE WITH VERY EARLY AD PATHOLOGY AND PREDICT AD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022014F

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHRMD, PHD, ENTITLED: (A2022017F) CAN THE NIACIN RECEPTOR HCAR2 MODULATE MICROGLIA TO LIMIT THE PROGRESSION OF ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON FORM OF DEMENTIA FOR WHICH THERE IS NO EFFECTIVE TREATMENT. INCREASED DIETARY NIACIN INTAKE HAS BEEN ASSOCIATED WITH REDUCED RISK OF AD. NIACIN IS ABLE TO CROSS THE BLOOD BRAIN BARRIER AND ACTIVATE THE NIACIN RECEPTOR HCAR2. THIS RECEPTOR INDUCES BENEFICIAL EFFECTS IN OTHER DISEASE MODELS BY 132212 11-11-21 Schedule O (Form 990) 2021 96

13420803 150872 191978

Schedule O (Form 990) 2021	Page <b>2</b>	
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229	
MODULATION OF BRAIN-RESIDENT IMMUNE CELLS (MICROGLIA). THU	S, WE	
HYPOTHESIZED THAT HCAR2 REGULATES A PROTECTIVE RESPONSE OF MICROGLIA IN		
AD, WHICH CAN BE PHARMACOLOGICALLY STIMULATED WITH A CLINI	CAL	
FORMULATION OF NIACIN. FOR MORE INFORMATION, VISIT THE BR	IGHTFOCUS	
WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022017F		

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TATSUKI NAKAGAWA,

PHD, ENTITLED: (A2022018F) UNDERSTANDING NEURAL CIRCUIT MECHANISMS FOR

ASSOCIATIVE MEMORY IMPAIRMENT IN APP-KI MICE. INVESTIGATOR'S SUMMARY:

ALZHEIMER'S DISEASE (AD) AFFECTS 6 MILLION PEOPLE IN THE US, BUT NO

CURE EXISTS. ALTHOUGH MOLECULAR AND CELLULAR MECHANISMS OF AD BECOME

CLEARER, IT IS STILL UNCLEAR WHAT TYPE OF NEURONAL BRAIN ACTIVITY IS

LOST IN AD. IF WE UNDERSTAND THIS, WE MAY BE ABLE TO DEVELOP A THERAPY

TO PREVENT MEMORY LOSS IN AD PATIENTS. IN THIS PROJECT, WE WILL

IDENTIFY THE UNDERLYING CAUSES OF BRAIN CELL DYSFUNCTION, AND TEST IF

ARTIFICIAL REACTIVATION OF BRAIN CELL ACTIVITY RESTORES ASSOCIATIVE

MEMORY IN AD MICE. THESE STUDIES ARE EXPECTED TO LEAD TO A NEW METHOD

FOR RESTORING MEMORY IN AD PATIENTS. FOR MORE INFORMATION, VISIT THE

BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022018F

NAME OF ORGANIZATION OR GOVERNMENT: MEMORIAL SLOAN KETTERING CANCER CENTER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAHIL SHARMA, PHD, ENTITLED: (A2022020F) DEVELOPMENT OF EPICHAPEROME IMAGING PROBES FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MATCHING THE RIGHT PATIENT TO THE RIGHT MEDICINE IS A GOAL OF THE FUTURE IN MEDICINE. IN THIS PROPOSAL I AIM TO BUILD TOOLS THAT CAN BE USED TO IMAGE AND SELECT THOSE ALZHEIMER DISEASE (AD) PATIENTS THAT ARE MOST 132212 11-11-21 Schedule O (Form 990) 2021

13420803 150872 191978

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
	23 7337223
LIKELY TO BENEFIT FROM A NEW EXPERIMENTAL MEDICINE WITH	
DISEASE-MODIFYING POTENTIAL. THIS MEDICINE, PU-AD, DEVELOP	ED BY MY
LABORATORY, WORKS BY REBALANCING CELLULAR NETWORKS AND BRA	IN CIRCUITS.
IN MOUSE MODELS, IT REVERTED COGNITIVE DYSFUNCTION AND IS	CURRENTLY IN
CLINICAL EVALUATION IN AD AND RELATED DISORDERS. TOOLS I D	EVELOP HERE
THEREFORE HAVE IMMEDIATE TRANSLATIONAL POTENTIAL. FOR MOR	E
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022020F	

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LORENA SORDO, PHD, ENTITLED: (A2022021F) THE ROLE OF LEPTIN ON ALZHEIMER'S DISEASE PATHOGENESIS IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: PEOPLE WITH DOWN SYNDROME (DS) HAVE A HIGH RISK OF DEVELOPING ALZHEIMER'S DISEASE (AD). MID-LIFE OBESITY AND LATE-LIFE WEIGHT LOSS INCREASE THE RISK OF AD. SINCE PEOPLE WITH DS TEND TO BE OVERWEIGHT, THEY MAY HAVE AN EVEN GREATER RISK OF DEVELOPING AD. WE WILL MEASURE LEVELS OF LEPTIN (A HORMONE THAT REGULATES APPETITE AND FOOD INTAKE THAT IS RELEASED IN RESPONSE TO THE AMOUNT OF FAT TISSUE IN THE BODY) IN PEOPLE WITH DS, WITH AND WITHOUT AD, AND WILL ASSESS THE ASSOCIATION BETWEEN LEPTIN LEVELS AND ABNORMAL DEPOSITION OF AMYLOID-BETA (AB) AND TAU, MAJOR HALLMARKS OF AD, IN THE BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022021F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED: NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LORENA SORDO, PHD, ENTITLED: (A2022021F) THE ROLE OF LEPTIN ON ALZHEIMER'S DISEASE 132212 11-11-21 Schedule O (Form 990) 2021 98 13420803 150872 191978

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
PATHOGENESIS IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: PE	OPLE WITH
DOWN SYNDROME (DS) HAVE A HIGH RISK OF DEVELOPING ALZHEIME	R'S DISEASE
(AD). MID-LIFE OBESITY AND LATE-LIFE WEIGHT LOSS INCREASE	THE RISK OF
AD. SINCE PEOPLE WITH DS TEND TO BE OVERWEIGHT, THEY MAY H	AVE AN EVEN
GREATER RISK OF DEVELOPING AD. WE WILL MEASURE LEVELS OF L	EPTIN (A
HORMONE THAT REGULATES APPETITE AND FOOD INTAKE THAT IS RE	LEASED IN
RESPONSE TO THE AMOUNT OF FAT TISSUE IN THE BODY) IN PEOPL	E WITH DS,
WITH AND WITHOUT AD, AND WILL ASSESS THE ASSOCIATION BETWE	EN LEPTIN
LEVELS AND ABNORMAL DEPOSITION OF AMYLOID-BETA (AB) AND TA	U, MAJOR
HALLMARKS OF AD, IN THE BRAIN. FOR MORE INFORMATION, VISI	T THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022021F	

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY - EVANSTON CAMPUS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY XIAOJING SUI, PHD, ENTITLED: (A2022023F) COMPREHENSIVE IDENTIFICATION OF THE METASTABLE SUBPROTEOME DYSREGULATED IN AGING AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS A LEADING CAUSE OF DEMENTIA AND AGING IS A STRONG RISK FACTOR. THIS STUDY WILL IDENTIFY THE PROTEINS THAT GO AWRY IN AGING AND ALZHEIMER'S DISEASE, USING AN ADVANCED TECHNOLOGY THAT CAN SCREEN THOUSANDS OF PROTEINS AT A TIME. THE ULTIMATE GOAL OF THE PROJECT IS TO IDENTIFY NEW PROTEIN BIOMARKERS OF AGING AND ALZHEIMER'S DISEASE AND PROVIDE NEW TREATMENT TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022023F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF COLORADO, BOULDER.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN VAN

ALSTYNE, PHD, ENTITLED: (A2022025F) ROLES AND APPLICATIONS OF SRRM2 IN
132212 11-11-21
Schedule O (Form 990) 2021
99

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
THE ASSEMBLY AND DISASSEMBLY OF TAU AGGREGATES. INVESTIGA	TOR 'S
SUMMARY: A KEY HALLMARK OF ALZHEIMER'S DISEASE IS TAU AGGR	EGATION WHICH
IS BELIEVED TO PLAY A ROLE IN NEURONAL DEGENERATION. WITH	NO CURATIVE
TREATMENTS AVAILABLE, IT IS CRITICAL TO BETTER UNDERSTAND	DISEASE
MECHANISMS TO DEVELOP EFFECTIVE TREATMENTS. WE RECENTLY IDENTIFIED TAU	
AGGREGATES CONTAIN A PROTEIN RELOCATED FROM NUCLEAR SPECKLES CALLED	
SRRM2. THIS RESEARCH PLAN WILL INVESTIGATE THE INTERACTION OF SRRM2	
WITH TAU AND EVALUATE EFFECTS IN DISEASE CONTEXTS. FURTHER, I WILL	
REPURPOSE THIS KNOWLEDGE TO IDENTIFY FACTORS THAT CAN MITIGATE TAU	
AGGREGATION WITH BROAD THERAPEUTIC POTENTIAL. FOR MORE IN	FORMATION,
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A	2022025F

NAME OF ORGANIZATION OR GOVERNMENT: BOSTON CHILDREN'S HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HUIXIN XU, PHD, ENTITLED: (A2022026F) HARNESSING THE CHOROID PLEXUS BARRIER AS A NEUROIMMUNE BARRIER IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MY ULTIMATE GOAL IS TO ENABLE TREATMENTS FOR ALZHEIMER'S DISEASE (AD) THAT CURB BRAIN INFLAMMATION AT THE BARRIERS SEPARATING THE BRAIN FROM THE REST OF THE BODY, FOCUSING ON A TISSUE CALLED THE CHOROID PLEXUS. I WILL APPLY NEWLY DEVELOPED IMAGING TOOLS THAT ENABLE EXPLORATION OF BLOOD-BORNE IMMUNE CELLS ENTERING THE CHOROID PLEXUS IN AD MODELS AND TEST FOR BARRIER BREAKDOWN AND BLOOD VESSEL LEAKAGE. THE INNOVATION FROM MY RESEARCH WILL LAUNCH MY INDEPENDENT CAREER TO CONTINUE THIS INQUIRY, AND BENEFIT RESEARCHERS OF OTHER INFLAMMATORY BRAIN DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022026F

100

|--|

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESE	EARCH BY
ANDREW YANG, PHD, ENTITLED: (A2022027F) UNDERSTANDING HOW	HUMAN BRAIN
VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEAS	SE.
INVESTIGATOR'S SUMMARY: THE RISK FOR LATE-ONSET ALZHEIMER'	S DISEASE
(AD) INVOLVES DOZENS OF RISK VARIANTS OPERATING IN DIVERSE	E CELL TYPES.
ELUCIDATING THE FUNCTIONS OF THESE RISK VARIANTS IS CRITIC	CAL TO INFORM
TREATMENTS BUT IS CHALLENGING, IN PART BECAUSE THE VASCULA	AR HALF OF
HUMAN BRAIN CELL TYPES HAS ELUDED POWERFUL SINGLE-CELL ASS	SAYS. WE WILL
USE OUR NEW VASCULAR-CAPTURING VINE-SEQ TECHNIQUE TO COMPR	REHENSIVELY
DETERMINE THE CELLS AND GENES DYSREGULATED AD VARIANTS. WE	E WILL THEN
USE OUR BIOORTHOGONAL LABELING APPROACHES TO DETERMINE HOW	AD VARIANTS
DYSREGULATE BRAIN VASCULAR TRANSPORT FUNCTIONS TO PROMOTE	AD RISK. FOR
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022027F	
NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL	HOSPITAL.
(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QIUC	CHEN ZHAO,
PHD, ENTITLED: (A2022028F) SLEEP RESTORATION, MICROGLIA, A	AND
ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S	DISEASE (AD)

IS ASSOCIATED WITH PROFOUND SLEEP DISTURBANCES THAT CONTRIBUTE TO THE

DISEASE PROGRESSION, PARTICULARLY AT EARLY STAGES OF DISEASE. USING

STATE-OF-THE-ART LABORATORY TECHNOLOGIES, WE WILL DEVELOP EFFECTIVE

STRATEGIES TO RESTORE SLEEP AND ASSESS ITS EFFECT ON MEMORY FUNCTION

AND PATHOLOGICAL PROGRESSION OF AD. ADDITIONALLY, WE WILL INVESTIGATE

THE RESPONSES OF MICROGLIA TO SLEEP RESCUE USING A MULTI-PRONGED DESIGN

101

ASSESSING THE MORPHOLOGICAL, FUNCTIONAL, AND GENETIC ASPECTS. THIS

STUDY WILL PROVIDE THE BASIS FOR NOVEL THERAPEUTIC STRATEGIES FOR AD.

FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

132212 11-11-21

Schedule O (Form 990) 2021

Name of the organization

BRIGHTFOCUS FOUNDATION

WWW.BRIGHTFOCUS.ORG/GRANT/A2022028F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KEVIN BEIER, PHD,

ENTITLED: (A2022031S) IDENTIFYING CIRCUIT DRIVERS OF EARLY AD

PATHOGENESIS. INVESTIGATOR'S SUMMARY: WE AIM TO IDENTIFY BRAIN REGIONS

AND CELL TYPES TO TARGET IN ORDER TO SLOW OR PREVENT THE DEVELOPMENT OF

ALZHEIMER'S DISEASE BEFORE SYMPTOM ONSET. WE HAVE IDENTIFIED A CHANGE

IN THE RETROSPLENIAL CORTEX THAT OCCURS EARLY IN AD PATHOGENESIS, AND

NEXT PLAN TO VERIFY THESE RESULTS IN A DIFFERENT RODENT MODEL AND

EXPLORE THE FUNCTIONAL CONSEQUENCES OF CHEMOGENETICALLY INHIBITING

THESE CELLS. OUR GOAL IS TO USE THESE DATA TO IDENTIFY BIOMARKERS OF

EARLY AD, AND POTENTIALLY CIRCUIT TARGETS FOR FUTURE AD THERAPEUTICS.

FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022031S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY THOMAS BRETT, PHD, ENTITLED: (A2022032S) STRUCTURAL BASIS AND MODULATION OF TREM2/OABETA42 SIGNALING. INVESTIGATOR'S SUMMARY: CURRENT STUDIES INDICATE THAT TREM2, A RECEPTOR MOLECULE FOUND IN THE BRAIN, PLAYS AN IMPORTANT ROLE IN NEURONAL HEALTH. IT HAS EMERGED AS A CRITICAL POTENTIAL DRUG TARGET TO DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE. TREM2 ENGAGES AND RESPONDS TO OTHER MOLECULES IN THE BRAIN. OUR PROJECT WILL DETERMINE HOW TREM2 ENGAGES AMYLOID BETA AND IDENTIFY HOW OTHER POTENTIAL DRUG MOLECULES MODULATE THIS INTERACTION. UNDERSTANDING AND MODULATING THIS INTERACTION WILL ENABLE THE DEVELOPMENT OF THERAPEUTICS FOR ALZHEIMER'S DISEASE THAT TARGET TREM2. FOR MORE INFORMATION, VISIT 102

13420803 150872 191978

Name of the organization

BRIGHTFOCUS FOUNDATION

THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022032S

NAME OF ORGANIZATION OR GOVERNMENT: NEW YORK UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OMONIGHO BUBU, MD, PHD, ENTITLED: (A2022033S) MECHANISMS OF RACIAL DIFFERENCES IN THE RELATIONSHIP BETWEEN OBSTRUCTIVE SLEEP APNEA AND IN VIVO TAU DEPOSITION IN THE CONTEXT OF AMYLOID BURDEN. INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL EXAMINE WHETHER BLACKS WITH OBSTRUCTIVE SLEEP APNEA (OSA) EXHIBIT HIGHER TAU-PET AND GREATER NEURODEGENERATION FOR A GIVEN LEVEL OF AMYLOID BURDEN COMPARED TO WHITES. THE PROPOSAL WILL ALSO EXAMINE THE ROLE OF SOCIOECONOMIC STATUS, CUMULATIVE STRESS EXPOSURE AND VASCULAR RISK AS MEDIATORS OF ANY OBSERVED RACE-SPECIFIC EFFECTS IN MICRO-LEVEL SLEEP PHYSIOLOGY AND INFLAMMATION ON TAU-PET AND NEURODEGENERATION. LONG-TERM GOAL IS TO INCREASE SLEEP QUALITY, AND CONTROL VASCULAR RISK USING NON-INVASIVE AMBULATORY METHODS AS NOVEL THERAPEUTIC TARGETS FOR AD PREVENTION IN BLACKS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022033S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KANSAS CENTER FOR

RESEARCH, INC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY

LAN GUO, PHD, ENTITLED: (A2022036S) MITOCHONDRIAL DNA OXIDATIVE DAMAGES

AND MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S

SUMMARY: MICROGLIA-MEDIATED NEUROINFLAMMATION CONTRIBUTES TO THE

PATHOGENESIS OF ALZHEIMER'S DISEASE (AD), THE MECHANISMS OF AD-RELATED

MICROGLIAL ACTIVATION ARE NOT FULLY UNDERSTOOD. IN VIEW OF OUR

PRELIMINARY DATA, WE AIM TO ESTABLISH A CAUSE-EFFECT RELATIONSHIP OF

OXIDATIVE DAMAGE AND THE SUBSEQUENT LEAKAGE OF MITOCHONDRIAL DNA 132212 11-11-21 Schedule O (Form 990) 2021 103

13420803 150872 191978

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
(MTDNA) WITH INFLAMMATORY MICROGLIAL RESPONSE VIA ACTIVATI	1
CYTOSOLIC DNA-SENSING SYSTEM IN AD-RELATED CONDITIONS, POSITIVE RESULTS	
WILL REVEAL A NOVEL MITOCHONDRIAL PATHWAY OF NEUROINFLAMMA	TION IN AD
AND HOLD PROMISE TO DEVELOP INNOVATIVE THERAPY FOR AD TREA	TMENT. FOR
MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	

WWW.BRIGHTFOCUS.ORG/GRANT/A2022036S

NAME OF ORGANIZATION OR GOVERNMENT: BRIGHAM YOUNG UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID HANSEN, PHD, ENTITLED: (A2022037S) VALIDATING PILRA, AN IMMUNE CHECKPOINT AND AD-ASSOCIATED GENE, AS A THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE EMERGING LANDSCAPE OF ALZHEIMER'S THERAPEUTICS INCLUDES DRUGS INTENDED TO PROMOTE THE PROTECTIVE FUNCTIONS OF MICROGLIA, THE BRAIN'S IMMUNE CELLS. THE MAJORITY OF THESE THERAPEUTICS SEEK TO DIRECTLY ACTIVATE TREM2, A KEY RECEPTOR FOR MICROGLIAL ACTIVATION AND HEALTHY CNS TISSUE MAINTENANCE. IN THIS PROPOSAL, WE EXPLORE THE THERAPEUTIC POTENTIAL OF BLOCKING MICROGLIAL CHECKPOINT PROTEINS AS AN INDIRECT WAY OF ENABLING MORE ROBUST TREM2 FUNCTION AT SITES OF MICROGLIAL ACTIVATION, WHICH MAY BE SAFER THAN CHRONIC ACTIVATION OF ALL MICROGLIA (AND POSSIBLY OSTEOCLASTS/MACROPHAGES). FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022037S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KEITH HENGEN,

PHD, ENTITLED: (A2022038S) ABERRANT NEURAL DYNAMICS IN EARLY LIFE WARN

OF FUTURE DISEASE. INVESTIGATOR'S SUMMARY: SYMPTOMS OF ALZHEIMER'S

DISEASE (AD) ONLY EMERGE AFTER TOXIC PROTEINS HAVE TAKEN A SIGNIFICANT 132212 11-11-21 Schedule O (Form 990) 2021 104

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
TOLL ON THE CIRCUITRY OF THE BRAIN. EFFECTIVE INTERVENTION	IN AD IS
BELIEVED TO BE STYMIED BY THE INABILITY TO DETECT THE DISE	ASE UNTIL IT
IS TOO LATE TO MAKE A DIFFERENCE. HERE WE DEMONSTRATE A NO	VEL METHOD TO
PREDICT AD BEFORE SYMPTOMS APPEAR BY MEASURING BRAIN ACTIV	ITY IN BOTH
HUMANS AND MOUSE MODELS OF DISEASE. FOR MORE INFORMATION,	VISIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022038S	
NAME OF ORGANIZATION OR GOVERNMENT: COLORADO STATE UNIVERS	ITY. (H)
PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SEONIL K	IM, PHD,
ENTITLED: (A2022039S) CO-ACTIVATION OF SELECTIVE NICOTINIC	
ACETYLCHOLINE RECEPTORS IMPROVES HIPPOCAMPAL ACTIVITY IN A	LZHEIMER'S
DISEASE. INVESTIGATOR'S SUMMARY: CHANGES IN BRAIN RHYTHMS	
(SYNCHRONIZED ACTIVITY BETWEEN NERVE CELLS) IN THE HIPPOCA	MPUS HAVE
BEEN LINKED TO MEMORY IMPAIRMENTS ASSOCIATED WITH ALZHEIME	R'S DISEASE
(AD). IMPORTANTLY, THESE ALTERATIONS IN BRAIN RHYTHM CAN B	E DETECTED
BEFORE AD PATIENTS DISPLAY SIGNS OF MEMORY LOSS. AS A RESU	LT, THESE
CHANGES COULD BE A PRECURSOR TO AD. KNOWING THIS, WE PLAN	ТО
INVESTIGATE WHETHER ABERRANT BRAIN ACTIVITY AND MEMORY LOS	S CAN BE
PREVENTED OR PERHAPS REVERSED IN THE EARLY STAGES OF AD.	FOR MORE
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/A2022039S	
NAME OF ORGANIZATION OR GOVERNMENT: RICE UNIVERSITY. (H)	PURPOSE OF
GRANT: ALZHEIMER'S DISEASE RESEARCH BY STEPHANIE LEAL, PHD	, ENTITLED:
(A2022040S) PRECISE NEUROBIOLOGICAL PROFILING OF THE LOCUS	COERULEUS
AND MEDIAL TEMPORAL LOBE FOR THE EARLY DETECTION OF ALZHEI	MER'S
DISEASE. INVESTIGATOR'S SUMMARY: THE CAUSE OF ALZHEIMER'S	DISEASE (AD)
IS UNKNOWN. WE HAVE BEGUN TO UNDERSTAND WHICH BRAIN REGION	
132212 11-11-21 105	Schedule O (Form 990) 2021
2021.04012 BRIGHTFOCUS F	FOUNDACOPY ¹⁹¹⁹⁷⁸

Schedule O (Form 990) 2021	Page 2
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
IMPACTED DECADES BEFORE CLINICAL SYMPTOM ONSET. HOWEVER, C	URRENT
RESEARCH HAS NOT UTILIZED TASKS SENSITIVE ENOUGH TO DETECT	THE EARLIEST
CHANGES IN MEMORY THAT COULD PREDICT AD. IN THIS PROPOSAL,	WE WILL USE
SENSITIVE MEMORY TASKS THAT TARGET THE EARLIEST BRAIN REGI	ONS IMPACTED
IN AD. PAIRED WITH STATE-OF-THE-ART BRAIN IMAGING TECHNIQU	ES, WE WILL
IDENTIFY EARLY COGNITIVE AND BRAIN CHANGES IN AD BEFORE CL	INICAL
SYMPTOMS MANIFEST, WHICH COULD AID IN EARLIER INTERVENTION	S TO PREVENT
OR SLOW AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS W	EBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2022040S	

NAME OF ORGANIZATION OR GOVERNMENT: SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NICOLE LIACHKO, PHD, ENTITLED: (A2022041S) MECHANISMS UNDERLYING SELECTIVE NEURON VULNERABILITY TO CO-MORBID TAU AND TDP-43 IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: OVER HALF OF ALZHEIMER'S DISEASE (AD) PATIENTS EXHIBIT NEURONAL AGGREGATES OF THE PROTEIN TDP-43 AS A CO-PATHOLOGY IN ADDITION TO AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES. THE PRESENCE OF TDP-43 PATHOLOGY CORRELATES WITH WORSE BRAIN ATROPHY, MORE SEVERE COGNITIVE IMPAIRMENT, AND MORE RAPID COGNITIVE DECLINE. THEREFORE, UNDERSTANDING ITS CONTRIBUTION TO NEURODEGENERATIVE DISEASE PROCESSES IS A CRITICAL NEED IN THE FIELD. THIS WORK WILL CHARACTERIZE MECHANISMS UNDERLYING NEURON VULNERABILITIES TO TDP-43 IN AD, AND IDENTIFY NEW THERAPEUTIC TARGETS AND STRATEGIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022041S

NAME OF ORGANIZATION OR GOVERNMENT: HEBREW REHABILITATION CENTER. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRAD MANOR, PHD, 132212 11-11-21 Schedule O (Form 990) 2021 106

Schedule O (Form 990) 2021 Name of the organization	Page 2 Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
ENTITLED: (A2022042S) MULTIFOCAL TRANSCRANIAL CURRENT STIM	ULATION FOR
COGNITIVE AND MOTOR DYSFUNCTION IN OLDER ADULTS LIVING WIT	H DEMENTIA.
INVESTIGATOR'S SUMMARY: MEMORY LOSS AND EXECUTIVE DYSFUNCT	ION ARE TWO
HALLMARKS OF ALZHEIMER'S DISEASE (AD) THAT MAP ONTO DIFFER	ENT,
SPATIALLY-DISTINCT BRAIN NETWORKS. THIS STUDY WILL COMBINE	AND
SIMULTANEOUSLY DELIVER TWO DIFFERENT TYPES OF TRANSCRANIAL	CURRENT
STIMULATION (TCS) TO PROVIDE MULTI-SYMPTOM RELIEF TO OLDER	ADULTS WITH
MILD AD. BY STIMULATING MORE THAN ONE BRAIN NETWORK AT THE	SAME, AND
STUDYING THE RELATIONSHIP BETWEEN THE ELECTRICAL FIELDS CR	EATED BY TCS
AND INDIVIDUAL THERAPEUTIC BENEFIT, THIS TRIAL WILL HELP T	O DEVELOP TCS
INTERVENTIONS WITH MAXIMAL IMPACT ON DAILY LIFE FUNCTION F	OR THIS
POPULATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS W	EBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2022042S	
NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICI	NE AT MOUNT
SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH	BY ALEJANDRO
MARTIN TRUJILLO, PHD, ENTITLED: (A2022043S) COMPREHENSIVE	STUDY OF
TANDEM REPEAT VARIATION AS A CAUSE OF ALZHEIMER'S DISEASE.	

INVESTIGATOR'S SUMMARY: TANDEM REPEATS (TRS) ARE STRETCHES OF DNA

COMPOSED OF TWO OR MORE CONTIGUOUS COPIES OF A SEQUENCE ARRANGED IN

HEAD-TO-TAIL PATTERN (EG. CAG-CAG-CAG), THAT, IN SOME CASES, GAIN

ADDITIONAL COPIES AND BECOME EXPANDED. DUE TO TECHNICAL LIMITATIONS,

TRS ARE USUALLY UNTRACEABLE USING STANDARD PROCEDURES, BEING LARGELY

IGNORED IN STANDARD GENETICS STUDIES. HOWEVER, NEWLY BIOINFORMATICS

TOOLS ARE NOW ABLE TO SCREEN THE WHOLE GENOME FOR REPEATS EXPANSIONS

AND TR VARIANTS. USING THESE TOOLS, WE WILL SCREEN THE GENOMES OF

THOUSANDS OF AD CASES AND CONTROLS FOR TR VARIANTS THAT ARE ASSOCIATED

WITH AD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: 132212 11-11-21 Schedule O (Form 990) 2021 107

13420803 150872 191978

Name of the organization

BRIGHTFOCUS FOUNDATION

Page 2

WWW.BRIGHTFOCUS.ORG/GRANT/A2022043S

NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA TECH RESEARCH CORPORATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANNABELLE SINGER, PHD, ENTITLED: (A2022048S) DRIVING BRAIN RHYTHMS TO REDUCE CHRONIC STRESS-INDUCED SYNAPTIC LOSS AND ALZHEIMER'S DISEASE RISK. INVESTIGATOR'S SUMMARY: CHRONIC STRESS LEADS TO A 2-FOLD OR MORE INCREASED RISK FOR ALZHEIMER'S DISEASE (AD). WE PROPOSE TO USE NOVEL NON-INVASIVE BRAIN STIMULATION TO PREVENT STRESS-INDUCED PATHOLOGY INCLUDING MEMORY IMPAIRMENT, ANXIETY, THE LOSS OF CONNECTIONS BETWEEN NEURONS, AND OVERACTIVE IMMUNE RESPONSES. BECAUSE THIS STIMULATION IS NON-INVASIVE, IT WILL READILY TRANSLATE TO HUMANS TO POTENTIALLY REDUCE THE RISK OF DEVELOPING AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022048S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: TRUSTEES OF BOSTON UNIVERSITY. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JULIA TCW, PHD,

ENTITLED: (A2022049S) MODULATION OF ASTROCYTE MATRISOME SIGNALS

REPROGRAM MICROGLIA THAT CAN BE TARGETED TO MITIGATE ALZHEIMER'S

DISEASE. INVESTIGATOR'S SUMMARY: THE STRONGEST GENETIC RISK FACTOR FOR

LATE-ONSET ALZHEIMER'S DISEASE (AD) IS APOLIPOPROTEIN E E4 (APOE4).

WITH THE GOAL OF EXPLAINING HOW APOE4 INFLUENCES RISK OF AD, WE WILL

SUPPRESS AN APOE4 RISK SIGNAL AND UNDERSTAND THE MECHANISM OF CELLULAR

REPROGRAMMING TO PREVENT AD IN OUR "BRAIN-IN-A-DISH" MODEL. WE HOPE

THIS APPROACH CAN IDENTIFY NEW DRUG TARGETS OF APOE4 AND OPEN DOORS TO

NOVEL THERAPEUTIC MODALITIES. FOR MORE INFORMATION, VISIT THE

BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022049S

108

132212 11-11-21

ENTITLED: (A2022050S) CD98HC BRAIN SHUTTLE FOR EFFICIENT DELIVERY OF A

NEUROPROTECTIVE TRKB AGONIST ANTIBODY IN ALZHEIMER'S DISEASE.

INVESTIGATOR'S SUMMARY: MONOCLONAL ANTIBODIES ARE REVOLUTIONIZING THE

TREATMENT OF HUMAN DISEASES. HOWEVER, AN ACHILLES HEEL OF THESE LARGE

MOLECULES IS THAT THEY POORLY PENETRATE THE BLOOD-BRAIN BARRIER, WHICH

GREATLY LIMITS THEIR USE FOR TREATING ALZHEIMER'S DISEASE (AD). WE HAVE

DEVELOPED A NOVEL APPROACH FOR DELIVERING ANTIBODIES TO THE BRAIN BY

ATTACHING A SMALL PROTEIN TO THEM TO MEDIATE ANTIBODY ENTRY INTO THE

BRAIN. IN THIS PROPOSAL, WE SEEK TO EVALUATE THE THERAPEUTIC EFFICACY

OF DELIVERING AN ANTIBODY TO THE BRAIN THAT STIMULATES NEUROPROTECTIVE

SIGNALING AND PREVENTS NEURONAL DEATH IN ANIMAL MODELS OF AD. FOR MORE

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022050S

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUSANNE VAN

VELUW, PHD, ENTITLED: (A2022051S) TARGETING APOE AS A TREATMENT

STRATEGY IN CEREBRAL AMYLOID ANGIOPATHY. INVESTIGATOR'S SUMMARY:

CEREBRAL AMYLOID ANGIOPATHY (CAA) IS A DISEASE IN WHICH AMYLOID BUILDS

UP IN THE BLOOD VESSELS OF THE BRAIN, WHICH CAN CAUSE BLEEDING AND

DEMENTIA. THERE ARE CURRENTLY NO TREATMENTS FOR CAA. REMOVING AMYLOID

WITH IMMUNOTHERAPY IS NOT RECOMMENDED DUE TO A HIGH BLEEDING RISK. THIS

RISK IS FURTHER INCREASED IN CAA PATIENTS WITH AN APOE4 GENOTYPE. A

RECENT STUDY SUGGESTED THAT REMOVING APOE, WHICH IS CO-DEPOSITED WITH

109

AMYLOID, COULD BE A SAFE ALTERNATIVE. HOWEVER, IT REMAINS UNCLEAR

Schedule O (Form 990) 2021

132212 11-11-21

WHETHER REMOVING APOE IMPROVES CAA AND PROTECTS BLOOD VESS	
	SELS. THIS
PROJECT WILL TEST THIS IN A MOUSE MODEL. FOR MORE INFORMA	ATION, VISIT
THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A20220	51S

NAME OF ORGANIZATION OR GOVERNMENT: PRESIDENT & FELLOWS OF HARVARD COLLEGE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LIMOR COHEN, PHD, ENTITLED: (A2022052F) SPATIAL TRANSCRIPTOMICS OF ISOFORM EXPRESSION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN IS A COMPLEX AND HIGHLY ORGANIZED TISSUE THAT CONSISTS OF DISTINCT FUNCTIONAL REGIONS. EACH BRAIN REGION CONSISTS OF MANY CELL TYPES THAT ARE SPATIALLY ORGANIZED IN A UNIQUE PATTERN THAT UNDERLIES BRAIN FUNCTION. HERE, I PROPOSE TO DEVELOP A NEW METHOD TO MAP THESE CELL TYPES IN HEALTHY AND ALZHEIMER'S DISEASE (AD) BRAINS. I WILL ALSO USE THIS METHOD TO UNDERSTAND WHICH CELL TYPES AND CELLULAR ENVIRONMENTS ARE VULNERABLE TO TAU PROPAGATION IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022052F

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE. (H)

PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021010)

MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM

OF MOLECULAR NEURODEGENERATION (MN) JOURNAL

(HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/) IS TO SERVE THE

SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND

FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE

DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE

CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION.

THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL

110

PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE

Schedule O (Form 990) 2021

13420803 150872 191978

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
PRACTITIONERS. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECEN	NT YEARS IN
PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION	. SOME OF
THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) THE USAGE	OF THE
JOURNAL: 1,034,660 DOWNLOADS (AS OF APRIL 22, 2022); 2) TH	E CITATIONS
TRACKED BY WEB OF SCIENCE: 4290 IN 2018, 5217 IN 2019, AND	6488 IN
2020.; 3) THE IMPACT FACTOR: 14.195 (AS OF APRIL 22, 2022)	; 4) THE
RANKING BY JCR: MOLECULAR NEURODEGENERATION HAS BEEN RANKE	D AS THE NO.
1 OPEN-ACCESS JOURNAL IN THE NEUROSCIENCE CATEGORY FOR 10	YEARS IN A
ROW (2013 PRESENT), AND RANKED NO. 15 AMONG ALL 272 NEURO	SCIENCE
JOURNALS (WITHIN THE TOP 5.5%).	
NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY	FOR MOLECULAR
NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISE	ASE RESEARCH
ENTITLED: (CA2021011) INTERNATIONAL SOCIETY FOR MOLECULAR	
NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THIS AWARD IS	FOR THE

CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR

NEURODEGENERATION (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND

EDUCATIONAL AND SCIENTIFIC PURPOSES. IN ACCORDANCE WITH SECTION

501(C)(3) OF THE INTERNAL REVENUE CODE AND THE PROVISIONS OF THE

FLORIDA NOT FOR PROFIT CORPORATION ACT. THE INTERNATIONAL SOCIETY FOR

MOLECULAR NEURODEGENERATION (ISMND) SHALL BE ORGANIZED AND OPERATED

PRIMARILY AND EXCLUSIVELY FOR EDUCATIONAL AND SCIENTIFIC PURPOSES. THE

INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION'S MISSION IS TO

SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE

HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM

FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND

SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE

111

SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE

Schedule O (Form 990) 2021

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED: NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BECKY CARLYLE,
(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BECKY CARLYLE,
PHD, ENTITLED: (A2019182S) INTEGRATED MULTIMODAL *OMICS OF NEUROPEPTIDE
PROTEOFORMS TO ASSESS THEIR SUITABILITY AS BIOMARKERS AND THERAPEUTIC
TARGETS FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: EMERGENCY
RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2019128S
NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY. (H)
PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER ABADIR, PHD,
ENTITLED: (A2019634S) CHARACTERIZING BRAIN ANGIOTENSIN SYSTEM.
INVESTIGATOR'S SUMMARY: EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19.
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/A2019634S
NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY. (H)
PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QUINCY SAMUS, PHD,
ENTITLED: (CA2021001) DISSEMINATION OF MIND AT HOME DEMENTIA CARE MODEL
TO DRIVE HEALTH CARE TRANSFORMATION AND GREATER VALUE. INVESTIGATOR'S
SUMMARY: INFORMED BY DECADES OF DEMENTIA CARE CLINICAL EXPERTISE, BEST
PRACTICE RECOMMENDATIONS, AND CLINICAL STUDIES, MIND AT HOME IS AN
EFFECTIVE, COMPREHENSIVE, HOMEBASED DEMENTIA CARE COORDINATION MODEL
THAT SYSTEMATICALLY ASSESSES AND ADDRESSES A BROAD RANGE OF
DEMENTIARELATED CARE NEEDS THAT PLACE ELDERS AT RISK FOR HEALTH
DISPARITIES, HOSPITALIZATIONS, UNWANTED LONG TERM CARE PLACEMENT, POOR
132212 11-11-21 Schedule O (Form 990) 2021 112
120803 150872 191978 2021.04012 BRIGHTFOCUS FOUNDACOPY 191978

Schedule O (Form 990) 2021

BRIGHTFOCUS FOUNDATION

Name of the organization

Page 2

Employer identification number

23-7337229

Schedule O (Form 990) 2021	Page <b>2</b>	
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229	
QUALITY OF LIFE AND FAMILY CAREGIVERS AT RISK FOR BURNOUT	AND HEALTH	
IMPACTS. YET TRANSLATION INTO PRACTICE HAS BEEN SLOW PRIMA	RILY DUE LACK	
OF DATA ON ITS POTENTIAL FOR RETURN ON INVESTMENT AND ITS	VALUE	
PROPOSITION TO HEALTH SYSTEMS, HEALTH PLANS, AND PROVIDERS	, AS WELL	
LACK OF DATA ON HOW TO EFFECTIVELY REFINE THE MODEL TO INT	EGRATE INTO	
EXISTING HEALTH CARE DELIVERY ENVIRONMENTS. THIS GRANT SUP	PORTS A	
PARTNERSHIP WITH UNIVERSITY OF MARYLAND BALTIMORE COUNTY,	JADE GONG &	
ASSOCIATES LLC, AND JOHNS HOPKINS HOME CARE GROUP, WITH TH	IE SUPPORT OF	
MARYLAND PRIMARY CARE PROGRAM, MARYLAND MEDICAID, AND JOHN	IS HOPKINS	
ALLIANCE FOR PATIENTS TO STRATEGICALLY ADVANCE THE DISSEMI	NATION AND	
TRANSLATION OF JOHN HOPKINS UNIVERSITY'S EVIDENCEBASED MIN	ID AT HOME	
MODEL, IN THE CONTEXT OF MARYLAND'S NEW PRIMARY CARE PROGR	AM (MDPCP) AS	
A TRANSFORMATIVE TOOL TO ACHIEVE GREATER CARE COORDINATION	I AND VALUE	
FOR A VULNERABLE COGNITIVELY IMPAIRED POPULATION. FOR MOR	E	
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:		
WWW.BRIGHTFOCUS.ORG/GRANT/CA2021001		
NAME OF ORGANIZATION OR GOVERNMENT: FOUNDATION FOR THE NAT	IONAL	
INSTITUTES OF HEALTH. (H) PURPOSE OF GRANT: ALZHEIMER'S D	DISEASE	
RESEARCH, ENTITLED: (CA2021012) PRE-COMPETITIVE ANALYTICA	L VALIDATION	
OF SV2A PET IMAGING AS A BIOMARKER OF SYNAPTIC DENSITY. INVESTIGATOR'S		
SUMMARY: THE SV2A PET PROJECT AIMS TO DEMONSTRATE THE RELI	ABILITY OF	
SV2A PET IMAGING AS A BIOMARKER OF SYNAPTIC DENSITY IN ALZ	HEIMER'S	
DISEASE AND ACCELERATE THE APPLICATION OF SV2A PET AS A TR	EATMENT	
RESPONSE MARKER IN DISEASE-MODIFYING CLINICAL TRIALS. FOR	MORE	
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:		

WWW.BRIGHTFOCUS.ORG/GRANT/CA2021012

132212 11-11-21

Schedule O (Form 990) 2021

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
NAME OF ORGANIZATION OR GOVERNMENT: BOSTON UNIVERSITY SCHO	OL OF
MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEA	RCH BY
BENJAMIN WOLOZIN, MD, PHD ENTITLED: (CA2020002) DEVELOPMEN	T OF
SYNTHETIC GENE FEEDBACK CIRCUITS TO PREVENT TAU AGGREGATIO	N
INVESTIGATOR'S SUMMARY: THIS PROPOSAL USES A RADICALLY NOV	EL APPROACH
TERMED "SYNTHETIC BIOLOGY", WHICH USES CONCEPTS FROM ELECT	RICAL
ENGINEERING TO DESIGN NEW TYPES OF GENETIC THERAPY FOR ALZ	HEIMER'S
DISEASE (AD). WE WILL CREATE NEW SYNTHETIC GENE CIRCUITS T	HAT CAN
DETECT AND THEN REMOVE HARMFUL TAU PATHOLOGY AS IT APPEARS	IN THE
BRAINS OF PATIENTS WITH AD. THESE NEW THERAPIES WILL SELEC	TIVELY TARGET
ONLY THOSE NERVE CELLS THAT ACTUALLY HAVE PATHOLOGY, INCRE	ASING THE
EFFECTIVENESS WHILE REDUCING THE POTENTIAL FOR UNWANTED SI	DE EFFECTS.
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/CA2020002	
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF DENVER.	(H) PURPOSE
OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANN CHARLOTTE	
GRANHOLM-BENTLEY, PHD, ENTITLED: (CA2018010) INTERNATIONAL	BRAIN BANK

FOR DOWN SYNDROME-RELATED ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY:

THE FOCUS OF THIS SPECIAL PROJECT IS TO DEVELOP A STRONG COLLABORATE

NETWORK BETWEEN SIX DIFFERENT RESEARCH GROUPS FOCUSED ON PROVIDING

MUCH-NEEDED INFORMATION ABOUT THE DOWN SYNDROME POPULATION, OF WHICH AS

MANY AS 80 PERCENT HAVE ALZHEIMER'S PATHOLOGY BY THE TIME THEY ARE IN

THEIR 50S AND 60S. ALTHOUGH THERE ARE MANY CENTERS AND RESEARCHERS THAT

FOCUS ON ALZHEIMER'S IN THE GENERAL POPULATION, FEW OF THEM FOCUS ON

PEOPLE WITH DOWN SYNDROME. THE INFORMATION GENERATED BY OUR PROJECT

WILL BE OF GREAT HELP TO THOSE WITH DOWN SYNDROME AND THOSE WITH

ALZHEIMER'S DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS

 March
 Schedule O (Form 990) 2021

 132212 11-11-21
 114

Name of the organization

#### WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2018010

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF

GRANT: NATIONAL GLAUCOMA RESEARCH BY ALESSANDRA CARMICHAEL-MARTINS,

PHD, ENTITLED: (G2022001F) ADAPTIVE OPTICS OPTICAL COHERENCE TOMOGRAPHY

AND SCANNING LASER GONIOSCOPY OF THE HUMAN TRABECULAR MESHWORK IN VIVO.

INVESTIGATOR'S SUMMARY: ELEVATED INTRAOCULAR PRESSURE, THE MAJOR RISK

FACTOR IN GLAUCOMA, IS PRIMARILY CONTROLLED BY THE RATE OF AQUEOUS

OUTFLOW THROUGH THE TRABECULAR MESHWORK AND SCHLEMM'S CANAL. IN

POST-MORTEM HUMAN TISSUE, CHANGES TO THESE STRUCTURES ARE ASSOCIATED

WITH GLAUCOMA, AND MANY GLAUCOMA TREATMENTS TARGET THIS REGION. THIS

PROPOSAL WILL ENABLE RESEARCHERS AND CLINICIANS TO ACHIEVE THREE

DIMENSIONAL IMAGES OF THE DRAINAGE STRUCTURES IN THE LIVING HUMAN EYE

AT CELLULAR-LEVEL RESOLUTION, ALLOWING A DEEPER UNDERSTANDING OF

CHANGES WITHIN THE TRABECULAR MESHWORK ASSOCIATED WITH AGE, GLAUCOMA,

AND TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2022001F

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY CATIA GOMES, PHD, ENTITLED: (G2022003F) THE ROLE OF REACTIVE ASTROCYTE-ASSOCIATED COMPLEMENT C3 IN GLAUCOMATOUS NEURODEGENERATION. INVESTIGATOR'S SUMMARY: GLAUCOMA IS CHARACTERIZED BY RETINAL GANGLION CELLS (RGCS) DYSFUNCTION AND LOSS. REACTIVE ASTROCYTES CLOSELY ASSOCIATE WITH RGCS IN THE OPTIC NERVE HEAD, WHERE THE INITIAL INSULT TO RGC AXONS OCCURS. A SPECIFIC NEUROTOXIC PHENOTYPE OF REACTIVE ASTROCYTES WAS RECENTLY IDENTIFIED. TO STUDY SUCH NEUROTOXIC EFFECTS, RGCS AND ASTROCYTES WILL BE Schedule O (Form 990) 2021 132212 11-11-21 115

13420803 150872 191978

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
	<u> </u>
DIFFERENTIATED FROM HUMAN PLURIPOTENT STEM CELLS, AND MICR	OFLUIDIC
PLATFORMS USED TO ALLOW THE SPECIFIC ANALYSIS OF RGC AXONS	. IDENTIFYING
REACTIVE ASTROCYTE-INDUCED AXONAL DEGENERATION PATHWAYS WI	LL ALLOW FOR
THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. FOR MORE	INFORMATION,
THE DEVELOPMENT OF NOVEL THERAPEOTIC STRATEGIES. FOR MORE	INFORMATION,
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G	2022003F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY PRABHAVATHI MADDINENI, PHD, ENTITLED: (G2022004F) EFFECT OF OCULAR HYPERTENSION ON SYNAPTIC FUNCTION AND PLASTICITY IN GLAUCOMATOUS NEURODEGENERATION. INVESTIGATOR'S SUMMARY: GLAUCOMA IS AN EYE DISEASE THAT CAN CAUSES BLINDNESS BY DAMAGING THE OPTIC NERVE. THE JOB OF THE OPTIC NERVE IS TO TRANSFER VISUAL INFORMATION FROM EYE TO THE BRAIN VIA ELECTRICAL IMPULSES. IN GLAUCOMA, AN INCREASED OCULAR PRESSURE CAUSES OPTIC NERVE DEGENERATION. SINCE OPTIC NERVE IS THE PART OF CENTRAL NERVOUS SYSTEM AND CONNECTED TO THE BRAIN, PRESSURE INDUCED OPTIC NERVE DAMAGE MAY ALSO DAMAGE SURROUNDING CELLS AND NEURONS IN THE BRAIN. IN THIS PROPOSAL, WE WILL STUDY HOW NEURONS IN THE BRAIN COMMUNICATE WITH EACH OTHER IN RESPONSE TO PRESSURE INDUCED DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/G2022004F

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY THOMAS JOHNSON, MD, PHD, ENTITLED: (G2022005S) IN VIVO ADAPTIVE OPTICS OPHTHALMOSCOPY TO CHARACTERIZE FUNCTIONAL RETINAL INTEGRATION OF TRANSPLANTED RGCS USING A NOVEL TRANSGENIC REPORTER PARADIGM. INVESTIGATOR'S SUMMARY: STEM CELL TRANSPLANTATION THERAPY HAS THE 132212 11-11-21 Schedule O (Form 990) 2021

116

13420803 150872 191978

Schedule O (Form 990) 2021 Name of the organization BRIGHTFOCUS FOUNDATION	Page 2 Employer identification number 23-7337229
POTENTIAL TO RESTORE VISION FOR TENS OF MILLIONS OF PEOPLE	WORLDWIDE
SUFFERING FROM OPTIC NERVE DISEASES SUCH AS GLAUCOMA. TO H	ELP USHER
THIS NEW APPROACH TOWARDS TREATING HUMAN PATIENTS, WE PROP	OSE TO
DEVELOP A NOVEL, SENSITIVE, RAPID EXPERIMENTAL TOOL THAT L	ABELS
SUCCESSFUL INTEGRATION OF TRANSPLANTED NEURONS IN THE RETI	NAS OF
RECIPIENT EYES, AND TO RIGOROUSLY VALIDATE THE EXPERIMENTA	L FRAMEWORK
USING MULTIPLE COMPLIMENTARY TECHNIQUES THAT INCLUDE HIGH-	RESOLUTION
THREE-DIMENSIONAL MICROSCOPY AND MEASUREMENTS OF ELECTRICA	L RESPONSES
TO LIGHT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEB	SITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022005S	
NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDAT	ION (LHS).
(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAZUHI	RO KUROKAWA,
PHD, ENTITLED: (G2022006S) MULTIFUNCTIONAL CELLULAR-SCALE	IMAGING IN
THE LIVING RETINA TO STUDY GLAUCOMA PATHOPHYSIOLOGY. INVE	STIGATOR'S
SUMMARY: THE CURRENT APPROACH USED BY EYE DOCTORS TO DETEC	T GLAUCOMA
AND ITS PROGRESSION IS BASED ON SIGNS THAT REPRESENT IRREV	ERSIBLE
DAMAGE, NAMELY LOSS OF VISION AND CELLS OF THE OPTIC NERVE	. NEW WAYS
ARE NEEDED FOR DETECTING DAMAGE EARLIER, AT A POINT WHEN T	REATMENT
COULD PRESERVE VISION, AND EVEN RESTORE THE HEALTH OF THE	EYE AND OPTIC
NERVE BEFORE IRREVERSIBLE DAMAGE OCCURS. WE PROPOSE TO CON	STRUCT AND
TEST A NEW ADVANCED MULTIFUNCTIONAL IMAGING SYSTEM CAPABLE	OF REVEALING
ASTOUNDING DETAILS IN THE LIVING EYE AS SMALL AS SINGLE CE	LLS AND
TRANSFORMING THE FUTURE OF CLINICAL TESTING FOR GLAUCOMA.	FOR MORE
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/G2022006S	

NAME OF ORGANIZATION OR GOVERNMENT: MICHIGAN STATE UNIVERSITY. (H)

117

Schedule O (Form 990) 2021

132212 11-11-21

Schedule O (Form 990) 2021 Name of the organization BRIGHTFOCUS FOUNDATION	Page 2 Employer identification number 23-7337229
PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ANDRAS KOM	
PHD, ENTITLED: (G2022007S) TARGETING EXERCISE FOR NEUROPRO	
GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A LEADING C	AUSE OF
PERMANENT VISION LOSS DUE TO PROGRESSIVE DEGENERATION OF T	HE OPTIC
NERVE THAT TRANSMITS VISUAL INFORMATION FROM EYE TO BRAIN.	THE ONLY
PROVEN METHOD TO TREAT GLAUCOMA AND SLOW VISION LOSS IS BY	LOWERING EYE
PRESSURE, BUT GLAUCOMA PROGRESSES DESPITE SUCH THERAPY. IN	DOGS WITH
NATURALLY-OCCURRING GLAUCOMA, WE WILL THUS DETERMINE IF RE	GULAR,
MODERATE-INTENSITY EXERCISE CAN SLOW GLAUCOMA DISEASE PROG	RESSION, AS
SUGGESTED BY EXPERIMENTAL MODELS IN MICE AND RATS. EXERCIS	E WOULD
PROVIDE AN EASY, LOW-COST, BENEFICIAL THERAPY AVENUE FOR G	LAUCOMA
PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEB	SITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022007S	
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	
NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDAT	ION (LHS).
(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HONGLI	YANG, PHD,
ENTITLED: (G2022008S) NOVEL TECHNIQUES TO CORRELATE STRUCT	URAL AND
MOLECULAR ALTERATIONS IN NON-HUMAN PRIMATE EARLY GLAUCOMA.	
INVESTIGATOR'S SUMMARY: THIS PROPOSAL'S GOAL IS TO IDENTIF	Y THE
CELLULAR AND MOLECULAR ALTERATIONS UNDERLYING LONGITUDINAL	STRUCTURAL
CHANGE IN AN EXPERIMENTAL GLAUCOMA MONKEY MODEL. WE PROPOS	E TO DEVELOP
AND OPTIMIZE NOVEL METHODS TO AUTOMATICALLY COLOCALIZE POS	T-MORTEM
IMMUNOHISTOCHEMISTRY IMAGES TO IN VIVO OPTICAL COHERENCE T	OMOGRAPHY
(OCT) SCANS. OVERALL, THIS PROJECT WILL INFORM AND ENHANCE	THE
INTERPRETATION OF HUMAN OCT IMAGING, ADVANCE OUR UNDERSTAN	DING OF
PATHOPHYSIOLOGIC MECHANISMS IN GLAUCOMA, AND PROVIDE GUIDA	NCE TO
<b>IMPROVE THERAPEUTIC OPTIONS BEFORE GLAUCOMATOUS DAMAGE BEC</b> 132212 11-11-21	OMES Schedule O (Form 990) 2021
118 420803 150872 191978 2021 04012 PRICHTEOCUS	

13420803 150872 191978

#### WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022008S

NAME OF ORGANIZATION OR GOVERNMENT: CEDARS-SINAI MEDICAL CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SHAOMEI WANG, MD, PHD, ENTITLED: (G2022009S) NEURAL PROGENITOR CELL ENGINEERED TO EXPRESS TROPHIC FACTOR FOR TREATING GLAUCOMA. INVESTIGATOR'S SUMMARY: ELEVATED INTRAOCULAR PRESSURE (IOP) IS A PROMINENT MANIFESTATION OF GLAUCOMA, A CHRONIC, PROGRESSIVE OPTIC NEUROPATHY CHARACTERIZED BY LOSS OF RETINAL GANGLION CELLS (RGCS) AND VISUAL FIELD DEFECTS. ACCUMULATING EVIDENCE HAS SHOWN THE SITE OF IOP INDUCED AXONAL DAMAGE IS THE OPTIC NERVE HEAD (ONH), WHERE ASTROCYTES RETRACT ITS PROCESSES AND FAIL TO PROVIDE ESSENTIAL METABOLIC AND TROPHIC SUPPORT TO RGCS. THE NOVEL APPROACH OF THIS STUDY IS TO DELIVER A COMBINED STEM CELL AND GENE THERAPY CLOSE TO THE SITE OF DISEASE TO PROTECT RGCS FROM SECONDARY DEGENERATION IN A RODENT MODEL OF GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022009S

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MYOUNGSUP SIM, PHD, ENTITLED: (G2022010S) AUTOPHAGY REGULATES ENDOTHELIAL NITRIC OXIDE (NO)SYNTHASE/NO IN SCHLEMM'S CANAL CELLS IN RESPONSE TO SHEAR STRESS. INVESTIGATOR'S SUMMARY: SEVERAL STUDIES HAVE SHOWN THAT NITRIC OXIDE (NO) LOWERS EYE PRESSURE. MORE, A NOVEL NO-DONATING DRUG (LATANOPROSTENE BUNOD) HAS BEEN RECENTLY APPROVED TO LOWER EYE PRESSURE IN PATIENTS WITH GLAUCOMA. HOWEVER, MOST OF THE NO-BASED DRUGS HAVE FAILED TO BE APPROVED BY FDA DUE TO SOME CHALLENGES RELATED TO THE EXOGENOUS DELIVERY OF NO, SUCH AS UNCONTROLLED NO RELEASE, SUGGESTING 138212 11-11-21 Schedule O (Form 990) 2021

13420803 150872 191978

Schedule O (Form 990) 2021	Page 2
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
THAT REGULATION OF ENDOGENOUS NO PRODUCTION COULD REPRE	ESENT A BETTER
STRATEGY FOR GLAUCOMA TREATMENT. HERE, WE SEEK TO INVES	STIGATE HOW TO
REGULATE ENDOGENOUS NO PRODUCTION TO IMPROVE THE CURREN	NT NO-BASED
GLAUCOMA THERAPY. FOR MORE INFORMATION, VISIT THE BRIG	GHTFOCUS WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022010S	
NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSI	ITY MEDICAL
CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEAR	RCH BY MICHAEL
RISNER, PHD, ENTITLED: (G2022011S) HARNESSING INTERCELI	LULAR
MITOCHONDRIAL TRANSFER IN HUMAN-DERIVED RETINAL CELLS	IO TREAT
GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS AN AGE-F	RELATED
NEURODEGENERATIVE DISEASE, CAUSING IRREVERSIBLE BLINDNE	ESS THROUGH
RETINAL GANGLION CELL DEATH. GLAUCOMA IS TYPICALLY TREA	ATED BY LOWING
INTRAOCULAR PRESSURE. HOWEVER, MANY PATIENTS DO NOT PRO	DDUCE A ROBUST
RESPONSE TO THIS TREATMENT AND CONTINUE TO LOSE VISION.	. FOR THESE
PEOPLE, CELL REPLACEMENT THERAPY MAY BE THE ONLY OPTION	N. THE MOST
IMPORTANT POINT OF THIS PROPOSAL IS UNDERSTANDING THE M	METABOLIC
INTERACTION BETWEEN HEALTHY AND STRESSED CELLS IN THE C	CONTEXT OF CELL
TRANSPLANTATION FOR THE TREATMENT OF GLAUCOMA. FOR MOP	RE INFORMATION,
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRAM	NT/G2022011S
NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY.	(H) PURPOSE OF

GRANT: NATIONAL GLAUCOMA RESEARCH BY JIAXING WANG, PHD, ENTITLED:

(G2022012S) GENETIC MUTATION ENHANCE OPTIC NERVE REGENERATION IN BXD29

MOUSE STRAIN. INVESTIGATOR'S SUMMARY: THE DAMAGE TO THE OPTIC NERVE

LEADS TO BLINDNESS IN MANY DISEASES SUCH AS GLAUCOMA. WE ARE LOOKING

FOR GENES THAT COULD MODULATE THE OPTIC NERVE REGENERATION TO SAVE

VISION. WE HAVE FOUND A MOUSE MUTANT WITH ENHANCED REGENERATION

 132212
 11-11-21

 Schedule O (Form 990) 2021

 120

13420803 150872 191978

Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
RESPONSE THAT IS CARRYING SUCH GENE AND WE ARE WORKING TO	IDENTIFY IT.
ONCE WE HAVE IT IDENTIFIED, WE WILL TEST THE FUNCTION OF T	HE GENE AND
SEE HOW DOES IT ALTER THE REGENERATION RESPONSE. THIS MAY	LEAD TO A
CLINICAL INTERVENTION FOR THE TREATMENT OF BLINDNESS DUE I	O OPTIC NERVE
DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSI	TE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022012S	
NAME OF ORGANIZATION OR GOVERNMENT: TRUSTEES OF BOSTON UNI	VERSITY. (H)
PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HAIYAN GON	IG, MD, PHD,
ENTITLED: (G2022013S) INVESTIGATIONS OF SEGMENTAL UVEAL AC	UEOUS
OUTFLOW. INVESTIGATOR'S SUMMARY: UVEAL OUTFLOW, ONE OF TW	O ROUTES FOR
FLUID DRAINAGE FROM THE EYE, PLAYS A ROLE IN MAINTAINING N	IORMAL
PRESSURE INSIDE THE EYE (IOP). GLAUCOMA, A POTENTIALLY BLI	NDING DISEASE
OFTEN ASSOCIATED WITH HIGH IOP, CAN BE TREATED BY IMPROVIN	IG FLUID
DRAINAGE OUT OF THE EYE AND DECREASING IOP. PROSTAGLANDIN	ANALOGUE
DRUGS LOWER IOP IN GLAUCOMA BY INCREASING UVEAL OUTFLOW. C	UR RECENT
STUDIES FOUND THAT UVEAL OUTFLOW IS SEGMENTAL OR NON-UNIFO	RM AROUND
EYE, THOUGH IT IS UNCLEAR WHAT FACTORS REGULATE IT. THIS S	TUDY AIMS TO
FURTHER INVESTIGATE SEGMENTAL UVEAL OUTFLOW AND THE FACTOR	S THAT MAY
REGULATE IT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS	WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/G2022013S	

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF

121

GRANT: NATIONAL GLAUCOMA RESEARCH BY JASON MEYER, PHD, ENTITLED:

(G2022014S) EXPLORING THE ROLE OF THE APBB2 RISK VARIANT IN GLAUCOMA

WITH HUMAN INDUCED PLURIPOTENT STEM CELLS. INVESTIGATOR'S SUMMARY:

AFRICAN AMERICANS ARE AT A SIGNIFICANTLY HIGHER RISK FOR GLAUCOMA

Schedule O (Form 990) 2021

13420803 150872 191978

132212 11-11-21

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
COMPARED TO OTHER ETHNICITIES. RECENTLY, A VARIANT IN THE	APBB2 GENE
WAS IDENTIFIED TO BE SIGNIFICANTLY ASSOCIATED WITH GLAUCOM	A IN AFRICAN
AMERICANS, REPRESENTING A NOVEL OPPORTUNITY TO EXPLORE THE	DEGENERATION
OF RGCS ASSOCIATED WITH THIS INCREASED RISK. THE OVERALL G	OALS OF THIS
APPLICATION FOCUS UPON THE USE OF HUMAN INDUCED PLURIPOTEN	T STEM CELLS,
AS WELL AS CRISPR/CAS9 GENE EDITING, AS AN IN VITRO MODEL	TO STUDY THE
EFFECTS OF THIS GENE VARIANT ON RGCS AND IDENTIFY HOW IT M	AY LEAD TO
GLAUCOMATOUS NEURODEGENERATION. FOR MORE INFORMATION, VIS	IT THE
BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022014S	
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORN	IA DAVIS.
(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY NICK	
MARSH-ARMSTRONG, PHD, ENTITLED: (G2022016S) LIVE IMAGING T	O DETERMINE
WHETHER MITOCHONDRIA AND AMYLOID BETA AXONAL RELEASES ARE	LINKED.
INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL USE LIVE IMAGIN	G OF THE
OPTIC NERVE IN YOUNG TADPOLES TO DETERMINE WHETHER AN AGEN	T BELIEVED TO
BE CENTRAL TO ALZHEIMER'S DISEASE MIGHT BE BEING RELEASED	FROM AXONS
TOGETHER WITH MITOCHONDRIA. IF ITS RELEASE IS LINKED TO TH	AT OF
MITOCHONDRIA, IT WOULD HAVE PROFOUND IMPLICATIONS FOR BOTH	ALZHEIMER'S
DISEASE AND GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRI	GHTFOCUS
WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022016S	_
NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA	. (H)
PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MICHAEL AN	DERSON, PHD,
ENTITLED: (G2022017S) TESTING THE INFLUENCE OF PODOSOMES O	N INTRAOCULAR
PRESSURE. INVESTIGATOR'S SUMMARY: THERE ARE ONGOING NEEDS	FOR IMPROVED
GLAUCOMA THERAPIES. ONE APPROACH IS TO FIND NEW WAYS TO DE	CREASE
AQUEOUS HUMOR OUTFLOW RESISTANCE AND THEREBY LOWER INTRAOC	ULAR

132212 11-11-21

Schedule O (Form 990) 2021

13420803 150872 191978

¹²² 2021.04012 BRIGHTFOCUS FOUNDACOPY^{191978_1}

Schedule O (Form 990) 2021 Name of the organization	Page 2
BRIGHTFOCUS FOUNDATION	23-7337229
PRESSURE. HERE, WE TEST THE ROLE OF SMALL FINGERLIKE PROTE	USIONS OF
CELLS CALLED "PODOSOMES". OUR EXPERIMENTS USE MICE TO MANI	PULATE
PODOSOMES AND ASSESS WHETHER THIS CHANGES INTRAOCULAR PRES	SURE. THIS
WORK WILL LEAD TO IMPORTANT INFORMATION ABOUT THE CELL BIC	LOGY OF
GLAUCOMA, PERHAPS IDENTIFYING THE PRECISE MOLECULAR LOCATI	ON OF OUTFLOW
RESISTANCE, AND MAY POINT TO COMPOUNDS ALTERING PODOSOMES	AS POTENTIAL
NEW GLAUCOMA THERAPIES. FOR MORE INFORMATION, VISIT THE B	BRIGHTFOCUS
WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022017S	
NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY.	(H) PURPOSE
OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG,	PHD,
ENTITLED: (CG2022001) A RANDOMIZED, SHAM CONTROLLED, MASKE	D PHASE II
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL INTRAVIT	REAL
IMPLANTATION OF NEUROPROTECTIVE CELL THERAPY FOR THE TREAT	MENT OF
GLAUCOMA. INVESTIGATOR'S SUMMARY: THE PROPOSED PROJECT IS	AN EXTENSION
OF THE CURRENT PHASE 2 CLINICAL TRIAL, TO ASSESS AND VALID	ATE THE USE
OF DUAL NT-501 CNTF ENCAPSULATED CELL THERAPY (ECT) ON VIS	UAL
IMPAIRMENT RELATED TO GLAUCOMA, IN HUMAN SUBJECTS. THE PRO	POSED STUDY
IS DESIGNED TO EXPAND OUR KNOWLEDGE OF THE DOSE-DEPENDENT	EFFECT OF
CNTF IN GLAUCOMA THROUGH DUAL IMPLANTATION OF NT-501 ECT.	FOR MORE
INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/CG2022001	
NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF NORT	'H CAROLINA AT
CHAPEL HILL. (H) PURPOSE OF GRANT: MACULAR DEGENERATION R	ESEARCH BY
YONGSU KWON, PHD, ENTITLED: (M2022001F) NANOCERIA-COATED M	IELANIN
NANOPARTICLES AS A NOVEL ANTIOXIDANT FOR AGE-RELATED MACUL	AR
DEGENERATION. INVESTIGATOR'S SUMMARY: THIS STUDY AIMS TO	DEVELOP A
132212 11-11-21 123	Schedule O (Form 990) 2021

13420803 150872 191978

^{2021.04012} BRIGHTFOCUS FOUNDATIONPY¹⁹¹⁹⁷⁸_1

Schedule O (Form 990) 2021 Name of the organization	Page 2 Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
COMBINATION OF A NEW ANTIOXIDANT SYSTEM TO SCAVENGE FREE R.	ADICALS
(TOXIC WASTE PRODUCTS THAT GRADUALLY BUILD UP IN THE CELLS	OVER TIME),
WHICH CAN POTENTIALLY ACHIEVE LONG-TERM EFFECTS AND REDUCE	THE DAMAGE
IN AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSI	TE:
WWW.BRIGHTFOCUS.ORG/GRANT/M2022001F	
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGT	ON. (H)
PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DANIEL	HASS, PHD,
ENTITLED: (M2022003F) DISINHIBITION OF FATTY ACID OXIDATIO	N TO DISPOSE
OF DRUSEN COMPONENTS. INVESTIGATOR'S SUMMARY: THIS STUDY	DETERMINES
THE EFFECT OF A SMALL MOLECULE ON FATTY ACID METABOLISM, C	ELL FUNCTION,
AND DEPOSIT LEVELS IN MULTIPLE CELL CULTURE AND MOUSE MODE	LS OF AMD.
THIS SMALL MOLECULE HAS BEEN TESTED IN HUMANS IN CLINICAL	TRIALS AND IS
SAFE, SO IF IT IS ALSO EFFECTIVE AT DECREASING DEPOSIT LEV	ELS THE
TRANSITION TO CLINICAL USE MAY BE MORE RAPID THAN FOR UNTE	STED
TREATMENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS W	EBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/M2022003F	
NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXA	S
SOUTHWESTERN MEDICAL CENTER. (H) PURPOSE OF GRANT: MACULA	R

DEGENERATION RESEARCH BY STEFFI DANIEL, PHD, ENTITLED: (M2022005F)

IDENTIFYING PHARMACEUTICS FOR AMD ASSOCIATED PATHOPHYSIOLOGY.

INVESTIGATOR'S SUMMARY: THIS STUDY WILL EMPLOY NOVEL

"DISEASE-IN-A-DISH" SYSTEM, TO SCREEN FOR MORE THAN 1500 FDA APPROVED

DRUGS FOR THEIR ABILITY TO REVERSE DISEASE. LEAD DRUGS FROM THIS SCREEN

WILL ALSO BE EXTENSIVELY AND RIGOROUSLY TESTED IN A PRE-CLINICAL MODEL

SYSTEM. IF SUCCESSFUL, THE RESULTS FROM THIS STUDY WILL CONTRIBUTE

132212 11-11-21

Schedule O (Form 990) 2021
124

13420803 150872 191978

BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022005F

NAME OF ORGANIZATION OR GOVERNMENT: SEATTLE CHILDREN'S HOSPITAL. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LEAH VANDENBOSCH, PHD, ENTITLED: (M2022006F) MOLECULAR AND MACHINE LEARNING APPROACHES TO NON-CODING RISK IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THIS STUDY WILL APPLY MACHINE LEARNING TO HUMAN RETINAL AND RETINAL PIGMENTED EPITHELIUM GENOMIC DATA TO PREDICT THE EFFECT OF VARIATIONS IN THE NON-CODING REGIONS, THE REGIONS OF DNA WITH NO KNOWN FUNCTION TO CONTRIBUTE DIRECTLY TO AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022006F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF ROCHESTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KRISTEN BOWLES JOHNSON, PHD, OD, ENTITLED: (M2022007F) CELLULAR SCALE CHARACTERIZATION OF THE RPE-PHOTORECEPTOR COMPLEX IN PENTOSAN-ASSOCIATED MACULOPATHY; A MODEL FOR GEOGRAPHIC ATROPHY PROGRESSION. INVESTIGATOR'S SUMMARY: IN THIS STUDY, RESEARCHERS WILL USE A CAMERA CALLED AN ADAPTIVE OPTICS OPHTHALMOSCOPE (A00) TO TAKE PICTURES OF FLUORESCENT CLUMPS IN RPE CELLS AND MEASURE HOW SICK PHOTORECEPTORS AS THE DISEASE PROGRESSES. COMPLETION OF THIS STUDY COULD IDENTIFY BIOMARKERS TO HELP IDENTIFY PATIENTS MOST LIKELY TO BENEFIT FROM A TREATMENT AND DETERMINATION OF TREATMENT EFFICACY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022007F

NAME OF ORGANIZATION OR GOVERNMENT: THE REGENTS OF THE UNIVERSITY OF

 MICHIGAN.
 (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY

 Schedule O (Form 990) 2021

 132212 11-11-21
 125

 13420803 150872 191978
 2021.04012 BRIGHTFOCUS FOUNDATION POINTS_191978_1

Schedule O (Form 990) 2021 Name of the organization	Page 2 Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229
THOMAS WUBBEN, PHD, ENTITLED: (M2022008N) METABOLIC UNCOUP	LING AND AMD:
ASSESSING THE ROLE OF PKM2 IN THE BIOENERGETIC CRISIS OF T	HE OUTER
RETINA. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGEN	ERATION (AMD)
IS A LEADING CAUSE OF VISUAL IMPAIRMENT IN THE ELDERLY. IT	AFFECTS
NEARLY 200 MILLION PEOPLE WORLDWIDE, AND THIS NUMBER IS EX	IPECTED TO
CONTINUE TO INCREASE IN THE COMING DECADES. WHILE THE EXAC	T CAUSE OF
AMD REMAINS UNKNOWN, DEREGULATION OF CELLULAR METABOLISM I	S BELIEVED
CRITICAL TO ITS PATHOGENESIS. THIS PROJECT WILL REVEAL THE	SIGNIFICANCE
OF MODULATING METABOLIC TARGETS IMPORTANT IN MACULAR DEGEN	IERATION,
WHICH MAY HAVE IMMEDIATELY TRANSLATABLE APPLICATIONS TO CL	INICALLY
TREAT PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOC	US WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/M2022008N	
NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENC	E UNIVERSITY.
(H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YIF	'AN JIAN, PHD,
ENTITLED: (M2022009N) MAPPING OF PHOTORECEPTOR NUCLEAR LAY	ER USING
VOLUMETRIC DIRECTIONAL OCT: APPLICATIONS IN AGE-RELATED MA	CULAR
DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR	DEGENERATION
(AMD) IS THE MOST COMMON CAUSE OF VISION LOSS IN THE ELDER	LY
POPULATION. HOWEVER, THERE IS NO TREATMENT OPTION AND VERY	LIMITED
UNDERSTANDING OF NON-EXUDATIVE AMD, THAT ACCOUNTS FOR MORE	THAN 90% OF
PATIENTS DIAGNOSED WITH AMD. WE ARE DEVELOPING A NOVEL RET	INA IMAGING
DEVICE CALLED VOLUMETRIC DIRECTIONAL OPTICAL COHERENCE TOM	OGRAPHY WHICH
CAN MEASURE A NEW BIOMARKER, THE TRUE THICKNESS OF OUTER N	UCLEAR LAYER
(ONL). THE ABILITY TO MEASURE ONL COULD LEAD TO IMPROVED U	INDERSTANDING
OF THE RETINAL DEGENERATION IN AMD, AND THE EFFECTS OF THE	RAPEUTIC
INTERVENTIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCU	US WEBSITE:
WWW.BRIGHTFOCUS.ORG/GRANT/M2022009N	
132212 11-11-21 126	Schedule O (Form 990) 2021

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED: NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NEVADA, RENO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ALBERT GONZALES, PHD, ENTITLED: (M2022010N) LIGHT-DEPENDENT CONSTRUCTION OF CHOROID VASCULATURE. INVESTIGATOR'S SUMMARY: THE CURRENT PROPOSAL CHALLENGES THE COMMONLY HELD VIEW THAT CAPILLARY NETWORKS ARE PASSIVE STRUCTURES WHOSE SOLE PURPOSE IS TO PROVIDE A CONDUIT INFRASTRUCTURE FOR BLOOD FLOW. WE WILL EXAMINE THE HOW BLOOD VESSELS CAN RESPOND TO LIGHT AND CHANGE BLOOD FLOW IN THE EYE. THIS PROCESS IS NOT ONLY IMPORTANT FOR THE DELIVERY OF VITAL OXYGEN AND NUTRIENTS FOR CELL SURVIVAL, BUT ALSO FOR THE REMOVAL OF WASTE DEPOSIT THAT CAN LEAD TO DISEASES LIKE AGE-RELATED MACULAR DEGENERATION. COMPLETION OF THE PROPOSAL WILL PROVIDE INSIGHTS INTO THE ACTIVE PHYSIOLOGICAL ROLE OF CAPILLARIES IN CHOROID VASCULATURE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022010N

NAME OF ORGANIZATION OR GOVERNMENT: THE REGENTS OF THE UNIVERSITY OF MICHIGAN. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LEV PRASOV, PHD, ENTITLED: (M2022011N) THE ROLE OF MYRF IN TRANSCRIPTIONAL REGULATION OF RETINAL PIGMENT EPITHELIAL MAINTENANCE. INVESTIGATOR'S SUMMARY: THE RETINAL PIGMENT EPITHELIUM (RPE) IS A SUPPORTING TISSUE THAT IS CRITICAL FOR VISION AND IS IMPLICATED IN THE EARLY PATHOLOGY OF AGE-RELATED MACULAR DEGENERATION (AMD). WE IDENTIFIED A NEW GENE, MYRF, THAT CONTROLS EXPRESSION OF OTHER GENES IN THE RPE AND LEADS TO DYSFUNCTION. OUR PROPOSAL EVALUATES THE ROLE OF THIS GENE IN MAINTAINING ADULT RPE FUNCTION AND ITS ABILITY TO PROTECT AGAINST STRESSES THAT LEAD TO AMD. UNDERSTANDING THIS MAY OPEN NEW AVENUES FOR 182212 11-11-21 Schedule O (Form 990) 2021

13420803 150872 191978

Schedule O (Form 990) 2021 Name of the organization BRIGHTFOCUS FOUNDATION	Page 2 Employer identification number 23-7337229
TREATMENT OF AMD BY TARGETING THIS GENE OR ITS DOWNSTREAM	
WILL ALSO IMPROVE OUR KNOWLEDGE OF RPE BIOLOGY. FOR MORE	
VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M	12022011N
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTH FI	ORIDA. (H)
PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MANAS E	SISWAL, PHD,
ENTITLED: (M2022012N) INVESTIGATING RETINAL PIGMENT EPITHE	LIUM (RPE)
INJURY RESPONSE IN AFRICAN SPINY MICE (ACOMYS). INVESTIGA	TOR'S
SUMMARY: DEGENERATION OF THE NEURAL RETINA AND IN THE RETI	NAL PIGMENT
EPITHELIUM (RPE) IS ASSOCIATED WITH THE ADVANCED ATROPHIC	FORM OF
DRY-AMD. SINCE PHOTORECEPTORS IN THE NEURAL RETINA AND RPE	ARE
POSTMITOTIC, THEY CANNOT BE REPLACED ONCE THEY DIE. THEREE	ORE, THE
TREATMENTS BOOSTING THE ENDOGENOUS FACTORS TO STIMULATE RE	TINAL TISSUE
REGENERATION COULD BE A NOVEL THERAPEUTIC STRATEGY. OUR GO	AL IS TO
STUDY OCULAR REGENERATION FOLLOWING TISSUE INJURY IN AN AN	IIMAL MODEL
THAT COULD FACILITATE STUDIES TO DEVELOP POTENTIAL TREATME	NTS FOR
DRY-AMD IN HUMANS. FOR MORE INFORMATION, VISIT THE BRIGHT	FOCUS
WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022012N	
NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSI	TY SCHOOL OF
MEDICINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESE	
SRINIVASA RAO SRIPATHI, PHD, ENTITLED: (M2022014N) SCREENI	
MOLECULES THAT MODULATE RPE EPITHELIAL-MESENCHYMAL TRANSIT	ION AND
RESPONSE TO AMD-RELATED STRESSORS AS LEADS FOR THE TREATME	NT OF AMD.
INVESTIGATOR'S SUMMARY: AN EARLY EVENT ASSOCIATED WITH AMI	IS DAMAGE TO
THE RETINAL-PIGMENTED EPITHELIUM (RPE), THE CELLS THAT HEI	P MAINTAIN
PHOTORECEPTOR CELL HEALTH AND FUNCTION. MULTIPLE FACTORS.	TNCLUDING

PHOTORECEPTOR CELL HEALTH AND FUNCTION. MULTIPLE FACTORS, INCLUDING

CIGARETTE SMOKE, HAVE BEEN IDENTIFIED AS BEING IMPORTANT IN INITIATING 132212 11-11-21 Schedule O (Form 990) 2021 128

Schedule O (Form 990) 2021	Page <b>2</b>
Name of the organization BRIGHTFOCUS FOUNDATION	Employer identification number 23-7337229
AND PROMOTING RPE INJURY. ONE OF THE WAYS THE RPE RESPONDS	TO INJURY IS
BY A PROCESS KNOWN AS EPITHELIAL-MESENCHYMAL TRANSITION (E	MT), WHERE
RPE LOSES ITS INTEGRITY. TO DEVELOP NOVEL TREATMENTS FOR A	MD, WE
PROPOSE TO UTILIZE HUMAN STEM CELL-DERIVED RPE CELLS TO SC	REEN FOR
MOLECULES (POTENTIAL DRUGS) THAT INHIBIT RPE DAMAGE AND RE	DUCE EMT.
FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:	
WWW.BRIGHTFOCUS.ORG/GRANT/M2022014N	
NAME OF ORGANIZATION OR GOVERNMENT: THE JACKSON LABORATORY	. (H)
PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY PATSY N	ISHINA, PHD,
ENTITLED: (M2022016I) TRANSLATIONAL VISION RESEARCH MODELS	FOR
SUBRETINAL FIBROSIS. INVESTIGATOR'S SUMMARY: TISSUE DAMAG	E IN THE BACK
OF THE EYE MAY LEAD TO FORMATION OF SCAR TISSUE OR FIBROSI	S THAT CAUSES
VISION IMPAIRMENT. WE DESCRIBE HERE TWO NEW GENETIC MODELS	THAT DEVELOP
SUBRETINAL FIBROSIS, A COMMON COMPLICATION OF WET AMD. WE	AIM TO
DETERMINE HOW CHANGES IN FUNCTION/STRUCTURE AND CELL SIGNA	LS LEAD TO
THE DISEASE USING CLASSIC GENETIC AND MOLECULAR METHODS. W	E WILL ALSO
TEST VARIOUS DRUGS TO DETERMINE THEIR EFFECTS ON THE DISEA	SE. AT THE
END OF THIS STUDY, WE WILL HAVE ROBUST, WELL CHARACTERIZED	SUBRETINAL
FIBROSIS MOUSE MODELS AND INSIGHTS INTO PATHWAYS THAT MAY	UNDERLIE THE
DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBS	ITE:
WWW.BRIGHTFOCUS.ORG/GRANT/M20220161	
NAME OF ORGANIZATION OR GOVERNMENT: DRUSOLV THERAPUTICS, I	NC. (H)
PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JOHN G.	EDWARDS,
MS/MBA, ENTITLED: (CM2022001) OCUSTATIN FOR TREATMENT OF I	NTERMEDIATE
AMD. INVESTIGATOR'S SUMMARY: DRUSOLV IS DEVELOPING A HIGH	-DOSE ORAL

STATIN FOR EARLY INTERVENTION IN A BLINDING EYE DISEASE CALLED
132212 11-11-21
1229
Schedule O (Form 990) 2021
129

Schedule O (Form 990) 2021				Page
Name of the organization BRIGHTFOCUS	FOUNDATION			Employer identification number 23-7337229
AGE-RELATED MACULAR DEGENE	ERATION (AMD).	FOR MORE	INFORMAT	ION, VISIT
THE BRIGHTFOCUS WEBSITE: W	WW.BRIGHTFOCU	S.ORG/GRAN	г/см20220	01
			• • • • •	-
132212 11-11-21				Schedule O (Form 990) 202

13420803 150872 191978

SCH	<b>IEDULE</b> R
<b>/</b>	

(Form 990)

## **Related Organizations and Unrelated Partnerships**

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.

Attach to Form 990.
 Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021 Open to Public Inspection

Employer identification number 23 - 7337229

Department of the Treasury Internal Revenue Service Name of the organization

# BRIGHTFOCUS FOUNDATION

Part I Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

<b>(a)</b> Name, address, and EIN (if applicable) of disregarded entity	<b>(b)</b> Primary activity	<b>(c)</b> Legal domicile (state or foreign country)	<b>(d)</b> Total income	<b>(e)</b> End-of-year assets	<b>(f)</b> Direct controlling entity
NATIONAL DEVELOPMENT, LLC - 23-7337229					
22512 GATEWAY CENTER DRIVE	PROPERTY RENTAL AND				
CLARKSBURG, MD 20871	MANAGEMENT	MARYLAND	542,987.	3,871,939.	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229					
22512 GATEWAY CENTER DRIVE	OWNER OF BRIGHTFOCUS				
CLARKSBURG, MD 20871	HEADQUARTERS	MARYLAND	0.	3,319,296.	BRIGHTFOCUS FOUNDATION
	-				

Part II Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

<b>(a)</b> Name, address, and EIN of related organization	<b>(b)</b> Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	<b>(e)</b> Public charity status (if section	<b>(f)</b> Direct controlling entity		<b>g)</b> 512(b)(13) rolled tity?
				501(c)(3))	3))		No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule R (Form 990) 2021



### Schedule R (Form 990) 2021 BRIGHTFOCUS FOUNDATION

Part III Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

		-	6.0		(2)						
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(I	n)	(i)	(j)	
Name, address, and EIN of related organization	Primary activity	Legal domicile (state or foreign	Direct controlling entity	Predominant income (related, unrelated, excluded from tax under sections 512-514)	Share of total income	Share of end-of-year assets		ortionate tions?	Code V-UBI amount in box 20 of Schedule	Genera manag partne	or Percentage ownership
		country)		sections 512-514)			Yes	No	K-1 (Form 1065)	Yes	io
											_ <b>_</b>

Part IV Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a corporation or trust during the tax year.

<b>(a)</b> Name, address, and EIN of related organization	(b) ( Primary activity Legal		(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	<b>(f)</b> Share of total income	<b>(g)</b> Share of end-of-year assets	(h) Percentage ownership	Sec 512(l conti ent	(i) ction (b)(13) trolled tity?
		country)		01 11 03 0		235013		Yes	No
									$\square$
									$\square$
									$\square$
									$\square$
	1								

COPY

### Schedule R (Form 990) 2021 BRIGHTFOCUS FOUNDATION

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

				Τ			
Not	e: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.		Yes	No			
1	During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?						
а	Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity	1a		<b>-</b>			
b	Gift, grant, or capital contribution to related organization(s)	1b		<u> </u>			
С	Gift, grant, or capital contribution from related organization(s)	1c					
d	Loans or loan guarantees to or for related organization(s)	1d					
	Loans or loan guarantees by related organization(s)	1e					
f	Dividends from related organization(s)	1f					
g	Sale of assets to related organization(s)	1g					
	Purchase of assets from related organization(s)	1h					
i	Exchange of assets with related organization(s)	1i					
j	Lease of facilities, equipment, or other assets to related organization(s)	1j					
k	Lease of facilities, equipment, or other assets from related organization(s)	1k					
I.	Performance of services or membership or fundraising solicitations for related organization(s)	11					
m	Performance of services or membership or fundraising solicitations by related organization(s)	1m					
	Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	1n					
	Sharing of paid employees with related organization(s)	10					
р	Reimbursement paid to related organization(s) for expenses	1p					
	Reimbursement paid by related organization(s) for expenses	1q		T			
r	Other transfer of cash or property to related organization(s)	1r					
s	s Other transfer of cash or property from related organization(s)						
2	2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.						

(a) Name of related organization	<b>(b)</b> Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1)			
(2)			
<u>(3)</u>			
_(4)			
(5)			
_(6)			
132163 11-17-21			Schedule R (Form 990) 2021

#### Schedule R (Form 990) 2021 BRIGHTFOCUS FOUNDATION

Part VI Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(-)	(1-)		(-1)			(0)	(.)			(*)	12	(1)
(a)	(b)	(c)	(d)	(e) Are al	dl I	(f)	(g)		h)	(i)	(j)	(k)
Name, address, and EIN	Primary activity	Legal domicile	Predominant income (related, unrelated, excluded from tax under sections 512-514)	partners 501(c)( orgs.	sec. (3)	Share of	Share of	UISPI tio	ropor- nate tions?	Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	General o managin	Percentage
of entity		(state or foreign	excluded from tax under	orgs.		total	end-of-year		tions?	of Schedule K-1	partner?	
		country)	sections 512-514)	Yes N	No	income	assets	Yes	No	(Form 1065)	Yes No	•
												<u> </u>
							ļ				$\vdash$	<b></b>
	ļ											
					_							
					-							<b> </b>
												1

Schedule R (Form 990) 2021



#### BRIGHTFOCUS FOUNDATION

Part VII Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

132165 11-17-21	Schedule R (Form 990) 2021

13420803 150872 191978